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Minister’s Foreword
I welcome the publication of this year’s National Healthcare Quality Reporting System (NHQRS) by my 
Department. The 5th annual report of the NHQRS is an example of this Government's commitment 
to ensuring that our health services provide safer and better healthcare to all, by benchmarking the 
performance of our health service year-on-year and against international standards.  
Once again this year the NHQRS Report has expanded the range of indicators to measure and report 
on the overall quality of our health service. This year’s report includes new information on lung cancer 
survival rates, CPE and benzodiazepine medicine use in people aged 65 years and older.  
I am delighted to see that this year’s report shows a number of areas where our health services are 
performing well. While there is undoubtedly more to do, I am encouraged to see that the number of 
people hospitalised for asthma and heart failure are below international averages. I am also heartened 
to see that the number of people availing of bowel cancer screening is increasing. Over the last decade, 
the percentage of people with broken their hips receiving surgery within 48 hours of hospital admission 
has been increasing and is the highest it has ever been. The mortality rate for heart attack and stroke 
continues to decrease year on year for the past 10 years. These outcomes are significant achievements 
in our health service but more importantly have a real life impact for patients.
However, the report also shows a number of areas where we could improve. Our national uptake of 
the MMR and Meningitis C vaccines are below target. I am very committed to addressing vaccination 
hesitancy, as it is one of the greatest threats to public health today. The report also shows that 
antibiotics usage in our hospitals remains high.  Using fewer antibiotics will help preserve their 
effectiveness for future generations of patients and consequently tackling antimicrobial resistance 
continues to be a priority for this Government.  One of the new indicators published for the first 
time this year in the NHQRS relates to the chronic usage of benzodiazepine medicines in people 
aged 65 years and older.  The data shows that chronic benzodiazepine usage in Ireland is higher than 
international averages.  Publishing this data in the NHQRS will bring a strong focus to this issue, and 
will be used by the HSE, health professionals and organisations across the health service as a source of 
information to identify examples of good practice which can be replicated with a view to improving the 
safety and quality of our health services.
I appreciate the contributions of all of those involved in this report's development. In particular, I thank 
the patient representatives and the various health care providers and organisations who sit on the 
Governance Committee and Technical Group.  I firmly believe that the transparent and regular reporting 
of information on the performance of our health service, by means of the NHQRS, is essential in 
informing the decisions that service providers, policy makers and the public make about how we design 
and reform our health services to meet the changing needs of our society.
Simon Harris TD
Minister for Health
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               Secretary General's Foreword 
The National Healthcare Quality Reporting System (NHQRS) is a part of the evolution of the Department 
of Health’s patient safety and quality work. This is the fifth annual publication of this report and we 
can now see and reflect on progress in our health system using the data presented in this report and 
previous reports.  
As a publicly available report the NHQRS is important in demonstrating the quality of Irish healthcare to 
people around the country and the world. Objectively evaluating the structures, processes and outcome 
measures of the health service is very important.  Without information and data, there is no reliable 
way to assess how our health service is performing. Understanding data and variation in that data is a 
cornerstone of the science of improvement. The information in this report shows where our service is 
performing well and gives direction on where to target quality improvement efforts. 
The annual NHQRS report has now been published for five annual cycles. I am delighted to see that our 
mortality rates for stroke and heart attacks are better than OECD averages and have been declining for 
several years now. This indicates that we are performing well in these areas.  Encouragingly, heart failure 
and asthma hospitalisation rates have also been falling for the past number of years.  
The report also shows areas where there is room for improvement. It is disappointing that national 
influenza vaccination rates for both those over 65 years and for healthcare workers are not reaching 
our target rate. Our hospitalisation rates for COPD continue to show scope for major improvement. The 
number of Caesarean sections continues to increase and is deviating further from the OECD average 
rate. Use of benzodiazepine medicines in those over 65 years of age, particularly in women, is higher 
than known international averages. While the causes for these gaps are undoubtedly multifactorial, this 
report serves to highlight them to healthcare providers and policy makers. 
The publication of this report is not the end of this process. Quality improvement must be continuous 
and requires the engagement of everyone within the health service.  This report is a tool for health 
service providers and policy makers to evaluate their services systematically and inform quality 
improvement initiatives. The insights that this report provides should be used constructively to improve 
our health services year on year. This is especially important as we move towards a more integrated 
health system, as envisioned under Sláintecare; one that is better designed to address the weaknesses 
identified in this report. 
The development of this publication is coordinated by the Patient Safety Surveillance Unit in the National 
Patient Safety Office in collaboration with the Statistics and Analytics Unit in the Department of Health. 
I thank the Governance Committee and the Technical Group for their time and efforts in developing this 
year’s report. The Department of Health looks forward to working in partnership with the members of 
these groups in the years to come as the report continues to describe the quality of our health service. 
Jim Breslin 
Secretary General
Department of Health 
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Executive Summary
This reports publicly gives information on a broad range of measures of health service structures, 
processes and outcomes.  with the purpose of providing a means of comparison against international 
data and internationally accepted best practice. It allows data on the health service to be transparently 
shared with patients, service providers and policy makers. 
The National Healthcare Quality Reporting System (NHQRS) aims to provide a mechanism through which 
data about the quality of Ireland's healthcare structures, processes and outcomes can be made publicly 
available so that this data may be compared against accepted standards or best practices. The reporting 
of performance and outcome indicators is designed to enable policy makers and service providers 
to improve the quality of health service provision. Indicators are presented to allow for comparisons 
between regions, nationally, internationally and over time. 
When examining a data report, variation as compared to other regions or previous years will become 
apparent. While it is universally acknowledged that variation in data can be attributed to differences in 
recording practices, the use of different definitions or even sheer chance, the data and variation should 
be used by service providers and policy makers to inform our strategies to improve healthcare. 
The NHQRS has evolved over time, including additional indicators as datasets within the Irish health 
service mature and become available. Annually, the NHQRS Governance Committee and Technical 
Group engage in an exercise deigned to ensure the validity, timeliness and accuracy of indicator data. 
This year's report includes 38 indicators of performance across five key domains. 
We can see improvements in hospitalisation rates for chronic conditions such as asthma and heart 
failure. We have also met our national targets for bowel cancer screening and time to surgery for 
patients who have broken their hips.  Our mortality rates for heart attack and stroke continue to fall and 
are the best we have seen in ten years. Significant improvements have also been seen in our cancer 
screening and treatment and we are on par with international averages. Our management of healthcare 
associated infections is improving. This is good news, as it will help preserve the effectiveness of 
antibiotics for future generations of patients. 84% of patients reported that they felt they were definitely 
treated with dignity and respect during their stay in hospital. 
There is also room for improvement in some areas. The flu vaccine uptake for our population aged over 
65 years has not yet achieved the target rate. Our caesarean section rates continues to rise year on year 
and is above the OECD average. Our national chronic use of benzodiazepine medications in people aged 
65 years and older in the community is high compared with international averages and we can see that 
more women than men are taking them. Our antibiotic use in hospitals continues to rise. Many patients 
reported that they did not feel they received the emotional support they needed while being cared for in 
our hospitals. 
This fifth annual report continues the development of the NHQRS as a national public reporting system 
which focuses on the quality of care provided by our health services. This year four indicators were 
added for the first time or changed in the way they were presented. These included indicators in the 
areas of cancer survival rates, medication safety and healthcare associated infections. 
The challenge for the audiences of this report is to ensure that the information presented here is used to 
improve the quality of our health service. 
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Glossary
ACS acute coronary syndrome
Age-sex  This allows the rate of an event in one hospital or country to be compared against the
standardised  rate for that event in another hospital or country. It is the rate of hospitalisation
rate (ASR) for a particular condition, taking into account differences in age and sex.
AMI acute myocardial infarction Arrhythmia: abnormal heart rhythm 
CDI Clostridium difficile infection
C. difficile Clostridium difficile
CHO  Community Healthcare Organisation
CIDR  Computerised Infectious Disease Reporting
CMO  Chief Medical Officer
Co-morbidities  When there are two or more diseases existing at the same time in the body
COPD  chronic obstructive pulmonary disease
CPE carbapenemase-producing Enterobacteriaceae
DCIS ductal carcinoma in-situ
DDD Defined Daily Dose
DID Defined Daily Dose per 1000 inhabitants per day
Domain a subset area of healthcare
EARS-net European Antimicrobial Resistance Surveillance Network
GP general practitioner
HCAI Health Care Associated Infection
HIPE Hospital In-Patient Enquiry – A database that collects clinical and administrative     
 information on patients each time they are discharged from a public hospital in Ireland.
HIQA Health Information and Quality Authority
HPO Healthcare Pricing Office
HPSC Health Protection Surveillance Centre
HPV human papilloma virus
HSE Health Service Executive
ICD-9-CM The International Classification of Diseases, Ninth Revision, Clinical Modification. 
 A system of assigning codes to diagnoses and procedure
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ICD-10-AM/ International Statistical Classification of Diseases and Related Health Problems, 
ACHI Tenth Revision - Australian Modification and the Australian Classification of    
 Health  Interventions. Classification systems that allows all medical conditions 
 and procedures to be assigned clinical codes.
KPI key performance indicator
MenC a vaccine against meningococcal subgroup C infection
MMR a vaccine against measles, mumps and rubella infections 
Morbidity illness related to a specific condition or disease 
Mortality death related to a specific condition or disease
MRSA methicillin-resistant Staphylococcus aureus 
NCEC National Clinical Effectiveness Committee 
NCRI National Cancer Registry Ireland
NHS National Health Service
NHQRS National Healthcare Quality Reporting System
NPES National Patient Experience Survey
NPSO National Patient Safety Office
NPRS National Perinatal Reporting System
OECD Organisation for Economic Co-operation and Development. A group of 34    
 countries that compares how each one is performing in areas such as health,    
 employment and education.
PCRS Primary Care Reimbursement Service.
Prevalence The proportion of the population who have a specific illness in a given time period.
Principal diagnosis The diagnosis established after assessment to be chiefly responsible for    
 occasioning the episode of admitted patient care.
S. aureus Staphylococcus aureus
Statistically  A result is said to be statistically significant when the chance of it being true is   
significant equal to or greater than 95 per cent.
STEMI ST elevation myocardial infarction
WHO World Health Organisation
95% Confidence  When a result has a high and low range attached, this range is called a confidence
Interval  interval. There is a 95 per cent chance that the real result lies within this high and  
 low range.
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Chapter 1: The National Healthcare 
Quality Reporting System
This is the fifth annual report of the National Healthcare Quality Reporting System (NHQRS). This report 
makes publicly available information on the quality and safety of healthcare across the Irish health system. Its 
focus is on a balanced set of healthcare data that gives an overview of how our health service is performing 
compared to international health systems. This framework has built over time and it is acknowledged that 
future editions will continue to incorporate measures of quality in the community and pre-hospital settings, 
as reliable and valid data becomes available.
The NHQRS provides the basis for a very important public discussion about the quality of health services 
in Ireland. It seeks to provide information of value to those who use our health services, work in our health 
services and to those who are tasked with developing health policy which aims to improve the quality of those 
services.
Previous years’ reports are available to read, download and print from the Department of Health’s website:  
https://health.gov.ie/national-patient-safety-office/patient-safety-surveillance/national-healthcare-quality-
reporting-system/
Background
To provide high quality safe care to patients, health services need to measure and monitor the quality of that 
care. Health services need to learn from practices of good quality care and improve quality if it falls below the 
expectations of patients, the public, policy makers and the service providers themselves. A number of countries 
have developed and put in place systems or frameworks to drive improvements in the quality and safety of 
healthcare. These systems are used to collect the required information to measure, monitor and publicly report 
on the performance of their health services. It is recognised that in healthcare, as in other areas, it is difficult to 
improve what cannot be, or is not, measured [1].
The importance of measuring and comparing performance in delivering quality healthcare outcomes between 
countries has also been recognised and facilitated by the establishment of international quality reporting 
systems, including the Organisation for Economic Co-operation and Development (OECD) Health Care 
Quality Indicators. These systems allow for the measurement, monitoring and public reporting of the quality 
of healthcare at regional, national and international level. They empower patients and service users to make 
informed decisions about their healthcare, facilitate healthcare providers to improve their performance 
through benchmarking with other services, and they enable system-wide quality improvement by informing 
national policies.
In Ireland, significant amounts of health data are collected through a number of health information systems 
including the Hospital Inpatient Enquiry System (HIPE), the National Cancer Registry of Ireland (NCRI), the 
National Screening Service, Immunisation Uptake Statistics, Primary Care Reimbursement Service (PCRS) 
and the Computerised Infectious Disease Reporting (CIDR) system. Information on how patients experience 
healthcare in acute hospital settings is now collected through the National Patient Experience Survey (NPES), 
which is planned to be expanded to include other healthcare settings including maternity services in future 
survey cycles. These information sources are used in various ways to measure, monitor and report on many 
healthcare related activities and outcomes.
The primary objective of the NHQRS is to provide publicly available information on the quality of 
healthcare. This in turn should inform and support decision-making by patients, policy makers and 
service providers.
14
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The Department of Health, with the establishment of the NHQRS, is committed to public reporting of 
information on the quality and safety of healthcare in Ireland. This is based on a commitment to openness, 
transparency, improving accountability within the health system and on an understanding that such public 
reporting of information on performance will help drive improvements in the quality of the care delivered. 
NHQRS monitoring and reporting
Monitoring the quality of healthcare includes measuring the performance of a service against a standard 
or expected level of performance. A reporting framework for the NHQRS has been developed that sets 
out in subsets (domains) the high level, patient-focused outcomes that a high quality healthcare service 
should achieve. The selected indicators in these domains measure an aspect of care that contributes to the 
achievement of the domain. It is accepted that performance measurement contributes to improving the 
quality of healthcare.
Users of This Report
Patients and the public can use this report to access health information about their county, their local health 
services, and the hospitals they attend. The report aims to present the information in user-friendly language. 
However, it is recognised that the language reflects the healthcare services being reviewed and therefore, 
it is not always possible to use language that is free from technical terms. An infographic accompanies the 
publication of this annual report with the aim of increasing interest in and understanding of the information 
contained in this report.
Health service providers should use this report to examine how their organisation or service is performing and 
allows comparison to other similar services. They should use this information in conjunction with other audit 
tools to assess their services’ performance against that of similar services. This report should enable services 
to recognise areas of good practice and identify areas in need of quality improvement. To allow for comparison 
between similar services, information in this report is presented at regional, local health area, hospital group, 
hospital level and internationally where possible. This should assist health service providers in focusing on key 
areas where enhanced outcomes can be achieved. Reducing variation in healthcare provision has been shown 
to improve quality and safety. Therefore, healthcare providers should strive to reduce variability in practice in 
order to standardise care across the country. 
Policy makers should use this report to compare performance of Irish health services with health services in 
other countries. The indicators are presented at national level with comparisons with international measures 
wherever this information is available. This intelligence should be used to plan, monitor and drive service 
improvement at all levels within our healthcare system. Importantly, this information should also be used to 
support evidence-based policy making.
The information provided in this report should be reviewed and examined by those tasked 
with the planning and delivery of healthcare; and/or the development of health policy locally, 
regionally and nationally. This information is important to ensure safe quality healthcare in Ireland 
through a process of systematic, continuous quality improvement.
15
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Intended Use of This Report
The indicators selected for this fourth annual report reflect on the quality and performance of services across 
the health system but it is important that what they tell us is not over interpreted. Differences can arise for 
a number of reasons. For example, issues like the quality of the data collected, differences due to patients 
attending one service being more unwell with more complex needs than those attending other services, or 
differences related to the quality of the service provided.
It is also important to remember that one indicator alone should not be used to measure whether an 
organisation or service is safe and providing quality care. A single measure or indicator cannot capture all 
aspects of the quality of the healthcare provided. Therefore, indicators should not be used in isolation but 
rather used with other information to assess the quality of care being provided by a service or organisation.
To allow for international comparisons, the findings for all of the indicators are presented at national level and 
compared, where relevant and available, with international findings. For many of the indicators this means 
comparison with other countries in the Organisation for Economic Cooperation and Development (OECD)`or 
other international patient surveys. Here it is also important to point out that there may be variation between 
countries in their coding practices, in the definitions used, and in the disease classification systems used. 
These differences may affect data comparability between countries. For example, Ireland uses the disease 
classification system ICD-10-AM/ACHI whereas many other countries use ICD-9-based classifications.
NHQRS Governance
The NHQRS and its governance structure is based in the National Patient Safety Office (NPSO) in the 
Department for Health. In 2016, a multi-agency committee was re-established to provide oversight and advice 
on the strategic direction of the NHQRS; to agree the selected indicators in line with international trends and 
health policy in Ireland; to agree definitions and metadata for the indicators; and to prepare and present an 
annual report to the Minister for Health. Committee members facilitate communication between their own 
organisations in relation to the NHQRS processes and the annual report.
The membership of this governance committee is set out in appendix 1. The committee is supported by a 
technical group (see appendix 2). The role of the technical group is to provide expertise and experience in 
measuring and monitoring the quality of healthcare using performance measures or indicators. Secretariat 
to both governance committee and technical group is provided by the Patient Safety Surveillance Unit in the 
NPSO.
The appropriate response to any reported differences in indicators is for service providers to further 
examine and to explain the positive and negative findings. This will necessitate more in-depth 
analysis and evaluation, which may include consideration of other sources of local data. Following 
this, follow up actions as appropriate should to be taken.
The collection of data is not an endpoint. It is important that the surveillance of patient safety 
profiles for patients, services and clinical cohorts is part of the cyclical quality improvement 
process and overall approach to patient safety and quality care.
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Indicators are generally used to describe measurement relating to healthcare system performance. For 
example: the Canadian Institute for Health Information (CIHI) define a health indicator as “a single measure 
that is reported on regularly and that provides relevant and actionable information about population health 
and/or health system performance and characteristics” [2].
A number of international health indicator frameworks are based around different themes or domains and 
often contain domains relating to healthcare quality, sometimes with subdomains and/or themes. Examples 
of terms used to describe these domains and/or themes are: healthcare system performance, access to 
care, patient safety, quality of care, appropriateness and effectiveness, efficiency, person-centeredness, 
responsiveness.
In the NHQRS, the Irish health indicator framework, it is important to describe high level, patient focused 
outcomes that a high-quality healthcare service should deliver. These outcomes are described as quality 
domains. These domains and dimensions of quality are informed by international evidence of what quality 
healthcare looks like, as well as the description given in the HIQA National Standards for Safer Better 
Healthcare 2012 [3].
The NHQRS five domains and indicators were informed by outcomes used in reporting systems in other 
jurisdictions including the National Health Service (NHS) Outcomes Framework [4], the Agency for Healthcare 
Research and Quality (AHRQ) [5], the Swedish Regional Comparisons [6], and also the OECD framework for 
health system performance assessment [7].
Domains of the National Healthcare Quality Reporting System
Domain 1: Helping people to stay healthy and well
Domain 2: Supporting people with long term conditions
Domain 3: Helping people when they are being treated and cared for in our health services
Domain 4: Supporting people to have positive experiences of healthcare
Domain 5: Treating and caring for people in a safe environment
An indicator is a measurement or value of something. It is often used with the prefix performance, 
quality or health. An indicator can provide comparable information, as well as track progress and 
performance over time. 
17
Chapter 2: National Healthcare 
Quality Reporting Framework
NHQRS Annual Report 2019
Evaluation and Selection of Indicators
To safeguard the integrity and validity of the NHQRS, the committee agreed a procedure for the selection 
of new indicators for inclusion in this report. In addition, a transparent annual screening exercise facilitates 
consideration of those indicators to be retained or de-selected in future editions of the NHQRS. This 
exercise will allow for the identification of gaps and will ensure that the NHQRS reflects developments in our 
health system over time.
The criteria for the inclusion of indicators for the 2019 annual report were:
• a focus on patient outcomes, patient safety and patient care
• availability of data in the Irish health system
• alignment to international indicators to allow for international comparison
• face validity of each indicator, i.e. sound clinical or scientific rationale for its use and measurement 
 of an important aspect of quality that may be within the control of the provider or healthcare system
• importance to patients
• contribution to service improvement and cost efficiencies
• alignment with the domains of the NHQRS framework
• alignment with current/future policy on health and healthcare in Ireland.
In addition, each year all indicators are evaluated for the quality of the data available. This evaluation process 
is informed by HIQA's Guidance on a data quality framework for health and social care. 
Domains and indicators
It must be acknowledged that the NHQRS will evolve over time as more high quality information is collected 
and as it becomes more embedded in the health system. So too, it is envisaged that the number and type of 
indicators selected will continuously evolve. The 38 included indicators are grouped under 5 quality domains 
as shown in Table 1.
The indicator: Primary percutaneous coronary intervention for acute myocardial infarction/heart attack 
was flagged for inclusion in 2016, but was withdrawn from Domain 4: Supporting people to have positive 
experiences of healthcare after the annual screening exercise as the data is not available from HIPE. 
Following the evaluation and selection process, new indicators were selected or changed under the following 
domains:
Domain 3: 
• Lung cancer survival rates 
Domain 5 
• Staphylococcal aureus and Methicillin resistant Staphylococcal aureus (MRSA) blood stream infection rates
• Carbapenemase-producing Enterobacteriales
• Chronic benzodiazepine usage in the community in people aged 65 years and over
18
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Domain Indicator
1. 
Helping people to 
stay healthy and well
Immunisation rates
• Immunisation rate for measles, mumps, rubella (MMR) vaccine
• Immunisation rate for meningitis C (MenC) vaccine
• Immunisation rate against influenza for persons aged 65 and older
• Immunisation rate against influenza among healthcare workers in hospitals
• Immunisation rate for human papillomavirus (HPV) vaccine
Cancer screening rates
• Screening rate for breast cancer
• Screening rate for cervical cancer
• Screening rate for colorectal cancer 
2.
Supporting people with 
long term conditions
Ambulatory care sensitive conditions
• Chronic obstructive pulmonary disease (COPD) hospitalisation rates
• Asthma hospitalisation rates
• Diabetes hospitalisation rates
• Heart failure hospitalisation rates
3.
Helping people when they are 
being treated and cared for in 
our health services
Cancer survival rates
• Breast cancer survival rates
• Cervical cancer survival rates
• Colorectal cancer survival rates
• Lung cancer survival rates
Cancer surgery
• Breast cancer surgical activity
• Colon cancer surgical activity
• Rectal cancer surgical activity
Acute hospital care
• In-hospital mortality within 30 days of admission for acute myocardial infarction  
(AMI)/heart attack
• Stroke admissions to hospitals with stroke units
• In-hospital mortality within 30 days of admission for haemorrhagic stroke
• In-hospital mortality within 30 days of admission for ischaemic stroke
• In-hospital waiting time for hip fracture surgery
• Caesarean section rates
4.
Supporting people to have 
positive experiences of 
healthcare
National Patient Experience Survey 
• Overall rating of experience
• Communication in emergency department 
• Pain control on the ward 
• Emotional support provided on the ward 
• Patient involvement in decision making regarding care 
• Communication regarding continuing medicines at patient discharge 
• Dignity and respect while in hospital  
5.
Treating and caring for people 
in a safe environment
Healthcare associated infection rates
• Staphylococcal aureus and Methicillin resistant Staphylococcal aureus (MRSA) blood 
    stream infection rates
• Clostridium Difficile (C. difficile) rates
• Carbapenemase-producing Enterobacteriales
Antibiotic consumption rates
• Antibiotic consumption in the community
• Antibiotic consumption in public acute hospitals
Medication Safety 
• Chronic benzodiazepine usage in the community in people aged 65 years and over
Table 1: Indicators in the Annual Report
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Indicators HPSC OECD NSS HIPE NCRI NPRS EARS-Net
EARC-
Net NPES PCRS
 
Immunisation rate for MMR vaccine �
Immunisation rate for MenC vaccine �
Immunisation rate against influenza for 
persons aged 65 and older
� �
Immunisation rate against influenza 
among healthcare workers in hospitals
�
Immunisation rate for human 
papillomavirus (HPV) vaccine
�
Screening rate for breast cancer � �
Screening rate for cervical cancer � �
Screening rate for colorectal cancer � �
COPD hospitalisation rates � �
Asthma hospitalisation rates � �
Diabetes hospitalisation rates � �
Heart failure hospitalisation rates � �
Breast cancer survival rates � �
Cervical cancer survival rates � �
Colorectal cancer survival rates � �
Lung cancer survival rates � �
Breast cancer surgical activity �
Colon cancer surgical activity �
Rectal cancer surgical activity �
In-hospital mortality within 30 days of 
admission for AMI
� �
Stroke admissions to hospitals with 
stroke units
�
In-hospital mortality within 30 days of 
admission for haemorrhagic stroke
� �
In-hospital mortality within 30 days of 
admission for ischaemic stroke
� �
In-hospital waiting time for hip fracture 
surgery
� �
Caesarean section rates � � �
Table 2: Indicators by domain and their data sources
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Indicators HPSC OECD NSS HIPE NCRI NPRS EARS-Net
EARC-
Net NPES PCRS
 
Overall Rating of Experience �
Patient Involvement in Decision 
Making regarding Care
�
Emotional Support Provided on the 
Ward
�
Pain Control on the Ward �
Communication regarding Continuing 
Medicines at Patient Discharge
�
Dignity and Respect while in Hospital �
Communication in Emergency 
Department
�
Methicillin-resistant Staphylococcal 
Aureus (MRSA) rates � �
Clostridium Difficile (C. difficile) rates �
Carbapenemase-producing
Enterobacteriales �
Antibiotic consumption in the 
community
� �
Antibiotic consumption in public acute 
hospitals
�
Chronic benzodiazepine usage in the
community in people aged 65 years 
and over 
� �
Sources of data
The analysis and commentary presented in this report was carried out by the Department of Health with 
assistance from various agencies. Data was accessed through the following sources and Table 2 also refers:
National Screening Service (NSS)
The NSS encompasses BreastCheck - The National Breast Screening Programme, CervicalCheck - The National 
Cervical Screening Programme, BowelScreen – The National Bowel Screening Programme and Diabetic 
RetinaScreen – The National Diabetic Retinal Screening Programme.
National Cancer Registry of Ireland (NCRI)
The NCRI is a publicly appointed body, established to collect and classify information on all cancer cases which 
occur in Ireland.
Health Protection Surveillance Centre (HPSC)
The HPSC is Ireland’s specialist agency for the surveillance of communicable diseases. This involves collecting 
data, collating it, analysing it and communicating information to those who need to know.
National Perinatal Reporting System (NPRS) managed by the Healthcare Pricing Office
The NPRS is the principal source of national data on perinatal events. Information on every birth in the Republic 
of Ireland is submitted to the NPRS by trained hospital administrative staff and all practicing independent 
midwives. The time frame to which the information relates is from 22 weeks gestation to the first week of life.
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Hospital In-Patient Enquiry (HIPE) managed by the Healthcare Pricing Office
The HIPE database collects clinical and administrative information on patients each time they are discharged 
from a public hospital in Ireland. Each HIPE discharge record represents one episode of care and patients 
may have been admitted to more than one hospital with the same or different diagnoses. In the absence of a 
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather than incidence of 
disease.
OECD Health Statistics
The OECD Health Database offers the most comprehensive source of comparable statistics on health and 
health systems across OECD countries. It is used to carry out comparative analyses and draw lessons from 
international comparisons of diverse health systems.
The European Antimicrobial Resistance Surveillance Network (EARS-Net)
EARS-Net is the largest publicly funded system for antimicrobial resistance (AMR) surveillance in Europe. 
Data from EARS-Net plays an important role in raising awareness at the political level, among public health 
officials, in the scientific community and among the general public. It is managed and coordinated by the 
European Centre for Disease Prevention and Control (ECDC).
The European Surveillance of Antimicrobial Consumption Network (ESAC-Net)
ESAC-Net is a Europe-wide network of national surveillance systems, providing European reference data on 
antimicrobial consumption. ESAC-Net collects and analyses data on antimicrobial consumption from EU and 
EEA/EFTA countries, both in the community and in the hospital sector. It is managed and coordinated by the 
European Centre for Disease Prevention and Control (ECDC).
National Patient Experience Survey 
The National Patient Experience Survey is a nationwide survey asking adult patients for feedback about their 
stay in acute hospital. The survey is a partnership between the Health Information and Quality Authority 
(HIQA), the Health Service Executive (HSE) and the Department of Health.
Primary Care Reimbursement Service (PCRS)
The PCRS is part of the HSE, and is responsible for making payments to healthcare professionals, like GPs, 
dentists and pharmacists, for the free or reduced costs services they provide to the public. In addition to the 
processing and making of payments on a national basis to key customers, the PCRS compiles statistics and 
trend analyses which are provided to other areas within the HSE, the Government, customers, stakeholders 
and to members of the public.
Presentation and analysis of data
Each of the indicators included in this report sets out to provide certain information. The indicators are 
presented as a national trend, usually as a ten year trend where possible. This gives a sense of the national 
picture. The source of data and information for each of the indicators is provided. Where the data is available, 
the indicators are also presented at regional and/or local and, where appropriate, hospital level, to give a clear 
picture of regional and local variation.
Data is presented by HSE Area of Residence, Local Health Office or Community Health Organisation (CHO) 
for a number of indicators. It should be noted that the Local Health Office structure was replaced in 2014 by 
nine Community Healthcare Organisations (CHOs). Wherever possible, information using both geographic 
groupings has been used. 
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It should be noted that for the mortality indicator (heart attack and stroke) age and sex were taken into 
account in the analysis so that they can be compared with the national average. As part of this age-sex 
standardisation adjustment, 95% confidence limits were calculated. If these resulting confidence intervals are 
outside the expected range, they are statistically significantly different and this requires further exploration to 
determine the reason behind this variation. 
The OECD uses the direct standardised death rate as the basis for its methodological approach. The reference 
population is based on the age and gender profile of the OECD 2010 population admitted to hospital with 
selected conditions. This allows direct comparison between OECD member states and is of greatest value 
when used to compare practice across international boundaries. The same methodological approach is taken 
in this report and this allows for the comparison of individual indicators between Ireland and other OECD 
countries.
An alternative method which can be used in the analysis of in-hospital mortality is the standardised mortality 
ratio (SMR), an approach which allows for adjustment for differences in population characteristics. This 
methodology is used in the National Audit of Hospital Mortality report produced by the National Office 
of Clinical Audit (NOCA), where adjustment is made for 8 variables (age, sex, pre-existing illness, previous 
emergency admission within 12 months, source of admission, type of admission, in-hospital palliative care and 
deprivation indicator (defined as access of services via the General Medical Services (GMS) Scheme, also known 
as the medical card)). A key difference between this methodology and that used in this report is that the SMR 
allows individual hospitals to compare their observed deaths against the deaths that would be expected in that 
hospital when those variables affecting mortality are taken into consideration. Standardised mortality ratios 
do not allow comparisons to be made between hospitals as no two hospitals will have the same patient profile. 
However, they do allow for hospitals, irrespective of their size, to be standardised to allow comparison against 
a national average. Due to the differences in methodology it is not possible to compare in-hospital mortality 
indicators in the NHQRS against those reported in the NOCA National Audit of Hospital Mortality Report. Both 
should be used by health service providers to assess the quality of care provided within that service. 
 
Additional technical information is presented in the metadata sheets. These present information about each 
indicator in tabular standardised format. Readers may refer there for more detailed definition, methodology 
and notes as relevant. The relevant National Clinical Programmes and data providers were contacted during 
the preparation of this report. The contribution from the various agencies has proven invaluable in defining 
the purpose of, and context for, the information included. This allows for better understanding of the data and 
should ensure responsible use of the information.
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The fact that a rate is statistically significantly different does not necessarily mean that there is a 
difference in the quality of care provided, either good or bad. Rather, it indicates that the rate is 
different from what would have been expected and the reasons for this should be examined further 
by those tasked with providing that health service. 
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Domain 1:
Helping people to
stay healthy and well
Immunisation rates:
-  Immunisation rate for MMR vaccine 27
-  Immunisation rate for Men C vaccine 30
-  Immunisation rate against influenza  
 for persons aged 65 years or older 33
-  Immunisation rate against influenza
 among healthcare workers in hospitals 35
-  Immunisation rate for human 
 papillomavirus (HPV) vaccine 39
Cancer screening rates:
-  Screening uptake rate for breast cancer 43
-  Screening uptake rate for cervical cancer 47
-  Screening uptake rate for colorectal cancer 51
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Overview of selected indicators
There are 8 indicators in this domain in the following 2 areas:
• Immunisation rates
• Cancer screening rates
Immunisation rates
Immunisation (getting a vaccine and becoming immune) 
is a simple and safe way of protecting people against 
harmful or communicable diseases such as meningitis, 
measles, mumps and rubella and influenza. These 
serious illnesses can have complications such as long-
term disability and death. The WHO estimates that 2 
to 3 million deaths are prevented every year through 
immunisation. Nonetheless, the WHO also estimates 
that vaccine preventable diseases are still responsible 
for 1.5 million deaths each year (1).
Vaccines not only protect those who receive them 
but can also protect against disease among other 
individuals in the community who may be too young or 
too sick to receive the vaccines. This is known as ‘herd 
immunity’ or ‘herd protection’. Many countries including 
Ireland have introduced immunisation programmes for 
their populations. This report focuses on two of the 
childhood vaccines, MMR (measles, mumps and rubella) 
and MenC (meningococcal C), as well as vaccination 
against seasonal influenza and the human papilloma 
virus (HPV).
Vaccination programmes are one measure used for 
prevention of infection. This in turn reduces the 
need for antibiotics to treat infection. Vaccination 
is recognised under Strategic Interventions 3.4 of 
iNAP, Ireland’s National Action Plan on Antimicrobial 
Resistance 2017 – 2020. 
All medical practitioners, including clinical directors 
of diagnostic laboratories, are required to notify the 
Medical Officer of Health (MOH)/Director of Public 
Health (DPH) of certain diseases. This information 
is used to investigate cases with the purpose of 
preventing the spread of infection and development of 
further cases. This information can also facilitate the 
early identification of outbreaks. Lastly, it is also used to 
monitor the burden and pattern of diseases, which can 
provide the evidence for public health interventions. 
Measles, mumps, rubella and influenza are all notifiable.
The indicators for immunisations are:
• Immunisation rate for MMR vaccine
• Immunisation rate for MenC vaccine
• Immunisation rate for influenza for persons aged 65 
and older
• Immunisation rate for influenza among healthcare 
workers in hospitals
• Immunisation rate for human papillomavirus (HPV) 
vaccine.
Cancer screening rates
The National Screening Service (NSS) 
was established in January 2007. The 
NSS encompasses BreastCheck - The 
National Breast Screening Programme, 
CervicalCheck - The National Cervical 
Screening Programme, BowelScreen – 
The National Bowel Screening Programme 
and Diabetic RetinaScreen – The National 
Diabetic Retinal Screening Programme. 
Screening for cancer helps prevent 
significant illness and death by detecting 
cancer at an earlier and therefore, more 
treatable stage. Screening is different 
from most other forms of healthcare 
and there is often uncertainty about its 
purpose. Screening is not a diagnostic 
tool; its purpose is risk reduction. Cancer 
screening uptake rates are an important 
measure of the performance and quality 
of preventative services and early 
detection. Public reporting of these rates 
also increases awareness and knowledge 
of these cancers in the population.
In this report the cancer screening rates 
for breast, cervical and colorectal cancers 
are included as a reflection of the quality 
of preventative services available in 
Ireland.
The importance of screening is recognised 
in Ireland’s National Cancer Strategy 
2017 – 2026, specifically Chapter 6 and 
Recommendations 5 and 6, which aim to 
enhance current screening services.
The indicators for cancer screening are:
• Screening rate for breast cancer
• Screening rate for cervical cancer
• Screening rate for colorectal cancer. 
26
NHQRS Annual Report 2019
D
O
M
A
IN
 1: IM
M
U
N
ISATIO
N
 R
ATES
Immunisation rate for MMR vaccine
Definition
Percentage of children who have received the one dose of the MMR (measles, mumps and rubella) vaccine at 
24 months of age.
Description
The MMR vaccine protects people against measles, mumps and rubella (also called German measles). These 
are highly infectious, viral childhood diseases, which can result in serious complications and even death. Prior 
to the introduction of vaccine programmes they commonly caused illness in children.
Two doses of the MMR vaccine are given in Ireland. The first dose is given at 12 months of age and the 
second dose is given at 4 to 5 years of age (2). In recent years, an anti-vaccine campaign has been covered 
in the media. Although, the safety of vaccines has been established in a large number of peer-reviewed, 
academic studies, there are still population groups that are not reaching the vaccination rate required for 
community protection or ‘herd immunity’. In 2018, an outbreak of measles affected at least 85 people across 
Ireland; of those who were eligible for vaccination (all of those 12 months of age or older), 72% had not been 
vaccinated (3). Measles outbreaks were reported in a number of European countries including Romania, Italy, 
France and Greece in 2018 (4).
The national vaccination rate for MMR over the last ten years and the regional vaccination rates are presented 
in this report. In Ireland, the national target for MMR vaccine uptake is 95% which is in line with international 
and European targets. Ireland has made progress to meet the European target for measles elimination (<1 case 
per million) in recent years. But the threat of outbreaks persists as long as there are immunity gaps within the 
population.
Rationale for the inclusion of indicator 
Over 12,000 cases of measles were reported in Europe in 2017 (4).
The number of identified cases of measles has been increasing in recent years. Ireland has experienced 
a number of regional outbreaks since 2016. As of June 2019, 60 cases have been identified in 2019, as 
compared to 76 for the year 2018. 
 
Notes on Measurement Changes for the MMR Vaccine
Please note that the map presented in previous NHQRS reports presented MMR immunisation rates by local 
health office. This information is still available in the Table 3. The map is now presented on community health 
organisation basis.
Commentary 
• The national immunisation uptake of MMR for children at 24 months of age from 2009 to 2018. Although 
the national target of 95% has not been achieved, the national immunisation rate increased over the ten 
year period by 3%, from 89% in 2008 to 92% in 2017. 
• For 2016, 2017 and 2018 the MMR vaccine uptake rate remained static at 92%. This requires ongoing 
review to ensure vaccine confidence is maintained.
• While most Community Health Organisations were close to meeting the target, no CHO met the target in 
2018. The Local Health Office with the highest uptake was Roscommon (96%) and the lowest uptake was in 
Wicklow (84%). In total, only 9 of 32 local health offices met the 95% target. 
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Figure 1: Immunisation rate for MMR for children at 24 months, percentage uptake, 2009 – 2018
Figure 2: Immunisation rate for MMR for children at 24 months by Community Health Organisation, 2018
Source: Health Protection Surveillance Centre (HPSC)
Notes: 
(i) The data for 2009 and 2010 are incomplete as data for some regions were unavailable.
(ii) The immunisation uptake data above relate to children who have reached their second birthday and have received one 
dose of the vaccine
Source: Health Protection Surveillance Centre (HPSC)
Note: 
(i) The immunisation uptake data above relate to children who have reached their second birthday and have received one 
dose of the vaccine. 
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The target for MMR immunisation rates for children at 24 months is 95%.
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Table 3: Immunisation rate for MMR for children at 24 months by Local Health Office and Community 
Health Organisation, 2018 
Source: Health Protection Surveillance Centre (HPSC)
Notes: 
i. 2018 data for Louth and Meath not available. 2017 figures used here  
ii. Due to incomplete data coverage, the national average is based on data from the first three quarters of 2018.   
iii. The immunisation uptake data above relate to children who have reached their second birthday and have received one 
dose of the vaccine.
Community Health Organisation Local Health Office MMR Uptake Rate 2018 %
CHO 1
Cavan/Monaghan 92
Donegal 89
Sligo/Leitrim 95
CHO 1 Total 92
CHO 2
Galway 95
Mayo 92
Roscommon 96
CHO 2 Total 94
CHO 3
Clare 94
Limerick 91
Tipperary NR/East Limerick 95
CHO 3 Total 93
CHO 4
North Cork 94
North South Lee 93
West Cork 90
Kerry 91
CHO 4 Total 92
CHO 5
Carlow/Kilkenny 92
South Tipperary 95
Waterford 93
Wexford 93
CHO 5 Total 93
CHO 6
Dublin South 92
Dublin South East 93
Wicklow 84
CHO 6 Total 89
CHO 7
Dublin South City 89
Dublin South West 95
Dublin West 87
Kildare/West Wicklow 92
CHO 7 Total 91
CHO 8
Laois/Offaly 94
Longford/Westmeath 95
Louthi 90
Meathi 90
CHO 8 Total 92
CHO 9
Dublin North West 95
Dublin North Central 95
Dublin North 89
CHO 9 Total 93
National Average 92
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Immunisation rate for Meningococcal C Vaccine
Definition
Percentage of children who have received two doses of the Meningococcal C (MenC) vaccine by 24 months of 
age.
Description
Meningococcal bacteria can cause meningitis, septicaemia (also known as “bloodstream infection”) or both. 
The disease can cause death or serious disability such as deafness, brain damage, or loss of limbs.
Meningococcal C (‘MenC’) is one of several different types of meningococcal bacteria.
As of July 2015, the current recommended schedule has changed to 2 doses of MenC vaccine at 4 months 
and 13 months with a further booster in first year of second level school (age 12-13 years) (5). The national 
target for uptake of the three doses is 95%, which is in line with international targets.
Rationale for inclusion of indicator
MenC was responsible for about 30% of cases of meningitis/septicaemia prior to the introduction of the 
MenC vaccine in 2000. 
Notes of Changes for the Meningococcal C Vaccine
Up to July 2015 the vaccine schedule for babies in Ireland consisted of three doses of MenC vaccine at 4 
months, 6 months and 13 months of age [11]. The updated recommended schedule has changed to 2 doses 
of MenC vaccine at 4 months and 13 months with a further booster in first year of second level school (age 
12-13 years)
Please note in previous NHQRS Reports, the map presented for this indicator was presented MenC 
immunisation rates by local health office. This information is still available in the Table 4. The map is now 
presented on community health organisation basis.
Commentary
• Although national uptake rates increased to a peak of 93% in 2009 this was not sustained and the national 
immunisation rate for the third dose of MenC vaccine decreased from 2009 to 2015. After the vaccine 
schedule was changes, the vaccination uptake rate has been between 87% and 89%. 2018 saw the highest 
uptake rate since this schedule change took place from 93% in 2009 to 89% in 2018. The 85% in 2018 is 
the highest rate seen since 2009. 
• In July 2008, the childhood immunisation schedule was changed resulting in a change of timing of MenC 
vaccine from 2, 4, 6 months to 4, 6, 13 months. This meant an additional visit to the GP at 13 months of 
age. This resulted in a large decline in reported uptake of the third dose of MenC from 2010. Research 
showed that most parents did not know their children were incompletely vaccinated and were unaware that 
their children required an additional dose of vaccine at 13 months of age. Further exploration into ways to 
increase uptake per the updated immunisation schedule and reach the 95% target are required to ensure 
that vaccine confidence is maintained at a population level.
• No Local Health Office or Community Health Organisation area achieved the National Target (95%). The 
Roscommon Local Health Office had the highest uptake rate (94%) and Wicklow had the lowest (82%). The 
reasons for the variation seen between areas require further investigation. 
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Figure 3: Immunisation rate for MenC for children at 24 months, percentage uptake, 2009 – 2018 
Source: Health Protection Surveillance Centre (HPSC)
Notes: 
(i) The data for 2009 and 2010 are incomplete as data for some regions were incomplete.
(ii) From 2015, the meningococcal immunisation schedule was changed. Caution is advised when 
comparing 2015 data to previous years.
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Figure 4: Immunisation rate for MenC for children at 24 months by Community Health Organisation, 2018
Source: Health Protection Surveillance Centre (HPSC)
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Table 4: Immunisation rate for MenC for children at 24 months by Local Health Office and Community 
Health Organisation, 2018
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Community Health Organisation Local Health Office MenC Uptake Rate 2018 %
CHO 1
Cavan/Monaghani 84
Donegal 85
Sligo/Leitrim 92
CHO 1 Total 89
CHO 2
Galway 92
Mayo 94
Roscommon 94
CHO 2 Total 93
CHO 3
Clare 91
Limerick 89
Tipperary NR/East Limerick 90
CHO 3 Total 90
CHO 4
North Cork 92
North South Lee 88
West Cork 85
Kerry 89
CHO 4 Total 89
CHO 5
Carlow/Kilkenny 86
South Tipperary 92
Waterford 89
Wexford 91
CHO 5 Total 90
CHO 6
Dublin South 90
Dublin South East 91
Wicklow 82
CHO 6 Total 88
CHO 7
Dublin South City 89
Dublin South West 86
Dublin West 85
Kildare/West Wicklow 87
CHO 7 Total 87
CHO 8
Laois/Offaly 93
Longford/Westmeath 94
Louthi 83
Meathi 84
CHO 8 Total 94
CHO 9
Dublin North West 89
Dublin North Central 89
Dublin North 85
CHO 9 Total 88
National Average  89
Source: Health Protection Surveillance Centre
Notes: 
i. 2018 data for Cavan/Monaghan, Louth and Meath not available, 2017 figures used here  
ii. Due to incomplete data coverage, the national average is based on data from the first three quarters of 2018.
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Immunisation for influenza for persons aged 65 years and older 
Definition
Percentage of people 65 years and older with a medical card or GP visit card, who have been vaccinated 
against influenza.
Description
Seasonal influenza is an acute respiratory infection caused by influenza viruses which circulate in all parts of 
the world. Most people with the illness recover quickly, but elderly people and those with chronic medical 
conditions, (e.g. chronic obstructive pulmonary disease (COPD)), are at higher risk of complications. Influenza 
can also have a major impact on health services particularly during the winter season.
Vaccines provide a safe way of preventing influenza and have been shown to reduce the risk of death by up 
to 55% among healthy older adults, as well as reducing the risk of hospitalisation by between 32% and 49% 
among older adults [14,15]. In 2003, countries participating in the World Health Assembly, including Ireland, 
committed to the goal of attaining vaccination coverage of the elderly population of at least 50% by 2006 and 
75% by 2010 [16]. In Ireland the target for influenza vaccination in the population group aged 65 years and 
older is 75%.
It is recommended that other vulnerable patients such as pregnant women and those with long term health 
conditions are also be vaccinated.
People are encouraged to avail of influenza vaccination in late September/early October each year. Vaccination 
uptake is measured from September of one year to August of the following year, rather than by calendar year, 
for example 2017-2018 refers to the vaccination uptake between September 2016 and April 2017. This 
provides a more accurate measurement for each flu season.
Rationale for the inclusion of indicator 
Influenza represents a large burden of disease worldwide and in Ireland. Influenza is a common infectious 
disease that affects between 5% and 15% of the population each year worldwide [13]. It has been estimated 
that between 200 and 500 people, mainly older people, die from influenza each winter in Ireland. The HPSC 
reports that 4,680 patients were hospitalized with confirmed influenza during the 2017/2018 influenza 
season.
Commentary 
• The national trend data shows that the target of 75% has not been reached. The uptake rate over the 
past four years has not exceeded 60%. Provisional data for the 2018/2019 season (uptake to the end of 
December 2019) suggests that uptake was approximately 56%. 
• It is notable that the vaccination rate among the 65 year and older population fluctuated significantly in the 
flu season between 2009/2010 and 2011/2012 but has become more stable in recent years. 
• Ireland’s failure to meet its national target notwithstanding, figure 6 shows Ireland’s uptake rate of 55% was 
above the average rate for OECD countries, 44% (2015 is the latest year for which OECD data is available). 
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Figure 5: Percentage of influenza immunisation uptake in the population 65 years and older with a 
medical card or GP visit card, 2009/2010-2018/2019
Figure 6: Immunisation for influenza in populations over 65 for selected OECD countries, 2016 
(or nearest year) 
Source: Health Protection Surveillance Centre (HPSC)
Note: Data for 2018/19 cover September - December 2018 due to incomplete data.
See appendix for detailed indicator definitions and methodology.
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Source: OECD Health Statistics
Note:  Data for Ireland are estimated.
Differences in coding practices and defintions among countries may affect the comparability of data.
See appendix for detailed indicator definitions and methodology. 
The World Health Organisation target influenza immunisation uptake rate for at risk groups including people aged 65 years 
and older is ≥ 75%.
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Immunisation rate for influenza among healthcare workers in hospitals
Definition
Percentage of healthcare workers (HCWs) in hospitals, who have been vaccinated against seasonal influenza.
Description
Influenza is a common infectious disease that affects between 5% and 15% of the population each year [13]. 
Most people with the illness recover quickly, but elderly people and those with chronic medical conditions, 
(e.g. chronic obstructive pulmonary disease (COPD)), are at higher risk of complications. It has been estimated 
also have a major impact on health services particularly during the winter season.
Every year influenza vaccine is offered to healthcare workers both to protect themselves and to prevent 
the spread of flu to vulnerable patients and to staff. At least 20% of healthcare workers are infected with 
influenza every year and many healthcare workers continue to work despite being ill, which increases the risk 
of influenza to their colleagues and patients. During hospitalisation, patients are up to 35 times more likely to 
acquire influenza if exposed to infected patients or healthcare workers [17]. 
Vaccination of healthcare workers has been shown to reduce flu-related deaths by up to 40%. The HSE aims 
to achieve a target of 40% influenza vaccine uptake among healthcare workers.
People are encouraged to avail of influenza vaccination in late September/early October each year. Vaccination 
uptake is measured from September of one year to August of the following year, rather than by calendar year, 
for example 2016-2017 refers to the vaccination uptake between September 2016 and April 2017.
Rationale for the inclusion of indicator 
Influenza represents a large burden of disease worldwide and in Ireland. As people who would have regular 
contact with vulnerable populations, HCWs are at greater risk for infection and exposure. Influenza is a 
common infectious disease that affects between 5% and 15% of the population each year worldwide [13]. It 
has been estimated that between 200 and 500 people, mainly older people, die from influenza each winter 
in Ireland. The HPSC reports that 4594 patients were hospitalised with confirmed influenza during the 
2017/2018 influenza season.
 
Commentary 
• Figure 7 shows the trend in immunisation rates against influenza among HCWs in participating hospitals 
over the past 8 years. In 2018/2019, 52 hospitals (including 4 private hospitals) participated in this survey.
• The percentage of vaccinated healthcare workers was just over 39%. This is slightly decreased from last 
year’s vaccination rate of 44%. This drop may be due to higher than average immunisation rates last year 
(2017/2018 season). These higher than average rates may have been due to the perceived virulence of the 
strains of influenza circulating last year.
• Uptake varied according to staff category (Figure 8); while 53% of medical and dental staff availed of the 
vaccine, just 36% of nursing staff did so. It is notable that the majority of staff categories increased their flu 
vaccine uptake rate as compared to last year.
• Table 5 shows the immunisation rate against influenza among HCWs in the 51 participating hospitals for the 
2018/2019 ‘flu season. Uptake varied substantially across these hospitals. 35 of the 52 hospitals exceeded 
the 40% target. In particular, the Children's Hospital Group achieved over 50% immunisation rate.
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Figure 7: Immunisation for influenza among healthcare workers in hospitals 2011/12 – 2018/2019
Figure 8: Immunisation for influenza among healthcare workers by staff category in HSE-funded 
hospitals, 2018/2019
Source: Health Protection Surveillance Centre (HPSC)
Notes: 
(i) Data for 2018-2019 includes returns for 4 private hospitals. 
(ii) Data for 2018-2019 are provisional and subject to change.
See appendix for detailed indicator definitions and methodology.
Source: Health Protection Surveillance Centre 
Notes:  
(i) Data for 2018-2019 includes returns for 4 private hospitals. 
(ii) Data for 2018-2019 are provisional and subject to change.
See appendix for detailed indicator definitions and methodology.
1. Bar Chart comparision of eligible vs. vaccinated staff - 2011/2012-2017/2018 with trend 
Total Eligible Staff Eligible Staff Not Vaccinated Vaccinated Staff Overall Percentage Vaccinated
2011-2012 46329 38054 8275 17.9
2012-2013 41995 34670 7325 17.4
2013-2014 50202 37968 12234 24.4
2014-2015 51324 39318 12006 23.4
2015-2016 59205 44372 14833 25.1
2016-2017 65442 43524 21918 33.5
2017-2018 69041 38418 30623 44.4
2018-2019 69157 42031 27126 39.2
Source: Health Protection Surveillance Centre (HPSC)
Note: 
(i) Data for 2018-2019 includes returns for 4 private hospitals.
(ii) Data for 2018-2019 are provisional and subject to change.
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The target influenza immunisation uptake rate for healthcare workers is ≥ 40%.
The target influenza immunisation uptake rate for healthcare workers is ≥ 40%.
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Table 5: Immunisation for influenza among healthcare workers in hospitals by hospital group and 
hospital, 2018/2019
Hospital Group Total Eligible % Uptake
Ireland East 13,396 42.0
Cappagh National Orthopaedic Hospital, Dublin 513 36.8
Mater Misericordiae University Hospital 3,529 40.1
Midland Regional Hospital Mullingar 1,000 51.1
National Maternity Hospital, Holles Street 914 60.7
National Rehabilitation Hospital, Dún Laoghaire, Co. Dublin 487 55.0
Our Lady's Hospital, Navan 593 49.7
Royal Victoria Eye & Ear Hospital, Dublin 318 49.4
St. Luke's General Hospital, Kilkenny 1,281 45.2
St. Michael's Hospital, Dun Laoghaire 440 50.0
St. Vincent's University Hospital 3,271 29.8
Wexford General Hospital 1,050 44.0
Dublin Midlands 12,603 43.0
Tallaght Hospital 3,192 59.4
Coombe Women's Hospital 960 54.1
Midland Regional Hospital Portlaoise 825 44.7
Midland Regional Hospital Tullamore 1,192 36.1
Naas General Hospital 819 35.3
St. James's Hospital 5,073 31.8
St. Luke's Hospital, Dublin 542 55.4
RCSI Hospitals 10,163 50.5
Beaumont Hospital 3,869 50.9
Connolly Hospital, Blanchardstown 1,401 37.3
Louth County Hospital, Dundalk 346 50.9
Our Lady Of Lourdes Hospital, Drogheda 2,320 56.3
Rotunda Hospital 895 68.4
Cavan General Hospital 1,087 41.1
Monaghan General Hospital 245 42.9
UL Hospitals 4,860 26.9
Croom Orthopaedic Hospital 179 27.4
Ennis Hospital 252 23.4
Nenagh Hospital 269 38.3
St. John’s Hospital, Limerick 642 29.1
University Hospital Limerick 3,090 25.9
University Maternity Hospital Limerick 428 25.2
South / South West 12,146 34.8
Bantry General Hospital 297 36.0
Cork University Hospital 4,591 75.9
Lourdes Orthopaedic Hospital, Kilcreene, Kilkenny 81 11.1
Mallow General Hospital 269 48.7
Mercy University Hospital, Cork 1,321 40.3
South Infirmary - Victoria University Hospital, Cork 989 23.7
South Tipperary General Hospital, Clonmel 1,034 26.3
University Hospital Kerry 1,266 21.3
University Hospital Waterford 2,296 37.5
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Hospital Group Total Eligible % Uptake
Saolta 10,221 24.4
Letterkenny General Hospital 1,814 15.7
Mayo General Hospital, Castlebar 1,288 21.0
Portiuncula Hospital, Ballinasloe 916 32.6
Roscommon County Hospital 356 25.8
Sligo General Hospital 1,832 27.0
University College Hospital Galway 4,015 26.1
Children's Health Ireland 3,520 56.6
Children's University Hospital, Temple Street 1,406 61.2
Our Lady's Hospital for Children, Crumlin 2,114 53.5
Other 2,248 41.5
Aut Even Hospital, Freshford Road, Kilkenny 311 30.5
Bon Secours Hospital, Glasnevin, Dublin 598 34.1
Bon Secours Hospital, Cork 1,116 50.7
Clontarf Hospital, Dublin 223 30.9
Total for All Hospitals 69,157 39.2
Table 5 contd.
Source: Health Protection Surveillance Centre (HPSC)
See appendix for detailed indicator definitions and methodology. 
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Immunisation rate for human papillomavirus (HPV) vaccine
Definition
Percentage of girls in first year of second level schools and their age equivalents who have received the HPV 
vaccine.
Description
The human papillomavirus (HPV) is the most common sexually transmitted virus worldwide. Two HPV types 
(16 and 18) cause 70% of cervical cancers and precancerous cervical lesions.
The HPV vaccine protects women from these strains of the virus, thereby providing protection against cancer. 
The vaccine was licensed in 2006 in Ireland. To date, over 100 million people have been vaccinated with HPV 
vaccine worldwide including over 220,000 girls in Ireland. Research conducted all over the world has shown 
that it is safe and prevents cancer. The introduction of a HPV immunisation programme in Australia in 2007, 
for example, led to a 90% reduction of HPV 6, 11, 16 & 18 infection, a 45% reduction in low-grade pre-
cancerous growths and an 85% reduction in high-grade precancerous growths [18].
Since 2010, all girls in first year in second level schools in Ireland are offered the HPV vaccine each 
year. Following a request from the Department of Health, HIQA agreed to conduct a Health Technology 
Assessment into the value of also providing this vaccine to boys in secondary school. The HTA recommended 
that the HPV immunisation programme be extended to include boys. A policy decision was made to 
implement this recommendation and also to introduce a 9-valent HPV vaccine in September 2019. The 
current national target is that at least 80% of the girls who are offered this vaccine will complete the required 
2 or 3 dose schedule.
Vaccination uptake is measured from September of one year to August of the following year, rather than by 
calendar year, for example 2016-2017 refers to the vaccination uptake between September 2016 and April 
2017. This is to align with the academic year.
Rationale for the inclusion of indicator 
About 80% of all women will have a HPV infection in their lifetime - usually in their late teens and early 20s. 
HPV causes virtually all cases of cervical cancer.
Every year in Ireland:
• 6,500 women need hospital treatment for a precancerous cervical growth
• 300 (many young) women get cervical cancer
• 90 women die from cervical cancer.
Commentary 
• Due to the unavailability of HPV immunisation data for the 2017/2018 academic year, data reported here is 
as was previously reported in the 2018 National Healthcare Quality Reporting System. 
• Figure 10 shows the trend in completed HPV immunisation rates in girls in first year of second level schools 
and their age equivalents for the academic years 2014/2015 and 2015/2016. This demonstrates that 
uptake declined substantially over these three years for which is available data, from 87% in 2014/2015 to 
72% in 2015/2016 and finally 51% in the 2016/2017 academic year.
• Figure 9 and Table 6 show uptake of the HPV vaccine by Local Health Office and Community Health 
Organisation for the academic year 2016/2017. Substantial variation is seen by area, ranging from just 40% 
uptake in Kerry to 74% uptake in South Dublin East. No areas achieved the national target (uptake ≥ 80%).
• The variation reported here requires further investigation at local level. It is noted that public views about 
some media coverage about this vaccine may have adversely impacted uptake levels in recent years. The 
World Health Organization and national experts and regulatory body in the world have refuted these 
allegations and stated that the HPV vaccine is safe and that it is not associated with an increased risk of any 
of the alleged side effects.
• In August 2017, the HPV Vaccination Alliance was launched with leadership from the National Immunisation 
Office. The alliance consists of a group of over 35 different organisations working in the areas of health, 
women’s rights, child welfare, and wider civil society that are committed to raising awareness of HPV 
vaccination. In 2017 and 2018, an information campaign was launched featuring vaccinated girls, which was 
strongly supported by the HPV Vaccination Alliance, the HSE, the Department of Health and the Minister for 
Health. A wide range of groups now promote the vaccine, which has had an immediate impact. This impact is 
not visible in the data presented here, as this report gives information on the previous academic year.
• Regretfully, data for the 2018/2019 academic year was not available at the time of NHQRS publication.
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Figure 9: Immunisation rate for HPV among girls in first year of second level schools and their age 
equivalents by county, for academic year 2016/2017
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Source: Health Protection Surveillance Centre (HPSC)
See appendix for detailed indicator definitions and methodology.
The target for uptake of two doses of vaccine for the routine HPV vaccination programme is ≥80%.
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Table 6: Immunisation rate for HPV among girls in first year of second level schools and their age 
equivalents by Community Health Organisation and Local Health Office, for academic years 
2015/2016 - 2016/2017
Community Health Organisation Local Health Office HPV uptake in academic year 2015/16 (%)
HPV uptake in academic 
year 2016/17 (%)
CHO 1
Cavan/Monaghan 70.8 57.5
Donegal 71.9 48.7
Sligo/Leitrim 70.9 48.5
CHO 1 Total 71.3 51.5
CHO 2
Galway 72.8 53.4
Mayo 67.9 43.0
Roscommon 67.1 48.5
CHO 2 Total 70.7 49.7
CHO 3
Clare 75.9 55.7
Limerick 74.0 59.1
Tipperary NR/East Limerick 74.1 54.0
CHO 3 Total 74.6 56.3
CHO 4
North Cork 62.3 48.3
North Lee Cork 72.1 52.7
North South Lee 68.8 53.8
West Cork 60.2 41.4
Kerry 60.3 39.8
CHO 4 Total 66.3 48.8
CHO 5
Carlow/Kilkenny 80.6 53.5
South Tipperary 71.8 48.4
Waterford 77.9 54.1
Wexford 66.2 41.6
CHO 5 Total 74.2 49.1
CHO 6
Dublin South 74.9 64.7
Dublin South East 81.2 73.8
Wicklow 73.7 46.2
CHO 6 Total 76.3 61.0
CHO 7
Dublin South City 82.5 60.4
Dublin South West 73.9 47.4
Dublin West 71.1 47.2
Kildare/West Wicklow 81.2 52.4
CHO 7 Total 77.6 51.8
CHO 8
Laois/Offaly 76.6 48.1
Longford/Westmeath 69.4 48.5
Louth 83.5 50.4
Meath 69.3 48.5
CHO 8 Total 74.1 48.8
CHO 9
Dublin North West 69.5 48.7
Dublin North Central 70.0 50.2
Dublin North 66.6 45.3
CHO 9 Total 68.3 47.5
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Source: Health Protection Surveillance Centre (HPSC)
See appendix for detailed indicator definitions and methodology.
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Figure 10: Immunisation rate for HPV among girls in first year of second level schools and their age 
equivalents, academic years 2014/2015 - 2016/2017
Source: Health Protection Surveillance Centre
See appendix for detailed indicator definitions and methodology.
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The target for uptake of two doses of vaccine for the routine HPV vaccination programme is ≥80%.
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Screening uptake rate for breast cancer
Definition
Percentage uptake of breast screening in Ireland by eligible women in the population.
Description
Breast cancer is the most common form of cancer in women. One in nine women will develop breast cancer at 
some point in their life and one in thirty will die from the disease. Breast screening is where a mammogram (an 
x-ray of the breast) is taken to look for signs of early breast cancer. In Ireland, the National Screening Service. 
BreastCheck invites women between the ages of 50 and 64 years for a free mammogram every two years. 
BreastCheck is currently being extended and by the end of 2021, all eligible women aged 50 to 69 will be 
invited for routine screening. The target uptake rate in Ireland is 70%.
Rationale for the inclusion of indicator 
On average, 2,949 patients were diagnosed with invasive breast cancer each year on average during 2012-
2014. This represents almost one third of all major malignancies diagnosed in women.
Notes of Measurement Changes for the Screening Rate Uptake for Breast Cancer  
Previously this indicator included information regarding the screening uptake rate for breast cancer for HSE 
regions/areas of residence. This information is now available and presented on a county basis.
Commentary 
• Over the past ten years, the uptake of breast cancer screening by those eligible has remained above the 
target of 70%.
• All counties are above the 70% national target, with the national average uptake rate at 76.4%. 
• Figure 13 shows that Ireland’s rate of uptake for breast screening is higher than the OECD average of 
60.8%. However, it should be noted that there may be differences in scheduling and eligibility for breast 
screening programmes in different countries and this needs to be taken into account when comparing 
uptake levels for screening programmes.
 Figure 11: Uptake of breast screening by the eligible population, 2008-2017
Source: National Screening Service 
Notes:  
i) The eligible population refers to the known target population (women of screening age that are known to the 
programme) less those women excluded or suspended by the programme based on certain eligibility criteria.
ii) Data is provisional for 2017.
See appendix for detailed indicator definitions and methodology.
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Figure 12: Percentage of eligible women screened by county of residence for the period 1st January 2016 
– 31st December 2017
Source: National Screening Service 
Note: Data for 2016-2017 is provisional.
See appendix for detailed indicator definitions and methodology.
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BreastCheck's target uptake rate is ≥70%.
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Source: National Screening Service 
Note: Data for 2016-2017 is provisional.
See appendix for detailed indicator definitions and methodology. 
Table 7: Percentage of eligible women screened by county of residence for the period 1st January 2016 – 
31st December 2017
County Percentage Uptake 2016-2017
Carlow 76.8%
Cavan 76.5%
Clare 77.5%
Cork 78.5%
Donegal 76.4%
Dublin 73.8%
Galway 79.9%
Kerry 75.3%
Kildare 78.9%
Kilkenny 77.9%
Laois 70.8%
Leitrim 77.1%
Limerick 75.3%
Longford 72.0%
Louth 73.9%
Mayo 79.5%
Meath 76.1%
Monaghan 73.0%
Offaly 73.4%
Roscommon 81.6%
Sligo 81.3%
Tipperary 75.5%
Waterford 76.5%
Westmeath 70.1%
Wexford 80.5%
Wicklow 79.2%
National Average 76.4%
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Figure 13:  Uptake of breast screening in women aged 50 to 69 in OECD countries, 2016 (or nearest year)
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1 Programme, 2Survey
Source: OECD Health Statistics 
Note on international comparability: Screening rates reflect the proportion of women who are eligible for a screening test 
and actually receive the test. Some countries ascertain screening based on surveys and others based on encounter data, 
which may influence the results. Survey-based results may be affected by recall bias. Programme data are often calculated 
for monitoring national screening programmes, and differences in target population and screening frequency may also lead 
to variations in screening coverage across countries.
See appendix for detailed indicator definitions and methodology.
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Screening uptake rate for cervical cancer
Definition
The proportion of the eligible population in Ireland who had a satisfactory1 smear test within a five year time 
period.
Description
Cervical cells change slowly and take many years to develop into cancer cells, making cervical cancer a 
preventable disease and having regular smear tests to pick up any early cell changes (precancerous growths) 
can significantly reduce the risk of cervical cancer.
In Ireland all women aged 25 to 60 years can avail of CervicalCheck, Ireland’s national cervical screening 
programme. The programme operates both an invitation entry system whereby eligible women receives an 
invitation letter, and “direct entry” whereby smear takers (e.g. general practitioner (GP), practice nurse) can 
directly screen eligible women.
Routine screening every 3 or 5 years depending on age is recommended for women whose previous cervical 
screening test results did not detect an abnormality. CervicalCheck aims to reach a target five-year coverage 
of 80%.
Cervical cancer screening uptake is measured from September of one year to August of the following year, 
rather than by calendar year, for example 2016-2017 refers to the uptake between September 2016 and 
August 2017.
Rationale for the inclusion of indicator 
Every year in Ireland 300 women are diagnosed with cervical cancer and 90 women die from it. Cervical 
cancer is the second most common case of death due to cancer in women aged 25 to 39 years.
Commentary 
• The coverage of CervicalCheck in the 2017, the latest time period for which data is provisionally available, 
was 78%. The coverage by age group shows that the highest coverage rate is among those women aged 25 
to 29. 
• At a county level, screening uptake rates 2012-2017 ranged from 70% in Laois to 91% in Carlow. Eight 
counties achieved the 80% target coverage for the time period. The reasons for the variation in uptake rates 
in different locations require further investigation.
• Although, Ireland has not yet reached its national target of 80% uptake, Ireland’s rate of uptake for cervical 
screening is significantly higher than the OECD average. However, it should be noted that there may be 
differences in scheduling and eligibility for cervical screening programmes in different countries and this 
needs to be taken into account in comparing uptake levels for screening programmes.
• The national target of 80% uptake rate was achieved by women in the following age groups: 25 to 29, 40 
 to 44 and 45 to 49. 
1. Satisfactory smear tests refer to those that had a sufficient number of cells within the test sample to allow for testing to be completed.
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Figure 15: Five year coverage of the cervical screening programme in Ireland by county for period from 
1st September 2012 – 31st August 2017
Source: National Screening Service 
Note: Data for 2016-2017 is provisional.
See appendix for detailed indicator definitions and methodology. 
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Figure 14: Five-year coverage of the cervical screening programme in Ireland by age group, 
1st September 2012 – 31st August 2017
Source: National Screening Service 
Notes: The national coverage of eligible women for the 5 year periods by 5-year age group has been adjusted for 
women who have had a hysterectomy.
See appendix for detailed indicator definitions and methodology.
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CervicalCheck's target five-year uptake rate is ≥ 80%.
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Source: National Screening Service 
Notes: 
i. Population based on CSO 2011 projected to 2013, not adjusted for hysterectomy  
ii. Eligible population based on CSO 2011, projected to 2014 , not adjusted for hysterectomy  
iii. Data for 2012-2017 is provisional 
See appendix for detailed indicator definitions and methodology.
Table 8: Percentage of eligible women screened for cervical cancer by county of residence for the period 
from 1st September 2012 - 31st August 2017
County Percentage Uptake 2012-2017
Carlow 91.4%
Cavan 79.7%
Clare 72.9%
Cork 79.8%
Donegal 76.2%
Dublin 77.1%
Galway 76.2%
Kerry 78.3%
Kildare 81.0%
Kilkenny 72.4%
Laois 70.3%
Leitrim 78.8%
Limerick 75.9%
Longford 80.2%
Louth 84.8%
Mayo 76.6%
Meath 79.2%
Monaghan 75.2%
Offaly 75.5%
Roscommon 72.7%
Sligo 78.0%
Tipperary 76.9%
Waterford 82.8%
Westmeath 86.5%
Wexford 82.9%
Wicklow 84.5%
National Average 78.3%
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Figure 16: Cervical screening in women aged 20 – 69 years in OECD countries, 2016 (or nearest year)
1 Programme, 2Survey
Source: OECD Health Statistics 
Note on international comparability: Screening rates reflect the proportion of women who are eligible for a screening test
and actually receive the test. Some countries ascertain screening based on surveys and others based on encounter data,
which may influence the results. Survey-based results may be affected by recall bias. Programme data are often calculated 
for monitoring national screening programmes, and differences in target population and screening frequency may also lead 
to variations in screening coverage across countries.
Ireland’s cervical cancer screening programme covers women aged 25 to 60. The age cohorts covered by screening
programmes in other countries may vary,
See appendix for detailed indicator definitions and methodology.
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Screening uptake rate for colorectal cancer
Definition
The proportion of the eligible population in Ireland who have availed of a bowel screen within a two year time 
period.
Description
Colorectal cancer, also known as bowel cancer, is a general term for cancer that begins in the large bowel. In 
Ireland, bowel cancer is the third most common type of cancer. An estimated 2,270 new cases are diagnosed 
each year in Ireland.
Currently, in Ireland men and women aged 60 to 69 years can avail of BowelScreen, Ireland’s national 
bowel screening programme. The programme will be expanded over time until all of the 55-74 age group is 
reached. Eligible people receive an invitation letter to receive an at-home bowel screening test called a FIT 
(faecal immunochemical test). BowelScreen reports that 95% of people will have a normal result following 
the at home test. BowelScreen offer a colonoscopy to everyone who has a BowelScreen home test result 
showing traces of blood not visible to the eye. A colonoscopy is the best way to diagnose bowel cancer and 
other conditions. A colonoscopy is carried out in a screening colonoscopy unit in a hospital organised by 
BowelScreen.
Routine screening every 2 years is recommended. BowelScreen aims to reach a target five-year coverage of 
50%.
Rationale for the inclusion of indicator 
In Ireland, bowel (colon, rectal or colorectal) cancer is the second most common newly diagnosed cancer 
among men and women. Each year over 2,270 new cases of colorectal cancer are reported. The number of 
new cases is expected to increase significantly over the next 10 years, due mainly to an increasing and ageing 
population. 
Colorectal cancer is currently the second most common cause of cancer death in Ireland.
Commentary 
• Nationally, the target uptake rate is 50%. In 2016-2017 (latest data available), 15 counties meet the target 
rate of 50% uptake. The national uptake rate is just above this target at 51%. 
• Following screening for breast and cervical cancers, population based colorectal cancer screening 
programmes have begun, targeting people in their 50s and 60s (OECD, 2013). The OECD’s 2017 Health at 
a Glance states that “Partly because of uncertainties about the cost-effectiveness of screening (Lansdorp-
Vogelaar et al.,2010), countries are using different methods. These include faecal occult blood test, and 
screening colonoscopies and flexible sigmoidoscopies. The OECD state that these differences, as well as 
the differences in frequency of screening in different international programmes make it difficult to compare 
screening uptake rates across countries. At this time they do not collect data on colorectal cancer screening 
and hence no international comparator is available here. 
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Figure 17: Percentage of eligible population screened for bowel cancer by county of residence for 
the period 1st January 2016 – 31st December 2017i
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Note: BowelScreen's target for five-year coverage of the eligible population is ≥50%. At the time of 
publication, two year's data is available and reported here.
Data for 2016-2017 is provisional.
See appendix for detailed indicator definitions and methodology.
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Source: National Screening Service 
Note: Data for 2016-2017 is provisional.
See appendix for detailed indicator definitions and methodology.
Table 9: Percentage of eligible population screened for colorectal cancer by county of residence for the 
period 1st January 2016 – 31st December 2018
County 
Bowel Screening 
Percentage Uptake of 
Population aged 60-69, 
2016-2017
Carlow 59.0%
Cavan 48.3%
Clare 52.4%
Cork 47.9%
Donegal 53.4%
Dublin 53.9%
Galway 45.9%
Kerry 48.2%
Kildare 53.1%
Kilkenny 53.2%
Laois 42.9%
Leitrim 54.7%
Limerick 54.0%
Longford 44.8%
Louth 58.3%
Mayo 49.9%
Meath 53.5%
Monaghan 51.1%
Offaly 46.0%
Roscommon 48.6%
Sligo 57.1%
Tipperary 38.3%
Waterford 41.2%
Westmeath 53.2%
Wexford 50.7%
Wicklow 53.6%
National Average 50.9%
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Domain 2:
Supporting people with 
long term conditions
Ambulatory care sensitive conditions
-  Chronic obstructive pulmonary disease 
 (COPD) hospitalisation rates 57
-  Asthma hospitalisation rates 61
-  Diabetes hospitalisation rates 65
-  Heart failure hospitalisation rates 70
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Overview of selected indicators
There are 4 indicators covered in this domain in the following area: 
Ambulatory care sensitive conditions 
Ambulatory care sensitive conditions
Ambulatory care sensitive conditions are those where good quality primary care can help prevent the 
need for hospital admission or for which early intervention can prevent complications or more severe 
disease. Avoiding hospital admissions is of benefit to individual patients and to the health service as a 
whole.
Data which shows the number of hospitalisations for different chronic conditions can give an insight into 
the performance and quality of services for these conditions in primary care. However, it is important to 
remember that the indicators included in this section are alerts which can highlight the need for further 
analysis rather than definitive measures of the quality of primary care services for specific medical 
conditions. As well as the quality of primary care, the number of hospital admissions for these conditions 
also depends on the prevalence of the medical condition in the geographical area, environmental 
conditions, and primary care access to diagnostic tests. For example brain natriuretic peptide (BNP) 
testing and echocardiography in heart failure.
Asthma, chronic obstructive pulmonary disease (COPD), diabetes and heart failure are four relatively
common conditions in Ireland. The models of care for diabetes, COPD, asthma, and heart failure are well 
established and suggest that most of this care can be delivered at primary care level in the community if 
properly resourced. A model of care has also been recently established for diabetes.
The 4 indicators for ambulatory sensitive conditions are:
• Chronic Obstructive Pulmonary Disease (COPD) hospitalisation rates
• Asthma hospitalisation rates
• Diabetes hospitalisation rates
• Heart failure hospitalisation rates.
While the need to go to hospital for these conditions will never be eliminated, differences between 
Ireland and other countries, and between counties in Ireland, indicate that there may be potential to 
improve the consistency of the care provided to these patients, specifically in primary care.
In the Sláintecare Action Plan 2019, it is noted that there are plans for a "Living Well with a Chronic 
Condition" Self-Management Framework. It also notes that Integrated Care Programmes for people 
living with chronic conditions will also be implemented, as well as plans to expand capacity in GP and 
community nursing to manage chronic disease.
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Chronic obstructive pulmonary disease (COPD) hospitalisation rates
Definition
The age-sex standardised hospitalisation rate per 100,000 population for people aged 15 years and older with 
a principal diagnosis of COPD.
Description
COPD is a common progressive lung disease. Although it is a preventable disease, exposure to inhaled 
gases and particles, e.g. tobacco smoke, which accounts for 85-90% of cases, usually begins decades before 
symptomatic disease can be detected (19)(20).
Although symptoms of COPD can usually be managed by the patient with their GP and the primary care 
team, patients with very severe symptoms or complications may need to be admitted to hospital. COPD is the 
commonest disease-specific cause of emergency hospital admissions among adults in Ireland.
The HSE National Clinical Programme for COPD aims to decrease morbidity and mortality associated with 
COPD through improving early diagnosis and treatment based on best practice guidelines. It also aims to 
reduce COPD admissions by 1,500 per year. 
It is important to note that not all hospitalisations due to COPD are avoidable and may be clinically 
appropriate.
Specifically, the HSE National Clinical Programme for COPD are developing a clinical guideline on COPD 
to be submitted to the National Clinical Effectiveness Committee for quality assurance. This will ensure the 
availability of high quality National Clinical Guideline to enable clinicians in Ireland to manage COPD in an 
evidence based and cost-effective way.
Rationale for the inclusion of indicator 
Based on the 2011 census, it is estimated that almost 500,000 people aged 40 years and over in Ireland have 
COPD, of whom over 200,000 have moderate or severe disease and only half are likely to be diagnosed; given 
that our population has become larger and older in the interim, it is likely that these figures are even higher 
today (21)(22).
Commentary 
• The national age-sex standardised hospitalisation rate for COPD increased slightly between 2009 and 2018, 
with 354 per 100,000 population in 2018 compared with 303 hospitalisations per 100,000 population in 
2009
• Most countries in the OECD have reported a reduction in hospitalisation rates for COPD over recent years, 
perhaps as a result of improvements in access to, and the quality of, primary care.
• As in previous years, the OECD reported that Ireland had the highest age-sex standardized hospitalisation 
rate for COPD in 2015, the latest year for which international data is available. While Ireland’s average 
rate has decreased from 379 hospitalisations per 100,000 population in 2005 to 367 in 2016, the OECD 
average also declined (214 to 187). 
• In Ireland during the three-year period from 2016-2018, the age-sex standardised hospitalisation 
rate by county of residence ranged from 242 hospitalisations per 100,000 population in Kerry to 552 
hospitalisations per 100,000 population in Offaly.
• Although geographic disparity in age-sex standardised hospitalisation rates for COPD is not unique to 
Ireland (20) (23), the precise reasons for the variation seen between areas require further investigation.
• There are a number of potential explanations for the variation seen, both between Ireland and other 
countries, and between counties in Ireland. The reasons potentially include, but are not limited to, issues 
related to the quality of the data, differences in the prevalence of risk factors (i.e. tobacco exposure or air 
pollution) or chronic conditions in the population, the availability of services at primary and community care 
level, access to specific treatments, and the availability of hospital beds.
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Figure 18: Age-sex standardised hospitalisation rates for COPD per 100,000 population in Ireland, 
2009-2018
Figure 19: Age-sex standardised hospitalisation rates for COPD per 100,000 population for selected 
OECD countries, 2015 (or nearest year)
Source: Hospital In-Patient Enquiry (HIPE)
Source: OECD Health Statistics
Note on international comparability: Differences in coding practices among countries and the definition of an 
admission may affect the comparability of data. Differences in disease classification systems, for example between ICD-9-CM 
and ICD-10-AM/ACHI, may also affect data comparability. 95% confidence intervals represented by        .
Notes: Deviation from OECD definition for Iceland and Luxembourg.
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Figure 20: Age-sex standardised hospitalisation rates for COPD per 100,000 population by county 
of residence, 2016-2018
Source: Hospital In-Patient Enquiry (HIPE)
Note: Data refer to the average annual age-sex standardised hospitalisation rate per 100,000 population from 2016-
2018. See table for 95% confidence limits.
See appendix for detailed indicator definitions and methodology. 
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Table 10: Age-sex standardised hospitalisation rate for COPD per 100,000 population by 
county of residence, 2016-2018
Source: Hospital In-Patient Enquiry
Notes: 
Data refer to the average annual age-sex standardised hospitalisation rate per 100,000 population from 2016-2018. 
See appendix for detailed indicator defintions and methodlogy.
County of Residence Number of Cases
Age-sex
Standardised 
Admission Rate
Lower 95% 
Confidence Limit for 
Admission Rate
Upper 95% 
Confidence Limit for 
Admission Rate
Carlow  622 495.0 456.1 533.9
Cavan  660 376.3 347.5 405.2
Clare  762 264.3 245.5 283.2
Cork  3,956 313.7 303.9 323.4
Donegal  2,013 488.4 467.1 509.7
Dublin  11,341 401.5 394.1 408.9
Galway  1,949 338.3 323.3 353.4
Kerry  890 224.6 209.7 239.4
Kildare  1,452 381.7 361.5 401.8
Kilkenny  776 327.0 304.0 350.0
Laois  815 506.5 471.2 541.9
Leitrim  268 289.9 255.0 324.8
Limerick  1,769 384.0 366.1 401.9
Longford  423 439.3 397.4 481.2
Louth  1,159 418.2 394.1 442.3
Mayo  1,346 363.5 344.1 383.0
Meath  1,220 338.7 319.5 358.0
Monaghan  412 282.4 255.1 309.6
Offaly  975 552.8 518.1 587.6
Roscommon  758 407.0 378.0 436.0
Sligo  706 405.9 376.0 435.7
Tipperary  1,745 419.1 399.4 438.7
Waterford  826 292.2 272.2 312.1
Westmeath  1,005 520.2 488.0 552.4
Wexford  1,713 463.3 441.3 485.2
Wicklow  883 274.7 256.4 293.0
National  40,444 375.7 372.1 379.4
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Asthma hospitalisation rates
Definition
The age-sex standardised hospitalisation rate per 100,000 population for people aged 15 years and older with 
a principal diagnosis of asthma.
Description
Asthma is a chronic inflammatory condition of the airways characterised by recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing. Ireland has the fourth highest prevalence of asthma in the 
world.
For most people with asthma it should be possible to maintain their health and quality of life so that they 
have few or no symptoms (asthma control). The HSE National Clinical Programme for Asthma (NCPA) was 
established in 2011. A key objective of this Programme is to improve asthma control in the community and 
the NCPA, in conjunction with the Irish College of General Practitioners (ICGP), published Guidelines for 
the Control of Asthma in General Practice in 2013 ( Irish College of General Practitioners Quality in Practice 
Committee 2013)
The NCPA also aims to reduce acute asthma attendances at emergency departments, in-patient admissions 
and needless deaths from asthma, and as part of this work, published an NCEC National Clinical Guideline for 
the Management of Acute Asthma in 2015 [27]. Hospitalisation with an acute exacerbation (attack) of asthma 
is a sign of uncontrolled asthma and may, in many cases, be preventable.
It is important to note that not all hospitalisations are avoidable and some may be clinically appropriate. 
In addition, it should be noted that a number of people with asthma are admitted on a planned basis, 
either to facilitate the administration of intramuscular medication or for diagnostic investigations such as a 
bronchoscopy (an examination of the airways under sedation) or CT scan. The vast majority of these will be 
admitted and discharged on the same day and hence are not included in the following analysis. However, a 
small number of patients will have been admitted overnight for these investigations/procedures and hence will 
have been incorrectly included as an acute hospitalisation in the data presented below.
Rationale for the inclusion of indicator 
Current estimates suggest that there are approximately 450,000 people with doctor-diagnosed asthma in 
Ireland (approx. 1 in 10 of population), of whom approximately 240,000 are estimated to have uncontrolled 
asthma (23). Evidence suggests that the prevalence of asthma within the Irish population is rising; for example, 
one study reported that there was a 42% relative increase in the prevalence of asthma in Irish teenagers 
between 1998 and 2003 (25).
Commentary 
• The age-sex standardised hospitalisation rate for asthma fluctuated over the period from 2009-2018, from 
a high of 45 per 100,000 population in 2016 to a low of 36 per 100,000 population in 2011 (Figure 21). In 
2018, there were 44 hospitalisations per 100,000 population. 
• During the three-year period from 2016-2018, the age-sex standardised hospitalisation rate by county 
of residence ranged from 23 hospitalisations per 100,000 population in Kerry to 67 hospitalisations per 
100,000 population in Donegal, an almost three-fold variation. Although this variation appears substantial, it 
should be noted that the low absolute number of hospitalisations in many counties makes the rate sensitive 
to small changes in these numbers year-on-year. This caveat notwithstanding, the precise reasons for the 
variation seen between areas require further investigation.
• There are a number of potential explanations for the variation seen, both between Ireland and other 
countries, and between counties in Ireland, and it should not be concluded that higher or lower rates are a 
reflection on the quality of care provided in primary and community care settings. The reasons potentially 
include, but are not limited to, issues related to the quality of the data, differences in the prevalence of risk 
factors and chronic conditions in the population, the availability of services at primary and community care 
level, access to specific treatments, and the availability of hospital beds.
• In 2015, Ireland had a rate of 43.7 hospitalisations per 100,000 population, which was just slightly below 
the OECD average of 45.6 hospitalisations per 100,000 population.
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Figure 21: Age-sex standardised hospitalisation rates for asthma per 100,000 population in Ireland, 
2009 – 2018
Source: Hospital In-Patient Enquiry (HIPE)
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Figure 22: Age-sex standardised hospitalisation rates for asthma per 100,000 population for
selected OECD countries, 2015 (or nearest year)
7.6
9.3
14.6
16.1
16.5
19
19.1
21.9
27.5
28
28.7
29.6
30.2
34.7
35.1
36
37.4
43.2
43.5
43.7
44.7
45.6
50.6
51.6
53.4
54.4
64.8
65.3
71
73.3
81.9
89.7
92.8
94.5
119.4
0 20 40 60 80 100 120 140 160
Italy
Mexico
Canada
Chile
Portugal
Sweden
Iceland
Luxembourg
Switzerland
Estonia
Germany
France
Norway
Japan
Czech Republic
Netherlands
Belgium
Slovenia
Austria
Ireland
Spain
OECD(34)
Denmark
Israel
Finland
Lithuania
Australia
New Zealand
United Kingdom
Hungary
Poland
United States
Slovak Republic
Korea
Latvia
Age-Sex Standardised Rate per 100,000 Population
Source: OECD Health Statistics
Note on international comparability: Differences in coding practices among countries and the definition of an admission 
may affect the comparability of data. Differences in disease classification systems, for example between ICD-9-CM and 
ICD-10-AM/ACHI, may also affect data comparability. 95% confidence intervals represented by       .
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Figure 23: Age-sex standardised hospitalisation rates for asthma per 100,000 population by county 
of residence, 2016 – 2018
Source: Hospital In-Patient Enquiry
Notes:
Data refer to the average annual age-sex standardised hospitalsations rate per 100,000 population from 2016-2018. 
See table for 95% confidence limits.
See appendix for detailed indicator definitions and methodology. 
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Table 11: Age-sex standardised hospitalisation rates for asthma per 100,000 population by county 
of residence, 2016–2018
Source: Hospital In-Patient Enquiry
Notes:
Data refer to the average annual age-sex standardised hospitalisations rate per 100,000 population from 2016 - 
2018. See appendix for detailed indicator definitions and methodology.
County of Residence Number of Cases
Age-sex
Standardised 
Admission Rate
Lower 95% 
Confidence Limit for 
Admission Rate
Upper 95% 
Confidence Limit for 
Admission Rate
Carlow 50 37.9 27.3 48.5
Cavan 69 40.0 30.4 49.5
Clare 95 33.8 27.0 40.7
Cork 549 43.5 39.8 47.1
Donegal 252 66.8 58.5 75.1
Dublin 1,492 48.7 46.2 51.2
Galway 218 37.4 32.4 42.4
Kerry 84 23.4 18.3 28.5
Kildare 273 57.5 50.4 64.5
Kilkenny 77 33.6 26.1 41.2
Laois 82 45.9 35.7 56.1
Leitrim 31 40.1 25.8 54.4
Limerick 265 57.6 50.6 64.6
Longford 32 34.4 22.4 46.4
Louth 193 65.1 55.9 74.4
Mayo 130 40.1 33.1 47.1
Meath 155 35.7 29.9 41.4
Monaghan 45 32.6 23.0 42.2
Offaly 80 43.2 33.7 52.8
Roscommon 49 31.5 22.5 40.4
Sligo 51 32.6 23.6 41.6
Tipperary 188 49.7 42.6 56.9
Waterford 96 34.8 27.8 41.8
Westmeath 111 55.6 45.2 66.1
Wexford 153 43.3 36.4 50.2
Wicklow 140 42.5 35.4 49.7
National 4,960 45.0 43.8 46.3
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Diabetes hospitalisation rates
Definition
The age-sex standardised hospitalisation rate per 100,000 population for people aged 15 years and older with 
a principal diagnosis of diabetes.
Description
Diabetes is a condition where the body cannot regulate levels of glucose (sugar) in the blood. Type 1 diabetes 
generally develops in childhood or adolescence, while Type 2 diabetes more often develops in adults. About 
90% of people with diabetes have Type 2 diabetes.
If not adequately controlled, diabetes can lead to a range of complications over the longer term including 
kidney or heart disease and stroke, foot problems and the need for amputation, and problems with vision. 
Poorly controlled diabetes has also been associated with cognitive dysfunction (poorer brain health). Patients 
with diabetes may be hospitalised for diabetic complications such as unstable diabetes, hypoglycaemia 
(low blood sugar), hyperglycaemia (high blood sugar) or diabetic coma, or as a result of the aforementioned 
complications associated with poor control of the condition over the longer term. It is important to note that 
not all hospitalisations are avoidable and they may be clinically appropriate.
In May 2018 the Department of Health has published the NCEC National Clinical Guideline on Type 1 
Diabetes in Adults. This was developed by the HSE National Clinical Programme for Diabetes through an 
innovative guideline adaptation process called ‘guideline contextualisation’ in partnership with the National 
Institute for Health and Clinical Excellence (NICE) in the UK.
Rationale for the selection of indicator 
It has been estimated that approximately 5% of adults (aged 18 and over) in Ireland have doctor-diagnosed 
diabetes [28]. Importantly, a substantial proportion (20-30%) of people with Type 2 diabetes remain 
undiagnosed. It is expected that the number of people with Type 2 diabetes will increase by 60% over the 
next 10-15 years [29].
Notes on Measurement Changes 
In 2015, an update to the coding system from ICD-10-AM from 6th to 8th edition which resulted in a 
change in how diabetes is reported in HIPE and hence the rates years subsequent to 2015 are not directly 
comparable with those from previous years’ the classification. While the number of patients with a primary 
diagnoses of diabetes has decreased since the measurement change in 2015, the number of patients with a 
secondary diagnoses of diabetes has increased. The measurement change is indicated as a break in figure 24.
Commentary 
• In 2018, the national age-sex standardised hospitalisation rate for diabetes was 89 hospitalisations per 
100,000 population. This rate has decreased slightly from 92 in 2015, when the HIPE coding system 
changed how diabetes was recorded. 
• In 2015, (the latest year for which OECD data are currently available), the age-sex standardised
 hospitalisation rate for Ireland was 92 hospitalisations per 100,000 population. This was below the OECD 
average of 138 hospitalisations per 100,000 population.
• The diabetes hospitalisation rate varied substantially by county of residence. It ranged from 66 
hospitalisations per 100,000 population in Kerry, to 145 hospitalisations per 100,000 population in 
Longford. The reasons for the variation seen between areas require further investigation.
• There are a number of potential explanations for the variation seen, both between Ireland and other 
countries, and between counties in Ireland, and it should not be concluded that higher or lower rates are a 
reflection on the quality of care provided in primary and community care settings. The reasons potentially 
include, but are not limited to, issues related to the quality of the data, differences in the prevalence of risk 
factors and chronic conditions in the population, the availability of services at primary and community care 
level, access to specific treatments, and the availability of hospital beds.
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Figure 24: Age-sex standardised hospitalisation rates for diabetes per 100,000 population in Ireland, 
2008-2018
Source: Hospital In-patient Enquiry (HIPE)
Note:
In 2015, an update to the coding system from ICD-10-AM from 6th to 8th edition  which resulted in a change in how 
diabetes is reported in HIPE and hence the rates years  subsequent to  2015 are not directly comparable with those from 
previous years’ the classification.  
See appendix for detailed indicator definitions and methodology.
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Figure 25: Age-sex standardised hospitalisation rates for diabetes per 100,000 population for
selected OECD countries, 2015 (or nearest year)
Source: OECD Health Statistics
Note on international comparability: Differences in coding practices among countries and the definition of an 
admission may affect the comparability of data. Differences in disease classification systems, for example between 
ICD-9-CM and ICD-10-AM/ACHI, may also affect data comparability. 95% confidence intervals represented by       .
See appendix for detailed indicator definitions and methodology.
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Figure 26: Age-sex standardised hospitalisation rates for diabetes per 100,000 population by county 
of residence, 2016 – 2018
Source: Hospital In-Patient Enquiry
Notes:
Data refer to the average annual age-sex standardised hospitalsations rate per 100,000 population from 2016-2018. 
See table for 95% confidence limits.
See appendix for detailed indicator definitions and methodology. 
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Table 12: Age-sex standardised hospitalisation rates for diabetes per 100,000 population by county 
of residence, 2016 – 2018
County of Residence Number of Cases
Age-sex
Standardised 
Admission Rate
Lower 95% 
Confidence Limit for 
Admission Rate
Upper 95% 
Confidence Limit for 
Admission Rate
Carlow  161 126.6 106.9 146.4
Cavan  173 95.8 81.4 110.1
Clare  237 83.5 72.7 94.3
Cork  948 75.4 70.6 80.2
Donegal  394 102.4 92.2 112.6
Dublin  2,440 82.6 79.3 85.9
Galway  542 94.0 86.1 102.0
Kerry  237 66.3 57.7 74.8
Kildare  466 105.7 95.7 115.6
Kilkenny  163 70.3 59.5 81.2
Laois  216 123.6 106.8 140.4
Leitrim  75 89.8 69.0 110.7
Limerick  487 106.5 97.0 116.0
Longford  135 145.8 120.9 170.6
Louth  296 106.0 93.8 118.2
Mayo  387 115.1 103.4 126.8
Meath  362 90.9 81.3 100.5
Monaghan  122 84.8 69.7 100.0
Offaly  178 100.0 85.1 114.8
Roscommon  178 108.2 92.0 124.4
Sligo  186 111.6 95.4 127.8
Tipperary  373 93.5 83.9 103.1
Waterford  321 115.1 102.5 127.8
Westmeath  195 96.8 83.1 110.5
Wexford  402 114.3 103.0 125.6
Wicklow  321 97.4 86.6 108.2
National 9,995 91.9 90.1 93.8
Source: Hospital In-Patient Enquiry
Notes:
Data refer to the average annual age-sex standardised hospitalisations rate per 100,000 population from 2016 - 2018. 
See appendix for detailed indicator definitions and methodology.
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Heart failure hospitalisation rates
Definition
The age-sex standardised hospitalisation rate per 100,000 population for people aged 15 years and older with 
a principal diagnosis of heart failure.
Description
Heart failure is a condition where the heart does not function as well as it should. Heart failure can be caused 
by a number of different conditions including ischaemic heart disease, hypertension (high blood pressure), 
disease of the heart valves and congenital heart disease.
Heart failure can lead to many complications over the longer term, including irregular heart rhythms, stroke, 
kidney failure and anaemia. Patients with heart failure may be hospitalised for complications. It is important to 
note that not all hospitalisations are avoidable and they may be clinically appropriate.
The National Clinical Programme for Heart Failure was established in 2011. The overall aim of this Programme 
is to improve quality of life for patients with heart failure and to reorganise the way heart failure patients 
are managed. Since 2011 twelve acute heart failure sites have become active units under the Programme 
and have introduced a structured specialist hospital service for patients presenting with acute heart failure, 
including post-discharge follow up.
The Programme has placed increasing emphasis on community care including its community prevention 
programme in the Midlands and a community new diagnostic clinic in Wexford (Gorey/ Wexford/St Vincents 
University Hospital Group). The latter provides direct access for GPs to brain natriuretic peptide (BNP) testing 
and echocardiography in the community with remote specialist advice when required, and has resulted in a 
substantial reduction in clinic reviews (63% reduction) and in need for echocardiography (37% reduction) in 
the diagnostic process for heart failure.
Rationale for the inclusion of indicator 
It has been estimated that approximately 2% of the population (90,000 people) in Ireland have heart failure 
which causes them symptoms (e.g. fluid retention, breathlessness and tiredness) and that another 2-4% 
(160,000 people) are at risk of developing heart failure [21].
Commentary 
• The national age-sex standardised hospitalisation rate for heart failure decreased between 2009 and 2018, 
from 198 hospitalisations per 100,000 population in 2008 to 162 per 100,000 population in 2018 – a 18% 
improvement in ten years.
• There was no significant change in the hospitalisation rate between 2016, 2017 and 2018.
• In 2015 (the latest year for which OECD data are currently available), the age-sex standardised
 hospitalisation rate for Ireland was 151 hospitalisations per 100,000 population which was statistically
 significantly below the OECD average of 242 hospitalisations per 100,000 population.
• During the three-year period from 2016-2018, the age-sex standardised hospitalisation rate for heart 
failure by county of residence ranged from 113 hospitalisations per 100,000 population in Leitrim, to 
232 per 100,000 population in Carlow. The reasons for the variation seen between areas require further 
investigation. It should be noted that the variation between the county with the highest and lowest 
hospitalisation rates decreased in 2018 as compared to 2017. 
• There are a number of potential explanations for the variation seen, both between Ireland and other
 countries, and between counties in Ireland, and it should not be concluded that higher or lower rates are a 
reflection on the quality of care provided in primary and community care settings. The reasons potentially 
include, but are not limited to, issues related to the quality of the data, differences in the prevalence of risk 
factors and chronic conditions in the population, the availability of services at primary and community care 
level, access to specific treatments, and the availability of hospital beds.
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Figure 27: Age-sex standardised hospitalisation rates for heart failure per 100,000 population by 
county of residence, 2009-2018
Source: Hospital In-patient Enquiry (HIPE)
Note: See appendix for detailed indicator definitions and methodology.
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Figure 28: Age-sex standardised hospitalisation rates for heart failure per 100,000 population for 
selected OECD countries, 2015 (or nearest year)
Source: OECD Health Statistics
Note on international comparability: Differences in coding practices among countries and the definition of an admission 
may affect the comparability of data. Differences in disease classification systems, for example between ICD-9-CM and 
ICD-10-AM/ACHI, may also affect data comparability. 95% confidence intervals represented by       .
See appendix for detailed indicator definitions and methodology.
D
O
M
A
IN
 2: A
M
B
U
LA
TO
RY C
A
R
E SEN
SITIV
E C
O
N
D
ITIO
N
S
72
62.1
93.5
97.7
100.6
136.9
150.5
151.0
159.8
166.8
167.2
174.5
180.2
180.9
189.4
195.6
216.3
216.9
225.9
241.9
247.8
250.4
259.1
261.2
266.3
269.1
311.5
346.9
379.5
386.9
416.7
441.3
463.8
575.8
0 100 200 300 400 500 600 700
Mexico
Korea
Chile
United Kingdom
Japan
Denmark
Ireland
Norway
Canada
Portugal
Switzerland
Iceland
Netherlands
Belgium
Spain
New Zealand
Australia
Italy
OECD(32)
Israel
Sweden
Austria
Slovenia
France
Estonia
Finland
United States
Czech Republic
Germany
Slovak Republic
Hungary
Poland
Lithuania
Age-Sex Standardised Rate per 100,000 poplation
NHQRS Annual Report 2019
Figure 29: Age-sex standardised hospitalisation rates for heart failure per 100,000 population by 
county of residence, 2016 – 2018
Notes: 
Data refer to the average annual age-sex standardised hospitalsations rate per 100,000 population from 2016-2018.
See table for 95% confidence limits.
See appendix for detailed indicator definitions and methodology.
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Table 13: Age-sex standardised hospitalisation rates for heart failure  per 100,000 population by 
county of residence, 2016 – 2018
Source: Hospital In-Patient Enquiry
Notes: Data refer to the average annual age-sex standardised hospitalisations rate per 100,000 population from 2016-
2018. See appendix for detailed indicator definitions and methodology.
County of Residence Number of Cases
Age-sex
Standardised 
Admission Rate
Lower 95% 
Confidence Limit for 
Admission Rate
Upper 95% 
Confidence Limit for 
Admission Rate
Carlow  274 232.3 204.7 259.9
Cavan  346 204.7 183.1 226.2
Clare  459 167.8 152.4 183.3
Cork  1,918 165.1 157.7 172.5
Donegal  630 161.3 148.6 173.9
Dublin  3,744 142.9 138.3 147.4
Galway  1,050 193.8 182.1 205.6
Kerry  431 113.5 102.8 124.3
Kildare  455 141.0 127.7 154.3
Kilkenny  430 194.5 176.1 212.9
Laois  301 204.0 180.6 227.4
Leitrim  100 112.5 90.2 134.7
Limerick  765 179.8 167.0 192.5
Longford  145 161.4 135.0 187.7
Louth  443 176.2 159.7 192.6
Mayo  766 211.6 196.6 226.5
Meath  598 193.8 178.1 209.5
Monaghan  244 177.9 155.6 200.1
Offaly  303 189.0 167.6 210.4
Roscommon  265 148.2 130.3 166.1
Sligo  299 181.0 160.5 201.5
Tipperary  723 181.8 168.6 195.1
Waterford  467 177.6 161.4 193.7
Westmeath  309 174.1 154.7 193.6
Wexford  662 202.3 186.8 217.7
Wicklow  482 174.6 158.9 190.3
National  16,609 166.7 164.1 169.2
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Overview of selected indicators
There are 13 indicators in this domain in the following 3 areas:
• Cancer survival rates
• Cancer surgery
• Acute hospital care
Cancer survival rates
Cancer survival is one of the key measures of
the effectiveness of cancer care, taking into
account both early detection of the disease
and the effectiveness of treatment. Organised
screening programmes for specific cancers,
shorter waiting times, and the provision of
evidence based treatment are associated
with improved survival [30]. Cancer survival
rates are reported by the National Cancer
Registry Ireland (NCRI) and the Organisation
for Economic Co-operation and Development
(OECD). In this fifth annual report, survival
rates for breast, cervical, colorectal and lung 
cancers are compared between Ireland and 
other OECD countries and also between 
regions of Ireland.
The indicators for cancer survival rates are:
• Breast cancer survival rates
• Cervical cancer survival rates
• Colorectal cancer survival rates
• Lung cancer survival 
Cancer surgery rates
Surgical treatment plays a pivotal role in cancer
care; it can be preventative, diagnostic, curative,
supportive, palliative and/or reconstructive.
Centralisation of cancer surgical services
for many types of cancer is supported by
international evidence [31, 32]. High quality 
care is provided, not only by high volume, 
specialised surgeons, but also by the 
availability of specialist knowledge across the 
multidisciplinary team (e.g. intensive care, 
nursing and allied health professionals) [33, 34, 
35].
Following the 2006 National Cancer Strategy,
eight designated cancer centres were identified
around Ireland, with an additional satellite unit
linked to one centre. It was envisaged that all
cancer surgery would be centralised to these
nine locations (12, 13). In July 2017, the 
Department of Health published the National 
Cancer Strategy, 2017-2026. Further detail 
on optimal cancer service delivery and 
centralisation has been included in this Strategy.
The indicators for cancer surgery are:
• Breast cancer surgical activity
• Colon cancer surgical activity
• Rectal cancer surgical activity.
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Acute hospital care
Stroke care
Stroke is a leading cause of morbidity and mortality globally. In Ireland, over 7,000 patients are admitted 
to hospital each year with a stroke diagnosis. To improve morbidity and mortality outcomes, international 
evidence recommends that all stroke patients, on diagnosis, should be admitted to a properly equipped 
stroke unit, staffed by a trained multidisciplinary team [36].
In-hospital mortality rates
International experts consider in-hospital mortality rates to be useful high level indicators of the quality 
of hospital care when used in association with other measures of quality of care [37]. In this report in-
hospital mortality indicators for heart attack [acute myocardial infarction (AMI)], haemorrhagic stroke 
(caused by bleeding) and ischaemic stroke (caused by a blood clot) are included. The two different types 
of stroke require different treatments and therefore early assessment of the cause of stroke is essential 
to ensure appropriate quality care. While in-hospital mortality rates are calculated in line with OECD 
methodologies to allow for comparison between countries, it must be noted that there are limitations 
associated with these three mortality indicators and these are discussed in the relevant section.
The indicators for in-hospital mortality are:
• In-hospital mortality within 30 days for acute myocardial infarction
• In-hospital mortality within 30 days for haemorrhagic stroke
• In-hospital mortality within 30 days for ischaemic stroke.
In-hospital waiting time for hip fracture surgery
While it is acknowledged that not all patients who experience a hip fracture will be suitable for 
immediate surgery (for example, because of other medical conditions which may need to be stabilised 
prior to surgery), it is also recognised that minimising the time between admission to hospital and 
performance of surgery results in better outcomes for patients. The time to hip fracture surgery is used 
internationally as a measure of quality and is included in this report.
Caesarean section rates
Most professional associations of obstetricians and gynaecologists encourage the promotion of normal 
childbirth without interventions such as caesarean sections [38]. High rates of caesarean section have 
been associated with increased rates of maternal death, maternal and infant morbidity, and increased 
risk of complications in subsequent pregnancies [39, 40]. Internationally, caesarean section rates 
are considered an important measure of the quality of maternity services and are, therefore, publicly 
reported. Caesarean section rates for relevant hospitals in Ireland are included in this report.
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Breast cancer survival rates 
Definition
Age-standardised estimates of cumulative 5-year net survival in Ireland and OECD countries for female breast 
cancer patients diagnosed during the period 2010-2014 and 2011-2015. 
Description
Breast cancer is the most common malignant tumour diagnosed in women in Ireland, with approximately 
2,800 cases diagnosed each year – this represents almost one third of all major cancers diagnosed in women. 
The number of cases of breast cancer diagnosed each year increased by approximately 1.5% between 
1994 and 2013, a trend which may have been influenced by the introduction of the BreastCheck Screening 
Programme in 2000 [41, 42]. Although survival from breast cancer is high, it remains the second most 
common cause of cancer death in women (after lung cancer).
Breast cancer survival reflects advances in treatments, as well as public health interventions to detect the 
disease early through BreastCheck Screening and greater awareness of the disease. The introduction of new 
evidence based treatment regimens and screening programmes has improved survival rates for breast cancer 
in the last few years, as well as improving quality of life for survivors.
For patients diagnosed with cancer, a period approach is used, which allows estimation of five-year survival, 
although five years of follow-up are not available for all patients.
Rationale for the inclusion of indicator 
One in nine women will develop breast cancer at some point in their life and one in thirty will die from the 
disease.
Commentary 
• Five year age-standardised net survival from breast cancer was 85% nationally; there was no statistically 
significant difference between the national rate and any of the four regions.
• The 5-year age-standardised net survival rate for breast cancer in Ireland for the cohort diagnosed in 2010-
2014 was below the OECD average (85%), although this difference was not statistically significant.
• It is important to note that there may be variations between countries due to difference in their coding 
practices, in the definitions and disease classification systems used. This needs to be taken into account 
when comparing the countries.
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Figure 30: Cumulative 5-year age-standardised net survival in Ireland for female breast cancer 
patients diagnosed in 2011-2015 
Source: National Cancer Registry Ireland, March 2018
Note: 
Net survival is an 'improved' version of relative survival which takes better account of competing mortality risks (allow-
ing greater comparability between different populations or age-groups) and represents the cumulative probability of a 
patient surviving a given time in the hypothetical situation in which the disease of interest is the only possible cause 
of death, i.e. survival having controlled for other possible cause of death (by comparison of observed survival with the 
expected survival of persons of the same age and gender in the general population).
See appendix for detailed indicator definitions and methodology.
Exclusions: 
Patients aged under 15 years or over 99 years at diagnosis; death-certificate-only (DCO) and autopsy-only cases; 
second or subsequent malignancies in the same patient (or the less serious of two or more synchronously-diagnosed 
malignancies); in situ carcinomas, benign tumours and tumours of uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on our database. 
As a result, the figures given here may not correspond exactly to those in previous reports or to those previously 
shown on our website.
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Figure 31: Cumulative 5-year age-standardised net survival, female breast cancer, 2010-2014 (or 
nearest period), OECD countries
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Source: Health Statistics, OECD
Note: 1Data with 100% national coverage of population 
Data is presented as published by the OECD; when comparing rates between countries it should be noted that
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as 
well as due to differences in the rates themselves. 95% confidence intervals represented by        .
See appendix for detailed indicator definitions and methodology.
Exclusions: Patients aged under 15 years or over 99 years at diagnosis; death-certificate-only (DCO) and autopsy-only 
cases; second or subsequent malignancies in the same patient (or the less serious of two or more synchronously-
diagnosed malignancies); in situ carcinomas, benign tumours and tumours of uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on our database. As a result, the 
figures given here may not correspond exactly to those in previous reports or to those previously shown in previous 
NHQRS publications .
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Cervical cancer survival rates
Definition
Age-standardised estimates of cumulative 5-year net survival in Ireland and OECD countries for cervical 
cancer patients diagnosed during the period 2010 – 2014 and 2011 - 2015.
Description
Cervical cancer survival reflects advances in treatments, as well as public health interventions to detect the 
disease early through CervicalCheck Screening and greater awareness of the disease.
For patients diagnosed with cancer, a period approach is used, which allows estimation of five-year survival,
although five years of follow-up are not available for all patients.
Rationale for the inclusion of indicator 
Every year in Ireland
• 6,500 women need hospital treatment for a precancerous cervical growth
• 300 (many young) women get cervical cancer
• 90 women die from cervical cancer.
Commentary 
• Five-year age-standardised net survival from cervical cancer was 66.2% nationally; there was no statistically 
significant difference between the national rate and any of the four regions.
• The 5-year age-standardised net survival rate for cervical cancer in Ireland (63.6%) for the period 2010-
2014 was below the OECD average (65.7%), although this difference was not statistically significant.
• It is important to note that there may be variations between countries due to difference in their coding 
practices, in the definitions and disease classification systems used. This needs to be taken into account 
when comparing the countries.
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Source: National Cancer Registry Ireland, March 2018. 
Notes: 
Net survival is an 'improved' version of relative survival which takes better account of competing mortality risks 
(allowing greater comparability between different populations or age-groups) and represents the cumulative probability 
of a patient surviving a given time in the hypothetical situation in which the disease of interest is the only possible 
cause of death, i.e. survival having controlled for other possible cause of death (by comparison of observed survival 
with the expected survival of persons of the same age and gender in the general population).
See appendix for detailed indicator definitions and methodology.
Exclusions: 
Patients aged under 15 years or over 99 years at diagnosis; death-certificate-only (DCO) and autopsy-only cases; 
second or subsequent malignancies in the same patient (or the less serious of two or more synchronously-diagnosed 
malignancies); in situ carcinomas, benign tumours and tumours of uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on our database. 
As a result, the figures given here may not correspond exactly to those in previous reports or to those previously 
shown on our website.
Figure 32: Cumulative 5-year age-standardised net survival in Ireland, cervical cancer, 2011-2015
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Source: OECD Health Statistics
Note: Data is presented as published by the OECD; when comparing rates between countries it should be noted that 
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as 
well as due to differences in the rates themselves. 95% confidence intervals represented by       .
See appendix for detailed indicator definitions and methodology.
Figure 33: Cumulative 5-year age-standardised net survival, cervical cancer, 2010-2014 (or nearest 
period, OECD countries
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Colorectal cancer survival rates 
Definition
Age standardised estimates of cumulative 5-year net survival in Ireland and OECD countries for colorectal 
cancer patients diagnosed during the period 2010 – 2014 and 2011 – 2015.
Description
There are approximately 2,500 cases of colorectal cancer diagnosed each year in Ireland and it is the second 
(after breast cancer) and third (after prostate and lung cancer) most common cancer diagnosed in women and 
men, respectively [42].
Colorectal cancer is the second most common cause of cancer death and causes approximately 1,000 deaths 
in Ireland annually [42].
Advances in diagnosis and treatment of colorectal cancer have increased survival over the last decade. There 
is compelling evidence in support of the clinical benefit of improved surgical techniques, radiation therapy 
and combined chemotherapy, with most countries in the OECD showing improvement in survival over recent 
periods.
For patients diagnosed with cancer, a period approach is used, which allows estimation of five-year survival,
although five years of follow-up are not available for all patients.
Rationale for the inclusion of indicator 
Colorectal cancer is the second most common cause of cancer death and causes approximately 1,000 deaths 
in Ireland annually [42].
Commentary 
• Five-year age-standardised net survival from colorectal cancer was 63% nationally; there was no statistically 
significant difference between the national rate and any of the four regions.
• The 5-year age-sex standardised net survival rate for colon cancer in Ireland (60.5%) for the period 2010-
2014 was below the OECD average (62.4%), although this difference was not statistically significant.
• For rectal cancer, Ireland (61.7%) is slightly above the OECD average (60.7%).
• It is important to note that there may be variations between countries due to difference in their coding 
practices, in the definitions and disease classification systems used. This needs to be taken into account 
when comparing the countries.
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Figure 34: Cumulative 5-year age-standardised net survival in Ireland, colorectal cancer,
2011-2015 
Source: National Cancer Registry Ireland, March 2018
Notes: 
Net survival is an 'improved' version of relative survival which takes better account of competing mortality risks 
(allowing greater comparability between different populations or age-groups) and represents the cumulative probability 
of a patient surviving a given time in the hypothetical situation in which the disease of interest is the only possible 
cause of death, i.e. survival having controlled for other possible cause of death (by comparison of observed survival 
with the expected survival of persons of the same age and gender in the general population).
See appendix for detailed indicator definitions and methodology.
Exclusions: 
Patients aged under 15 years or over 99 years at diagnosis; death-certificate-only (DCO) and autopsy-only cases; 
second or subsequent malignancies in the same patient (or the less serious of two or more synchronously-diagnosed 
malignancies); in situ carcinomas, benign tumours and tumours of uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on our database. 
As a result, the figures given here may not correspond exactly to those in previous reports or to those previously 
shown on our website.
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Figure 35: Cumulative 5-year age-standardised net survival, colon cancer, 2010-2014 (or nearest 
period), OECD countries
Source: OECD Health Statistics
Notes: Data is presented as published by the OECD; when comparing rates between countries it should be noted that 
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as 
well as due to differences in the rates themselves. 95% confidence intervals represented by        .  
See appendix for detailed indicator definitions and methodology.
1 Data with 100% national coverage of the population.' 
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Figure 36: Cumulative 5-year age-standardised net survival, rectal cancer, 2010-2014 (or nearest 
period), OECD countries
Source: OECD Health Statistics
Notes: Data is presented as published by the OECD; when comparing rates between countries it should be noted that 
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as 
well as due to differences in the rates themselves. 95% confidence intervals represented by        .
See appendix for detailed indicator definitions and methodology.
1 Data with 100% national coverage of the population.
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Lung cancer survival rates 
Definition
Age standardised estimates of cumulative 5-year net survival in Ireland and countries contributing data to the 
CONCORD-3 study for lung cancer patients diagnosed during the period 2010 – 2014 and 2011 - 2015.
Description
Lung cancer is the leading cause of cancer death in both men and women in Ireland (ECIS - European Cancer 
Information System, 2019) (Central Statistics Office , 2019) (National Cancer Registry Ireland, 2015). Incidence 
rates of lung cancer in the most deprived areas in Ireland are more than twice as high as rates in the least 
deprived areas, reflecting the strong association with smoking. (National Cancer Registry Ireland, 2015)
Lung cancer remains by far the most common cause of death from cancer among men (25% of all cancer 
deaths across the EU) and the second most common among women (after breast cancer). (OECD/EU, 2018).
For patients diagnosed with cancer, a period approach is used, which allows estimation of five-year survival,
although five years of follow-up are not available for all patients. 
Rationale for the inclusion of indicator 
Net survival rates for lung cancer are very poor in comparison with many other cancers, with an age-
standardised 1-year survival of 37% and a 5-year survival of 15.3% in the period 2008-2012. (National 
Cancer Registry Ireland, 2015). 
Commentary 
• The national 5-year age standardised net lung cancer survival rate for those patients diagnosed between 
2011 and 2015 was 19.5%. 
• For those diagnosed between 2010 and 2014, th 5-year net survival rate was 17.5% as reported in the 
CONCORD-3 study. 
• It is important to note that there may be variations between countries due to difference in their coding
 practices, in the definitions and disease classification systems used. This needs to be taken into account
 when comparing the countries.
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Figure 37: Cumulative 5-year age-standardised net survival in Ireland for lung cancer patient diagnosed 
in 2011-2015
Source: National cancer Registry of Ireland
Notes: 
*Net survival is an 'improved' version of relative survival which takes better account of competing mortality risks (allow-
ing greater comparability between different populations or age-groups) and represents the cumulative probability of a 
patient surviving a given time in the hypothetical situation in which the disease of interest is the only possible cause 
of death, i.e. survival having controlled for other possible cause of death (by comparison of observed survival with the 
expected survival of persons of the same age and gender in the general population).
Estimates here are 'Pohar Perme' estimates of net survival, implemented using the 'Strs' algorithm in Stata.
Exclusions: 
Patients aged under 15 years or over 99 years at diagnosis; death-certificate-only (DCO) and autopsy-only cases; 
second or subsequent malignancies in the same patient (or the less serious of two or more synchronously-diagnosed 
malignancies); in situ carcinomas, benign tumours and tumours of uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on our database. As a result, the fig-
ures given here may not correspond exactly to those in previous reports or to those previously shown on our website.
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Figure 38: Cumulative age-standardised 5-year net survival, lung cancer, 2010-2014 (or nearest 
period), European countries 
7.7
10.0
10.6
11.2
13.0
13.3
13.5
14.4
14.8
14.9
15.7
15.9
16.6
16.9
17.3
17.5
18.2
18.3
18.7
19.0
19.5
19.7
20.2
20.4
20.4
0 5 10 15 20 25
Bulgaria
Croatia
Czech Republic
Slovakia
Finland
United Kingdom
Spain
Poland
Slovenia
Malta
Portugal
Italy
Denmark
Estonia
France
Ireland
Belgium
Germany
Cyprus
Netherlands 1
Sweden 1
Austria
Iceland 1
Latvia
Switzerland
Age-standardised survival (%)
Source: National Cancer Registry of Ireland; Global surveillance of trends in cancer survival 2000–14(CONCORD-3): anal-
ysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries 
in 71 countries.
Notes: 
When comparing rates between countries it should be noted that differences may be due to the method of collection, 
the scope of data collection or the quality of the data collected as well as due to differences in the rates themselves. 95% 
confidence intervals represented by       .
See appendix for detailed indicator definitions and methodology.
1 Data with 100% coverage of the national population. 
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Hospital location of breast cancer surgery in patients with breast cancer
Definition
The number of breast cancer surgical procedures undertaken in designated cancer centres each year, in 
patients whose principal diagnosis is breast cancer. The proportion of all breast cancer surgical procedures 
nationally that is undertaken in designated cancer centres, in patients whose principal diagnosis is breast 
cancer.
Description
Most breast cancers are treated with a combination of treatments; surgery, radiotherapy, hormone therapy, 
chemotherapy and/or immunotherapy. The majority (85%) of patients will have some form of surgical 
intervention as part of their treatment [41].
International evidence advises that breast cancer patients experience better outcomes when treated by 
surgeons who perform high volumes of breast cancer surgery (a minimum of 50 per year) and when that 
treatment is received in high volume centres [43, 44, 45].
In 2006, breast cancer surgery was undertaken in 32 public hospitals in Ireland, and several hospitals recorded 
less than 50 procedures in the year.
In 2007, the National Cancer Control Programme (NCCP) was established to reorganise the way cancer
care was delivered in Ireland. Eight hospitals were designated as cancer centres. An additional satellite for 
breast cancer services was provided in one location in Ireland. Surgical treatment of breast cancer has been 
centralised to these designated cancer centres. The National Cancer Strategy 2017 - 2026 envisages the 
complete centralisation of cancer surgical services by 2020.
Rationale for the inclusion of indicator
Breast cancer is the most common malignant tumour diagnosed in women in Ireland, with approximately 
2,800 cases diagnosed each year. This represents almost one third of all major cancers diagnosed in women.
Commentary 
• Figure 39 shows breast cancer surgical activity in the designated cancer centres 2009-2018. The number of 
cases has increased each year since 2013. In 2018, there were 3,133 breast cancer surgeries nationally.
• Figure 40 shows the proportion of all breast cancer surgery nationally that is undertaken in designated 
cancer centres 2009-2018, in patients whose principal diagnosis is breast cancer. The graph demonstrates 
that since 2010 almost all breast cancer surgical activity has been centralised to the designated cancer 
centres.
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Figure 39: Number of breast cancer surgeries undertaken in designated cancer centres in patients 
whose principal diagnosis is breast cancer, 2009-2018
Figure 40: Proportion of breast cancer surgery nationally in patients whose principal diagnosis is 
breast cancer undertaken in designated cancer centres, 2009-2018
Source: Hospital In-patient Enquiry (HIPE) 
Notes: Includes ductal carcinoma in situ.
See appendix for detailed indicator definitions and methodology.
Source: Hospital In-patient Enquiry (HIPE) 
Notes: Includes ductal carcinoma in situ.
See appendix for detailed indicator definitions and methodology. 
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Hospital location of colon cancer surgery in patients with colon cancer
Definition
The number of colon cancer surgical procedures undertaken in each hospital in patients whose principal 
diagnosis is colon cancer. The proportion of all colon cancer surgical procedures nationally that is undertaken 
in designated cancer centres, in patients whose principal diagnosis is colon cancer.
Description
In 2006, colon cancer surgical procedures in patients with colon cancer were undertaken in 35 hospitals in 
Ireland. In 2007, the National Cancer Control Programme (NCCP) was established to reorganise the way that 
cancer care was delivered in Ireland. Cancer services were centralised to eight designated cancer centres.
The data presented in this report includes both elective (planned) and emergency procedures; subject to data 
availability, it is intended that future editions of this report will present the number of elective and emergency 
procedures performed and will report this data by hospital. All cancers diagnosed under the national screening 
programme, BowelScreen, are treated electively in the designated cancer centres.
It was envisaged that curative surgical treatment of primary colon cancer was to be centralised to the eight 
designated centres. A significant proportion of colon cancer surgery still occurs outside designated cancer 
centres.
Rationale for the inclusion of indicator
There are approximately 2,500 cases of colorectal cancer diagnosed each year in Ireland. International 
evidence suggests that patients with colorectal cancer experience better overall five year survival when 
treated in a high volume hospital by a high-volume specialist surgeon [46].
Commentary 
• Figure 41 shows the number of colon cancer surgical procedures undertaken in the designated cancer 
centres 2009-2018, in patients whose principal diagnosis is colon cancer. The annual number of cases 
undertaken in a designated cancer centre increased from 462 in 2009 to 619 in 2018. In 2017, there was a 
decline in this number to 580, however, this number has since increased. 
• Figure 42 shows the proportion of this activity that is undertaken in the designated cancer centres. This 
percentage has dropped from 2016 (63.5%) to 2017 (59.0%), as the number of surgical cases for colon 
cancer dropped. However, this increased in 2018 to the same proportion seen in 2016: 63.5%. 
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Source: Hospital In-patient Enquiry System 
Notes: Includes colonic carcinoma in situ. In 2015, there was an update to ICD-10 AM/ACHI from the 6th to the 
8th edition, which resulted in addition procedure codes related to colon cancer surgical treatment. See appendix for 
definitions and methodology. 
See appendix for detailed indicator definitions and methodology.
Source: Hospital In-patient Enquiry System 
Notes: Includes colonic carcinoma in situ. In 2015, there was an update to ICD-10 AM/ACHI from the 6th to the 
8th edition, which resulted in addition procedure codes related to colon cancer surgical treatment. See appendix for 
definitions and methodology. 
See appendix for detailed indicator definitions and methodology.
Figure 41: Number of colon cancer surgeries undertaken in designated cancer centres in patients 
whose principal diagnosis is colon cancer, 2009-2018
Figure 42: Proportion of colon cancer surgery nationally in patients whose principal diagnosis is 
colon cancer undertaken in designated cancer centres, 2009-2018
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Hospital location of rectal cancer surgery in patients with rectal cancer
Definition
The number of rectal cancer surgical procedures undertaken in each hospital in patients whose principal 
diagnosis is cancer of the rectum. The proportion of all rectal cancer surgical procedures nationally that is 
undertaken in designated cancer centres, in patients whose principal diagnosis is rectal cancer.
Description
In 2006, rectal cancer surgical procedures in patients with rectal cancer were undertaken in 33 hospitals 
in Ireland. Eight hospitals were designated as cancer centres. The National Cancer Strategy 2017 – 2026 
envisages the complete centralisation of cancer surgical services by 2020.
The data presented in this report includes both elective (planned) and emergency procedures; subject to data 
availability. It is intended that future editions of this report will present the number of elective and emergency 
procedures performed and will report this data by hospital. All cancers diagnosed under the national screening 
programme, BowelScreen, are treated electively in the designated cancer centres.
It is noted that in 2008, the Royal College of Surgeons of Ireland (RCSI), in collaboration with the National 
Cancer Registry of Ireland (NCRI) and funded by the National Cancer Control Programme (NCCP), undertook 
a retrospective audit of all rectal cancers that underwent surgery in 2007 in a public hospital in Ireland. 
Following the audit, the Irish Association of Coloproctology recommended that:
• Rectal cancer surgery should not be performed in hospitals where fewer than 20 rectal cancer surgeries are 
carried out annually.
• Rectal cancer surgery should be performed in all eight designated cancer centres with provisos in relation to 
number of operations, adherence to guidelines, surgeon training, nomination of a lead surgeon, discussion of 
patients at multidisciplinary team meetings and participation in audit.
• Rectal cancer surgery could be performed in a small number of high volume non-designated centres, with 
similar provisos as the cancer centres, on an interim basis [47].
The centralisation of surgical services for rectal cancer is being reviewed in light of current evidence and new 
treatment modalities. Further concentration of these services is envisaged.
Rationale for the inclusion of indicator 
International evidence advises that patients with cancer of the rectum experience better overall five-year 
survival when treated in a high-volume hospital by a high-volume surgeon [46].
Commentary 
• Figure 43 shows the number of rectal cancer surgical procedures undertaken in the designated cancer 
centres 2009-2018, in patients whose principal diagnosis is cancer of the rectum. The number of surgeries 
in designated cancer centres increased annually from 2009 (265 cases) to 2018 (425 cases).
• Figure 44 shows the proportion of this activity that is undertaken in the designated cancer centres; this 
proportion increased from 50% of all activity undertaken in 2009 to 82% in 2018.
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Source: Hospital In-Patient Enquiry
 
Notes: Includes rectal carcinoma in situ. In 2015, there was an update to ICD-10 AM/ACHI from the 6th to the 8th 
edition, which resulted in addition procedure codes related to colon cancer surgical treatment. See appendix for 
definitions and methodology.
See appendix for detailed indicator definitions and methodology.  
Source: Hospital In-Patient Enquiry 
Notes: Includes rectal carcinoma in situ. In 2015, there was an update to ICD-10 AM/ACHI from the 6th to the 8th 
edition, which resulted in addition procedure codes related to colon cancer surgical treatment. See appendix for 
definitions and methodology. 
See appendix for detailed indicator definitions and methodology.
Figure 43: Number of rectal cancer surgeries undertaken in designated cancer centres in patients 
whose principal diagnosis is rectal cancer, 2009-2018
Figure 44: Proportion of rectal cancer surgery nationally in patients whose principal diagnosis is 
rectal cancer undertaken in designated cancer centres, 2009-2018
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In-hospital mortality within 30 days for acute myocardial infarction (AMI)/ 
heart attack
Definition
The number of patients aged 45 and over who die in hospital within 30 days of being admitted with a 
principal diagnosis of an AMI, as a proportion of the total number of patients aged 45 and over admitted to 
that hospital with a principal diagnosis of an AMI.
Description
AMIs are life-threatening emergencies that happen when the coronary arteries, the blood vessels supplying 
blood to the heart muscle, are suddenly blocked. Lack of blood damages the heart muscle, weakening its 
function or stopping it altogether. Evidence links the processes of care for AMI, such as thrombolysis and 
early treatment with aspirin and beta-blockers, to survival improvements. The use of the 30-day mortality rate 
after AMI is a recognised outcome measure of acute care quality, and is one of the OECD Health Care Quality 
Indicators.
Rationale for the inclusion of indicator
By 2020 the number of adults with clinically diagnosed coronary heart disease is expected to rise to more 
than 103,000 [48]. One of the potential consequences for those with heart disease is that they experience an 
AMI which is one of the leading causes of death in Ireland.
Commentary 
• The national trend in the age-sex standardised mortality rates (also known as age-sex standardised death 
rates or ASDR) following AMI over the last 10 years (2009 to 2018) is shown below. Between 2009 and 
2018, there was a 30% reduction in the age-sex standardised in-hospital mortality rates within 30 days of 
admission for AMI in this time (7.5 in 2009 to 5.1 in 2018). 
• In 2015, (the latest year for which OECD data is available) the average age-sex standardised in-hospital 
mortality rate in the 30 days following admission to hospital for AMI in Ireland was lower than the OECD 
average rate (i.e. 6.4 deaths per 100 cases admitted in Ireland, compared to the OECD average of 7.5 
deaths per 100 cases admitted), although this difference was not statistically significant.
• Reviewing the three year period from 2016-2018, it was found that in most hospitals the age-sex 
standardised mortality rates were within or lower than the expected range. 
• It is important to note however, that the age-sex standardised rates presented here are high level indicators 
only. There can be many reasons why the age-sex standardised mortality rates for a hospital would be higher 
or lower than the national average, including
a)  differences in the types of patients attending different hospitals (for example some hospitals may have a 
higher or lower proportion of patients with other medical conditions attending than others and this may 
influence outcomes),
b)  inconsistencies in the quality of the data gathered in different hospitals,
c)  differences in access to medical care prior to arrival at the hospital,
d)  transfer patterns of patients between different hospitals,
e)  variations in the quality of care delivered in different hospitals.
• Therefore, it cannot be concluded that a high mortality rate is indicative of poorer quality care. Rather it 
provides an indication that a further evaluation should be carried out to determine the reasons for the 
identified variation.
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Source: Hospital In-Patient Enquiry
Note: See appendix for detailed indicator definitions and methodology.
Figure 45: Age-sex standardised in-hospital mortality rates within 30 days of admission for AMI, 
2009 – 2018
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Source: Hospital In-Patient Enquiry
Note:  Data is presented as published by the OECD; when comparing rates between countries it should be noted 
that differences may be due to the method of collection, the scope of data collection or the quality of the data 
collected as well as due to differences in the rates themselves. 95% confidence intervals represented by       .
See appendix for detailed indicator definitions and methodology.
1 Three year average
2 Results do not include deaths outside of acute care hospitals.
Figure 46: Age-sex standardised in-hospital mortality rates within 30 days of admission for AMI for 
selected OECD countries, 2015 (or nearest year)
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Source: Hospital In-Patient Enquiry
Notes: Hospitals with small numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 cases, although the data for these hospitals have been included 
in the calculation of the national rates. However some hospitals with more than 100 cases may still have unstable rates 
and caution should be exercised in interpreting rates with wide confidence intervals. The data presented above are age-
sex standardised mortality rates per 100 cases. 95% confidence intervals for hospitals and hospital groups are shown 
by       . Where the 95% confidence interval for a hospital or hospital group overlaps the 95% confidence interval of the 
national rate (i.e. the dashed green lines), it can be concluded that the rate is not statistically significantly different from 
the national rate and so is within the expected range. Where the 95% confidence interval for a hospital or hospital group 
does not overlap the confidence interval of the national rate, it implies that the mortality rate is statistically significantly 
different from the national rate and is therefore outside the expected range.
See appendix for detailed indicator definitions and methodology.
Figure 47: Age-sex standardised in-hospital mortality rates within 30 days of admission for AMI by 
hospital group and hospital, 2016-2018
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Source: Hospital In-Patient Enquiry
Note: Hospitals with small numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 cases, although the data for these hospitals have been included in 
the calculation of the national rates. However some hospitals with more than 100 cases may still have unstable rates and 
caution should be exercised in interpreting rates with wide confidence confidence intervals. See Appendix 3 for detailed 
indicator definitions and methodology.
Table 14: Age-sex standardised in-hospital mortality within 30 days of admission for AMI by hospital group 
and hospital, 2016 – 2018
Hospital Group Number of Cases
Age-sex Standardised 
Mortality Rate (ASDR) 
per 100 Cases
Lower 95% 
Confidence 
Limit for ASDR
Upper 95% 
Confidence Limit 
for ASDR
Dublin Midlands  3,340 5.66 4.77 6.56
St. James's Hospital  1,820 6.07 4.79 7.36
Tallaght University Hospital  651 5.81 3.42 8.19
Naas General Hospital  343 5.74 3.10 8.37
Midland Regional Hospital Portlaoise  273 4.70 1.95 7.45
Midland Regional Hospital Tullamore  253 4.04 1.66 6.43
Ireland East  4,329 5.27 4.58 5.96
Mater Misericordiae University Hospital  1,586 6.32 4.95 7.68
St. Vincent's University Hospital  804 6.88 5.18 8.59
St. Luke's General Hospital  560 4.60 2.76 6.44
Wexford General Hospital  635 2.74 1.51 3.97
Our Lady's Hospital Navan  378 1.56 0.18 2.95
Midland Regional Hospital Mullingar  319 5.97 3.76 8.18
St. Columcille's Loughlinstown  18 - - -
St. Michael's Hospital  29 - - -
RCSI  2,093 5.67 4.67 6.67
Beaumont Hospital  607 4.92 2.99 6.85
Our Lady of Lourdes Hospital  540 6.40 4.44 8.35
Connolly Hospital  414 5.57 3.14 7.99
Cavan General Hospital  532 5.09 3.38 6.79
Saolta  3,624 4.95 4.25 5.66
Galway University Hospital  1,707 4.77 3.66 5.87
Mayo University Hospital  618 4.85 3.24 6.45
Letterkenny University Hospital  557 5.80 4.10 7.51
Sligo University Hospital  434 2.64 0.90 4.39
Portiuncula University Hospital  300 8.53 5.4 11.66
Roscommon University Hospital  8 - - -
South / South West  3,456 5.56 4.75 6.36
Cork University Hospital  1,800 5.10 3.91 6.29
University Hospital Waterford  564 6.85 4.68 9.01
University Hospital Kerry  377 7.21 5.25 9.16
South Tipperary General Hospital  276 5.35 2.85 7.85
Mercy University Hospital  237 5.75 2.59 8.90
Bantry General Hospital  148 8.93 4.28 13.58
Mallow General Hospital  54 - - -
UL Hospitals  1,537 4.51 3.47 5.56
University Hospital Limerick  1,387 4.57 3.43 5.71
Ennis Hospital  68 - - -
Nenagh Hospital  64 - - -
St. Johns Hospital  18 - - -
Total for All Hospitals  18,379 5.29 4.96 5.63
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Stroke admissions to hospitals with stroke units
Description
The proportion of patients nationally, whose principal diagnosis is stroke, who are admitted to a hospital with 
a Stroke Unit on diagnosis.
Rationale for the inclusion of indicator 
A stroke is the sudden death of brain cells in a localised area due to inadequate blood flow caused by a 
haemorrhage (bleeding) or ischaemia (blood clot). Stroke is a leading cause of morbidity and mortality in 
Ireland; over 7,000 people in Ireland are hospitalised following stroke each year [49] and approximately 2,000 
people die as a result of stroke each year.
In 2010 the National Clinical Programme for Stroke was developed with the key aims of:
• National rapid access to best-quality stroke services including acute stroke unit care and fast door-to-
decision times for thrombolysis and thrombectomy where appropriate.
• Prevent 1 stroke every day
• Avoid death and dependence in 1 patient every day.
To improve morbidity and mortality outcomes, international evidence recommends that all stroke patients, on 
diagnosis, should be admitted to a properly equipped stroke unit, staffed by a multidisciplinary team, which 
should include, at a minimum, appropriately trained medical and nursing staff, physiotherapists, occupational 
therapists and speech and language therapists [36]. The Irish Council for Stroke Guidelines state that all 
hospitals providing care for acute stroke patients must make available immediate access to a specialist, acute 
stroke unit or comprehensive stroke unit (providing acute care and rehabilitation) with the capacity to monitor 
and regulate basic physiological functions [50].
The National Clinical Programme for Stroke reports that 22 hospitals provide acute stroke unit care. 
The HSE has a KPI for stroke unit care of 90% admission of acute stroke patients to stroke units. The current 
level of performance in this regard is 70%. A lack of acute stroke unit beds for case numbers presenting has 
been reported in hospital sites. This is being quantified in the new national stroke strategy. 
Commentary 
• Figure 48 shows the proportion of patients whose principal diagnosis is stroke who were admitted to a 
hospital with a stroke unit in 2018. Although this does not mean that all these patients were admitted 
directly to the stroke unit, it does suggest that these patients had access to an expert stroke team. 
• In 2018, 85% of stroke patients were admitted to a hospital with a stroke unit. This is a slight increase on 
figures seen in 2015, 2016 and 2017, where 83% of patients with a principal diagnosis of stroke were 
admitted to hospitals with stroke units. 
Figure 48: The proportion of patients whose principal diagnosis is stroke who were admitted to a 
hospital with a stroke unit, 2018
Source: Hospital In-Patient Enquiry
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In-hospital mortality within 30 days for haemorrhagic stroke
Description
The number of patients aged 45 years and over who die in hospital within 30 days of being admitted with a 
principal diagnosis of an haemorrhagic stroke, as a proportion of the total number of patients aged 45 years 
and over admitted to that hospital with a principal diagnosis of an haemorrhagic stroke.
Rationale for the selection of indicator 
A stroke is the sudden death of brain cells in a localised area due to inadequate blood flow caused by a 
haemorrhage (bleeding) or ischaemia (blood clot). Stroke is a leading cause of morbidity and mortality in 
Ireland; over 7,000 people in Ireland are hospitalised following stroke each year [49] and approximately 2,000 
people die as a result of stroke each year.
In 2010 the National Clinical Programme for Stroke was developed with the key aims of:
• National rapid access to best-quality stroke services including acute stroke unit care and fast door to 
decision times for thrombolysis and thrombectomy where appropriate.
• Prevent 1 stroke every day
• Avoid death and dependence in 1 patient every day.
To improve morbidity and mortality outcomes, international evidence recommends that all stroke patients, on 
diagnosis, should be admitted to a properly equipped stroke unit, staffed by a multidisciplinary team, which 
should include, at a minimum, appropriately trained medical and nursing staff, physiotherapists, occupational 
therapists and speech and language therapists [36]. The Irish Council for Stroke Guidelines state that all 
hospitals providing care for acute stroke patients must make available immediate access to a specialist, acute 
stroke unit or comprehensive stroke unit (providing acute care and rehabilitation) with the capacity to monitor 
and regulate basic physiological functions such as heart rate and rhythm, arterial oxygen saturation, blood 
pressure and blood glucose [50].
Variations in stroke mortality rates reflect many factors including early recognition of symptoms, seeking 
medical care as quickly as possible and, potentially, differences in the care provided.
Commentary 
• The age-sex standardised in-hospital mortality rate within 30 days of admission for haemorrhagic stroke has 
reduced by 16% over the ten year period from 2009 to 2018, with 27.9 deaths per 100 cases admitted in 
2009 compared to 23.4 deaths per 100 cases admitted in 2018.
• In 2016, the average age-sex standardised in-hospital mortality rate within 30 days of admission with
 haemorrhagic stroke in Ireland was above the OECD average rate (i.e. 24.6 deaths per 100 cases for Ireland 
in that year compared to the OECD average of 22.8 deaths per 100 cases). 
• During the three year period from 2016-2018, the age-sex standardised in-hospital mortality rate for 
three hospitals (in orange, Figure 51) was statistically significantly higher than the national rate at the 95% 
confidence level. The rates for all other hospitals were within or lower than the expected range (Table 15, 
Figure 51).
• It is important to note however, that the age-sex standardised rates presented here are high level indicators 
only. There can be many reasons why a hospital would have higher or lower rates than the national average, 
including:
a) differences in the types of patients attending different hospitals (for example, some hospitals may have a 
higher or lower proportion of patients with other medical conditions attending than others, and this may 
influence outcomes),
b) inconsistencies in the quality of the data gathered in different hospitals,
c) differences in access to medical care prior to arrival at the hospital,
d) transfer patterns of patients between different hospitals,
e) variations in quality of care delivered in different hospitals.
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• Therefore, it cannot be concluded that a high mortality rate is indicative of poor quality care. Rather it 
provides an indication that a further evaluation should be carried out to determine the reasons for the 
identified variation in mortality rates.
• The National Clinical Programme for Stroke is clear that care in stroke units improves outcomes and reduces 
mortality for all groups and subtypes of stroke. A stroke unit ensures that core stroke services in terms 
of enhanced monitoring, swallow screening for dysphagia, and nutritional assessment are all delivered 
through the context of organised care and stroke units but only 70% of acute stroke cases nationally were 
admitted to a stroke unit, well below the 90% KPI. Some sites report that a lack of acute stroke unit beds 
remain a challenge for individual hospital site activity e.g. Cork University Hospital. The acute stroke unit 
bed requirement has been mapped for individual sites by the national stroke programme as part of its new 
national stroke strategy. Certain sites such as Beaumont hospital are tertiary referral centres for suitable 
cases of intracerebral haemorrhage and thus  have higher rates of admission for intracerebral haemorrhage  
on a largely  ‘treat and return’ basis which may influence figures.. In 2018, 85% of patients experiencing 
a stroke in Ireland were admitted to a hospital with a stroke unit. Hospitals with the highest age- sex 
standardised in-hospital mortality rates for haemorrhagic stroke should examine the reasons for identified 
variation including examination of access to core stroke services and access to standard protocols and care 
pathways to facilitate timely identification and transfer of suitable patients to neurosurgical centres.
 The National Office of Clinical Audit (NOCA) has recently announced that the Irish national Audit for Stroke 
will now sit within the National Cardiovascular Disease Audit Programme in NOCA. In time, this may give 
additional information on the quality of stroke care provided. 
Figure 49: Age-sex standardised in-hospital mortality rates within 30 days of admission for
haemorrhagic stroke, 2009 – 2018
Source: Hospital In-Patient Enquiry
Note: See appendix for detailed indicator definitions and methodology. 
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Figure 50: Age-sex standardised in-hospital mortality rates within 30 days of admission for
haemorrhagic stroke for selected OECD countries, 2016 (or nearest year)
Source: OECD Health Statistics
Notes: 12011, 22012, 32013, 42014
Norway, Slovak Republic and Mexico deviate from the OECD definition. 
Data is presented as published by the OECD; when comparing rates between countries it should be noted that 
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as 
well as due to differences in the rates themselves. 95% confidence intervals represented by        .
See appendix for detailed indicator definitions and methodology.
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Figure 51: Age-sex standardised in-hospital mortality rates within 30 days of admission for
haemorrhagic stroke by hospital group and hospital, 2016 – 2018
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Source: Hospital In-Patient Enquiry
Notes:
Hospitals with small numbers of cases tend to have unstable rates and wider confidence intervals. For this report rates 
are not displayed for hospitals with less than 100 cases, although the data for these hospitals have been included in the 
calculation of the national rates. However some hospitals with more than 100 cases may still have unstable rates and 
caution should be exercised in interpreting rates with wide confidence intervals. The data presented above are age-sex 
standardised mortality rates per 100 cases. 95% confidence intervals for hospitals and hospital groups are shown by       . 
Where the 95% confidence interval for a hospital or hospital group overlaps the 95% confidence interval of the national 
rate (i.e. the dashed green lines), it can be concluded that the rate is not statistically significantly different from the national 
rate and so is within the expected range. Where the 95% confidence interval for a hospital or hospital group does not 
overlap the confidence interval of the national rate, it implies that the mortality rate is statistically significantly different 
from the national rate and is therefore outside the expected range.
See appendix for detailed indicator definitions and methodology.
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Table 15: Age-sex standardised in-hospital mortality rates within 30 days of admission for
haemorrhagic stroke by hospital group and hospital, 2016-2018
Hospital Group Number of Cases
Age-sex Standardised 
Mortality Rate (ASDR) 
per 100 Cases
Lower 95% 
Confidence
 Limit for ASDR
Upper 95% 
Confidence Limit for 
ASDR
Dublin Midlands 548 27.05 23.30 30.79
Midland Regional Hospital Portlaoise 33 - - -
Midland Regional Hospital Tullamore 68 - - -
Naas General Hospital 126 33.19 25.25 41.13
St. James's Hospital 183 28.18 21.34 35.02
Tallaght University Hospital 138 25.69 18.34 33.03
Ireland East 1,018 25.93 23.31 28.54
Mater Misericordiae University Hospital 301 19.98 15.42 24.53
Midland Regional Hospital Mullingar 82 - - -
Our Lady's Hospital Navan 67 - - -
St. Columcille's Loughlinstown 17 - - -
St. Luke's General Hospital 107 32.73 24.68 40.79
St. Michael's Hospital 13 - - -
St. Vincent's University Hospital 325 28.73 23.63 33.83
Wexford General Hospital 106 26.57 18.88 34.27
RCSI Hospitals 1,494 17.16 15.14 19.19
Beaumont Hospital 1,131 12.31 10.13 14.50
Cavan General Hospital 102 28.26 20.56 35.97
Connolly Hospital 131 29.43 21.90 36.95
Our Lady of Lourdes Hospital 130 26.49 18.37 34.61
Saolta 590 24.83 21.35 28.30
Galway University Hospital 196 32.04 25.55 38.53
Letterkenny University Hospital 94 - - -
Mayo University Hospital 122 23.03 15.20 30.85
Portiuncula University Hospital 74 - - -
Roscommon University Hospital <10 - - -
Sligo University Hospital 97 28.73 22.48 34.97
South / South West Hospital Group 980 25.90 23.24 28.57
Bantry General Hospital 43 - - -
Cork University Hospital 541 28.93 25.11 32.74
University Hospital Kerry 115 24.17 17.93 30.40
Mallow General Hospital 10 - - -
Mercy University Hospital 58 - - -
South Tipperary General Hospital 99 - - -
University Hospital Waterford 114 29.11 21.25 36.97
UL Hospitals 284 26.69 21.72 31.66
Ennis Hospital 12 - - -
Nenagh Hospital 18 - - -
St. Johns Hospital 8 - - -
University Hospital Limerick 250 29.35 24.04 34.66
Total for All Hospitals 4,914 23.50 22.34 24.67
Source: Hospital In-Patient Enquiry
Note: Hospitals with small numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 cases, although the data for these hospitals have been included 
in the calculation of the national rates. However some hospitals with more than 100 cases may still have unstable rates 
and caution should be exercised in interpreting rates with wide confidence intervals. *Due to the low number of cases for 
certain hospitals, data in the above table has been suppressed in a number of cells for data protection reasons.
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In-hospital mortality within 30 days for ischaemic stroke
Description
The number of patients aged 45 years and over who die in hospital within 30 days of being admitted with a 
principal diagnosis of an ischaemic stroke, as a proportion of the total number of patients aged 45 years and 
over admitted to that hospital with a principal diagnosis of an ischaemic stroke. 
Rationale for the selection of indicator 
A stroke is the sudden death of brain cells in a localised area due to inadequate blood flow caused by a 
haemorrhage (bleeding) or ischaemia (blood clot). Stroke is a leading cause of morbidity and mortality in 
Ireland; over 7,000 people in Ireland are hospitalised following stroke each year [49] and approximately 2,000 
people die as a result of stroke each year.
An ischaemic stroke is caused by death of brain cells in a localized area due to inadequate blood flow caused 
by ischaemia (blood clot). Ischaemic strokes account for approximately 85% of all strokes which result in 
hospitalisation in Ireland annually [51].
In 2010 the National Clinical Programme for Stroke was developed with the key aims of:
• National rapid access to best-quality stroke services including acute stroke unit care and fast door to 
decision times for thrombolysis and thrombectomy where appropriate 
• Prevent 1 stroke every day
• Avoid death and dependence in 1 patient every day.
To improve morbidity and mortality outcomes, international evidence recommends that all stroke patients, on 
diagnosis, should be admitted to a properly equipped stroke unit, staffed by a multidisciplinary team, which 
should include, at a minimum, appropriately trained medical and nursing staff, physiotherapists, occupational 
therapists and speech and language therapists [36]. The Irish Council for Stroke Guidelines state that all 
hospitals providing care for acute stroke patients must make available immediate access to a specialist, acute 
stroke unit or comprehensive stroke unit (providing acute care and rehabilitation) with the capacity to monitor 
and regulate basic physiological functions such as heart rate and rhythm, arterial oxygen saturation, blood 
pressure and blood glucose [50].
Variations in stroke mortality rates reflect many factors including early recognition of symptoms, seeking 
medical care as quickly as possible and, potentially, differences in the care provided.
Commentary 
• The age-sex standardised in-hospital mortality rate within 30 days of admission for ischaemic stroke 
decreased from 10.2 deaths per 100 cases admitted in 2009 to 6.8 deaths per 100 cases admitted in 2018, 
a reduction of 33%. 
• In 2015, the average age-sex standardised in-hospital mortality rate within 30 days of admission with 
ischaemic stroke in Ireland was above the OECD average rate (i.e. 9.7 deaths per 100 cases admitted for 
Ireland in that year compared to the OECD average of 8.4 deaths per 100 cases admitted). 
• During the three-year period from 2016-2018, age-sex standardised in-hospital mortality rate for two 
hospitals (in orange, Figure 54) were statistically significantly higher than the national rate at the 95% 
confidence level. The rates for all other hospitals were within or lower than the expected range (Table 16 
and Figure 54).
• It is important to note however that the age-sex standardised rates presented here are high level indicators 
only. There can be many reasons why a hospital would have higher or lower rates than the national average, 
including
a) differences in the types of patients attending different hospitals (for example, some hospitals may have a 
higher or lower proportion of patients with other medical conditions attending than others and this may 
influence outcomes),
b) inconsistencies in the quality of the data gathered in different hospitals,
c) differences in access to medical care prior to arrival at the hospital,
d) transfer patterns of patients between different hospitals,
e) variations in quality of care delivered in different hospitals.
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• Therefore, it cannot be concluded that a high mortality rate is indicative of poor quality care. Rather it 
provides an indication that a further evaluation should be carried out to determine the reasons for the 
identified variation in mortality rates.
• The National Clinical Programme for Stroke is clear that care in stroke units improves outcomes and reduces 
mortality for all groups and subtypes of stroke. A stroke unit ensures that core stroke services in terms 
of enhanced monitoring, swallow screening for dysphagia, and nutritional assessment are all delivered 
through the context of organised care and stroke units. In 2017, 83% of patients experiencing a stroke in 
Ireland were admitted to a hospital with a stroke unit. Hospitals with the highest age-sex standardised in-
hospital mortality rates for ischaemic stroke should examine the reasons for identified variation including 
examination of access to core stroke services.
 
 The National Office of Clinical Audit (NOCA) has recently announced that the Irish National Audit for Stroke 
will now sit within the National Cardiovascular Disease Audit Programme in NOCA. In time, this may give 
additional information on the quality of stroke care provided. 
Figure 52: Age-sex standardised in-hospital mortality rates within 30 days of admission for
ischaemic stroke, 2009 – 2018
Source: Hospital In-Patient Enquiry
Note: See appendix for detailed indicator definitions and methodology.
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Figure 53: Age-sex standardised in-hospital mortality rates within 30 days of admission for
ischaemic stroke for selected OECD countries, 2015 (or nearest year)
Source: OECD Health Statistics
Notes: Data is presented as published by the OECD; when comparing rates between countries it should be noted that 
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as 
well as due to differences in the rates themselves. 95% confidence intervals represented by        .
12012, 22013, 32014, 4 Deviation from OECD definition
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Figure 54: Age-sex standardised in-hospital mortality rates within 30 days of admission for
ischaemic stroke by hospital group and hospital, 2016 – 2018
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Source: Hospital In-Patient Enquiry
Note: Hospitals with small numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 cases, although the data for these hospitals have been included in 
the calculation of the national rates. However, some hospitals with more than 100 cases may still have unstable rates and 
caution should be exercised in interpreting rates with wide confidence intervals.
The data presented above are age-sex standardised mortality rates per 100 cases. 95% confidence intervals for hospitals 
and hospital groups are shown by . Where the 95% confidence interval for a hospital or hospital group overlaps the 95% 
confidence interval of the national rate (i.e. the dashed green lines), it can be concluded that the rate is not statistically 
significantly different from the national rate and so is within the expected range. Where the 95% confidence interval for a 
hospital or hospital group does not overlap the confidence interval of the national rate, it implies that the mortality rate is 
statistically significantly different from the national rate and is therefore outside the expected range. There can be many 
reasons for variations in mortality rates including differences in patient profiles; data quality issues; and differences in the 
quality of care.
Age-sex standardised mortality rates that are statistically significantly higher at the 95% confidence level than the national 
rate are shown in amber. Rates for all other hospitals and hospital groups are below or within the expected range of the 
national rate.
See appendix for detailed indicator definitions and methodology.
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Table 16: Age-sex standardised in-hospital mortality within 30 days of admission for Ischaemic 
Stroke by hospital group and hospital, 2016 – 2018
Hospital Group Number of Cases
Age-sex Standardised 
Mortality Rate (ASDR) 
per 100 Cases
Lower 95% 
Confidence
Limit for ASDR
Upper 95% 
Confidence Limit for 
ASDR
Dublin Midlands  2,123 7.09 5.98 8.21
Tallaght University Hospital  632 6.71 4.65 8.76
Midland Regional Hospital Portlaoise  131 9.31 4.48 14.14
Midland Regional Hospital Tullamore  218 9.55 5.56 13.54
Naas General Hospital  480 8.76 6.17 11.34
St. James's Hospital  662 4.99 3.34 6.64
Ireland East  3,077 8.85 7.87 9.84
Mater Misericordiae University Hospital  862 7.82 6.04 9.61
Midland Regional Hospital Mullingar  327 7.52 4.88 10.16
Our Lady's Hospital Navan  196 9.23 5.35 13.11
St. Columcille's Loughlinstown  62 - - -
St. Luke's General Hospital  309 13.08 9.07 17.08
St. Michael's Hospital  29 - - -
St. Vincent's University Hospital  915 9.91 8.17 11.66
Wexford General Hospital  377 10.22 7.36 13.09
RCSI Hospitals  2,742 6.60 5.66 7.54
Beaumont Hospital  1,438 5.59 4.35 6.83
Cavan General Hospital  389 6.15 3.86 8.45
Connolly Hospital  431 7.48 5.07 9.89
Our Lady of Lourdes Hospital  484 8.79 6.16 11.41
Saolta  2,365 8.35 7.29 9.40
Galway University Hospitals  761 7.23 5.48 8.99
Letterkenny University Hospital  483 9.89 7.36 12.42
Mayo University Hospital  485 9.69 7.31 12.06
Portiuncula University Hospital  191 6.95 3.76 10.15
Roscommon University Hospital  18 - - -
Sligo University Hospital  427 7.50 5.05 9.96
South / South West  2,765 8.31 7.30 9.32
Bantry General Hospital  180 7.67 3.50 11.84
Cork University Hospital  1,202 10.03 8.31 11.75
University Hospital Kerry  446 9.03 6.58 11.48
Mallow General Hospital  33 - - -
Mercy University Hospital  269 5.98 3.21 8.74
South Tipperary General Hospital  294 7.96 4.92 11
University Hospital Waterford  341 5.31 3.00 7.62
UL Hospitals  1,074 6.23 4.79 7.67
University Hospital Limerick  926 6.80 5.16 8.43
Ennis Hospital  76 - - -
Nenagh Hospital  37 - - -
St. John's Hospital  35 - - -
Total for All Hospitals  14,146 7.82 7.38 8.26
Source: Hospital In-Patient Enquiry
Note: Hospitals with small numbers of cases tend to have unstable rates and wider confidence intervals. For this report rates are 
not displayed for hospitals with less than 100 cases, although the data for these hospitals have been included in the calculation 
of the national rates. However some hospitals with more than 100 cases may still have unstable rates and caution should be 
exercised in interpreting rates with wide confidence intervals. See appendix for detailed indicator definitions and methodology.
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Figure 55: In-hospital waiting time for hip fracture surgery - proportion of cases undergoing surgery 
within 2 days of admission, 2009 – 2018
Source: Hospital In-Patient Enquiry
Note: See appendix for detailed indicator definitions and methodology.
In-hospital waiting time for hip fracture surgery
Definition
The in-hospital waiting time for hip fracture surgery indicator is defined as the proportion of patients aged 65 
years and older with a hip fracture who have surgery within two days of admission.
Description
There are a number of reasons why surgery may be delayed. In some cases, patients need to be treated for 
other medical conditions in order to ensure that they are fit to undergo surgery. However, delays may also 
occur as a result of administrative or logistical issues. These issues notwithstanding, based on evidence which 
demonstrates better outcomes associated with timely surgery, the HSE has a target which states that 95% of 
emergency hip fracture surgeries should be carried out within 48 hours (2 days) of the patient’s admission.
Rationale for the inclusion of indicator
Hip fracture, which is associated with increasing age, can lead to a significant risk of serious illness and
sometimes death [52, 53]. The standard treatment for hip fracture is surgery. Outcomes for patients are better 
if this surgery is timely (i.e. that the surgery happens as soon as possible after admission and when the patient 
is ready and fit for surgery) [54].
Commentary 
• The proportion of patients aged 65 years and older with a hip fracture undergoing surgery within two days 
of admission increased over the ten year period from 2009 to 2018, with 86% of cases in 2017 and in 2018 
undergoing surgery within two days compared to 81% in 2009.
• In 2015 (the latest year for which OECD data is available), the average proportion of patients with a hip 
fracture undergoing surgery within two days in Ireland was 82% - slightly above the OECD average of 80%.
• During the three-year period 2016-2018 there was a variation between hospitals in the proportion of hip 
fracture cases undergoing surgery within two days. Hospital rates varied from 76% to 97% of surgeries 
occurring within the two-day target.
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Figure 56: In-hospital waiting time for hip fracture surgery - proportion of cases undergoing surgery 
within two days of admission for selected OECD countries, 2015 or latest year
Source: OECD Health Statistics
Notes: Data is presented as published by the OECD; when comparing rates between countries it should be noted that 
differences may be due to the method of collection, the scope of data collection or the quality of the data collected as well 
as due to differences in the rates themselves.
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Figure 57: In-hospital waiting time for hip fracture surgery - proportion of cases undergoing surgery 
within 2 days of admission by hospital group and hospital, 2016 – 2018
Source: Hospital In-patient Enquiry (HIPE)
Note: See appendix for detailed indicator definitions and methodology.
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Table 17: In-hospital Waiting Time for Hip Fracture Surgery - Proportion of Cases with Surgery within 
2 Days of Admission, 2016 – 2018
Hospital Group Number of Hip Fracture Admissions
Percentage with Surgery 
within 2 Days
Ireland East                                                1,287 94.0
Mater Misericordiae University Hospital                                                    422 87.2
St. Vincent's University Hospital                                                    865 97.3
Dublin Midlands                                                1,448 88.9
Midland Regional Hospital Tullamore                                                    538 83.5
St. James's Hospital                                                    411 90.5
Tallaght University Hospital                                                    499 93.4
RCSI Hospitals                                                1,597 86.2
Beaumont Hospital                                                    516 82.4
Connolly Hospital                                                    502 95.8
Our Lady of Lourdes Hospital                                                    579 81.4
UL Hospitals                                                    819 73.8
University Hospital Limerick  - -
South / South West                                                2,642 80.7
Cork University Hospital                                                1,167 76.4
University Hospital Kerry 371 84.9
University Hospital Waterford                                                1,104 83.9
Saolta                                                1,612 90.4
Galway University Hospital 578 92.9
Letterkenny University Hospital 363 83.5
Mayo University Hospital 336 96.7
Sligo University Hospital                                                    335 87.2
Total for All Hospitals                                                9,405 85.8
Source: Hospital In-patient Enquiry (HIPE)
Note: Due to the low number of cases for hospitals, data in the above table has been suppressed in a number of cells for 
data protection purposes.
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Source: National Perinatal Reporting System
Notes: 
(i)  The National Perinatal Reporting System (NPRS) 2017 data are provisional only at time of publication due to issues with the 
introduction of a new electronic health record system. These data are subject to change.
(ii)  Based on Live births for total maternities.
(iii)  Percentages are subject to rounding.
(iv) In accordance with the WHO guidelines, only births weighing 500 grams or more are included in any analysis of NPRS data.
(v)  Data refer to the rate of caesarean sections per 100 live births (weight ≥500g) in public hospitals only and were provided by 
the Healthcare Pricing Office [March 2018]. See appendix for detailed indicator definitions and methodology.
Caesarean section rates
Definition
The rate of caesarean section deliveries per 100 live births.
Description
Rates of caesarean delivery as a percentage of all live births have increased in almost all OECD countries in recent 
decades with the average rate across countries going up from 20% in 2000 to 28% in 2015, although the growth 
rate in many countries has slowed down since 2005. There are many possible reasons suggested by the OECD 
for these increases including reduced risks associated with caesarean delivery, increasing litigation, increases in 
first births among older women, and the rise in multiple births resulting from assisted reproduction [56].
The rates of caesarean sections per number of live births are commonly reported internationally and are 
also reported by the OECD. To allow for comparison with other OECD countries, rates of caesarean section 
deliveries per 100 live births in Ireland were calculated. These calculations do not take into account multiple 
births, history of caesarean section, or other factors which may impact on the likelihood of having a caesarean 
section.
Rationale for the inclusion of indicator
The National Maternity Strategy (2016-2026) aims to ensure that women have access to safe, high quality, 
nationally consistent woman-centred maternity care [55].
Commentary 
• The national rates of caesarean section per 100 live births increased between the years 2007 and 2016.
• In 2016 the caesarean section rate for Ireland was 31.4 per 100 live births, which was above the OECD rate 
of 27.7.
• There was some variation observed in the rates of caesarean section per 100 live births in 2016 in maternity 
hospitals in Ireland. However, it should be noted that the findings presented in this report are from a 
high level analysis which does not take into account a number of factors that are known to impact on 
caesarean section rates including age of the mother, history of caesarean section, multiple births, or complex 
presentations and pregnancies.
• The National Women and Infants’ Health Programme recommends that hospitals examine their C-section 
rates in light of their individual case mixes in line with Ten-Group Robson classification as this is the global 
standard recommended by the World Health Organisation. Additionally, the C-section rate should be 
considered along with appropriate outcome measures.
Figure 58: Caesarean section rates per 100 live births, 2008-2017
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Figure 59: Casarean section rates per 100 live births for selected OECD countries, 2016 or nearest year
Source: OECD Health Statistics
Notes: 
1 Data refer to inpatient cases only 
Data is presented as published by the OECD; when comparing rates between countries it should be noted that differences 
may be due to the method of collection, the scope of data collection or the quality of the data collected as well as due to 
differences in the rates themselves.
Data for Ireland refer to the rate per 100 live births (including those <500g) in 2015 (excluding private hospitals). This 
data is sourced from live births data at the Central Statistics Office (CSO) and hence the rate differs from that reported in 
Figure 56 – for which data was sourced from the Healthcare Pricing Office.
See appendix for detailed indicator definitions and methodology.
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Figure 60: Caesarean section rates per 100 live births by hospital group and hospital, 2016
Source: National Perinatal Reporting System
Notes: 
(i)  The National Perinatal Reporting System (NPRS) 2017 data are provisional only at time of publication due to issues 
with the introduction of a new electronic health record system. These data are subject to change.
(ii)  Based on Live births for total maternities.
(iii) Percentages are subject to rounding.
(iv)  In accordance with the WHO guidelines, only births weighing 500 grams or more are included in any analysis of NPRS 
data.
(v)  Data refer to the rate of caesarean sections per 100 live births (weight ≥500g) in public hospitals only and were 
provided by the Healthcare Pricing Office [March 2018]. See appendix for detailed indicator definitions and 
methodology.
See appendix for detailed indicator definitions and methodology.
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Table 18: Caesarian Section Rates per 100 live births by hospital group and hospital, 2017
Hospital Group Number of Live Births
Rate of Caesarean Sections 
per 100 Live Births, 2017
Ireland East 13,785 29.4
National Maternity Hospital 8,401 27.2
Midland Regional Hospital Mullingar 2,070 34.2
Wexford General Hospital 1,725 25.9
St. Luke's General Hospital 1,589 38.3
Dublin Midlands 9,460 31.1
Coombe Hospital 7,950 31.9
Midlands Regional Hospital Portlaoise 1,510 27.0
RCSI Hospitals 12,771 35.0
Rotunda Hospital 8,184 34.2
Our Lady of Lourdes Hospital 3,015 35.4
Cavan General Hospital 1,572 38.4
UL Hospitals 4,319 35.1
University Maternity Hospital Limerick 4,319 35.1
South / South West 11,313 31.5
Cork University Maternity Hospital 7,200 31.6
University Hospital Waterford 1,795 26.8
University Hospital Kerry 1,349 33.4
South Tipperary General Hospital 969 36.4
Saolta             8,876 33.2
Galway University Hospital 2,789 33.6
Portiuncula University Hospital 1,634 35.3
Letterkenny University Hospital 1,649 30.1
Mayo University Hospital 1,516 35.4
Sligo University Hospital 1,288 31.0
National  60,524 32.2
Source: National Perinatal Reporting System
Notes; 
(i)  The National Perinatal Reporting System (NPRS) 2017 data are provisional only at time of publication due to issues 
with the introduction of a new electronic health record system. These data are subject to change.
(ii)  Based on Live births for total maternities.
(iii)  Percentages are subject to rounding. 
(iv)  In accordance with the WHO guidelines, only births weighing 500 grams or more are included in any analysis of NPRS 
data.
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Domain 4:
Supporting people 
to have positive 
experiences of 
healthcare
-  Overall Rating of Patient Experience  124
-  Communication in the Emergency 
 Department  125
-  Pain Control on the Ward 126
-  Emotional Support Provided on the Ward 127
-  Patient Involvement in Decision Making 
 Regarding Care  128
-  Communication Regarding Continuing  
 Medicines at Patient Discharge   129
-  Dignity and Respect while in Hospital 130
4
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National Patient Experience Survey
Description 
There is evidence confirming links between patient experience and clinical safety and effectiveness (Doyle, et 
al., 2013) (Issac, et al., 2010) (Lawton, et al., 2015). Patient experience surveys are a means of promoting and 
achieving patient-centred care. They provide valuable insights into the strengths of hospital care as well as 
areas in need of focus and improvement.
The National Patient Experience Survey (NPES) is a national survey that asks patients about their recent 
experience in hospital. The purpose of the survey is to learn from patients’ feedback to improve the planning 
and delivery of healthcare. The survey is part of a broader programme to help improve the quality and safety of 
healthcare services in Ireland. All adult patients (16 years old or older)1 discharged during May 2018 who spent 
a minimum of one night in an acute public hospital were invited to complete the survey and provided with a 
letter and information leaflet on discharge. Patients receiving maternity, psychiatric and paediatric services were 
not included in the 2018 survey.
The response rate for the Irish National Patient Experience Survey was over 50%. This is an exceptional 
response rate compared to similar surveys in other countries. This indicates that Irish patients are interested in 
sharing their views on their care.
National, hospital group and hospital reports were published on www.patientexperience.ie in November 2018. 
These identify areas of good experience and highlight areas for improvement at national, hospital group and 
hospital level. In February 2019, a technical report, which describes the analysis methodologies used was also 
published and is available on https://www.patientexperience.ie/about-the-survey/survey-model-methodology/. 
The HSE has also published their response and quality improvements plans in response to the findings of the 
NPE Survey, which are available on https://www.hse.ie/eng/services/publications/hospitals/national-patient-
experience-survey-2018.pdf.
Rationale for the Inclusion of Indicators  
Seven indicators from the 61 survey questions were selected for NHQRS inclusion using the following 5 
principles:
1. Patient-centeredness.
2. International comparability.
3. Importance of measuring information unique to the NPES dataset.
4. The purpose of the NHQRS in driving improvements in the health service in specific areas deemed valuable.
5. Importance in capturing the patient’s journey of care.
The seven questions include at least one question from each segment of the patient journey though hospital: 
admission to hospital, care on the ward, examination, diagnosis and treatment, discharge from hospital, and 
other aspects of care, as well as the overall patient rating of their experience.
International Comparability
Measuring patient reported indicators of their experiences of care is increasingly an indicator for the quality 
of a healthcare system. Jurisdictions internationally also conduct patient experience surveys. The results from 
international survey reports from accessible jurisdictions who used identical questions are summarised in 
table 19. The limitations of making international comparisons of patient experience survey results should be 
noted. The methodologies in other jurisdictions in terms of sampling, frequency and timeliness, survey delivery 
method, analysis and other aspects differ. As such, the results may not be affected simply by the quality or 
experience of care. Caution is advised when comparing this information.
National Patient Experience Commentary  
• Of those who were eligible to participate in the survey, 50% responded (13,404 patient respondents). This is 
a high response rate relative to other patient experience surveys conducted abroad. In 2017, the response 
rate in Ireland was 51%. 
1 In 2018 the age threshold for inclusion was lowered from 18 years of age to 16 years of age to reflect the age of consent for medical 
treatment and the age of digital consent under GDPR legislation.
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• 84% of respondents indicated a good or very good experience of their hospital stay overall. This is 
comparable to other patient experience surveys internationally. This is the same as was observed in the 
2017 study. 
• Ireland’s patient experience survey results compared favourably with international counterparts regarding 
dignity and respect shown to patients in hospital as well as the amount of patient involvement in decision 
making occurred.
• Other countries scored higher than Ireland on questions regarding the level of understanding patients had 
about their medicines at discharge and regarding the amount of emotional support available to patients 
while they were on the ward.
• In the 2018 NPES, it appears that patients discharged from smaller hospitals and specialty hospitals 
reported higher ratings for their care experience than those discharged from larger hospitals.
• For the 2018 NPES results, on the whole there was little variation between Hospital Group averages for 
each of the indicators.
• It should be noted that Ireland’s NPES has only collected data twice thus far and hence caution should be 
taken when comparing these results. 
Table 19: Summary of Patient Experience Survey Measures as Reported Internationally
Ireland 
(2018)
England 
(2016)
Scotland 
(2016) 
Wales 
(2015)
Northern 
Ireland 
(2017)
New 
Zealand 
(2017)
Communication in the Emergency Department 84% 76%1 71% - - - 
Patient Involvement in Decision 
Making Regarding Care  92% 90% 64% - 93% 70% 
Emotional Support Provided on the Ward 54% - - - - -
Pain Control on the Ward 82% 93% 91%4 97%3 96% 83%
Communication Regarding Continuing 
Medicines at Patient Discharge 73% 91% 95%
2,4 - 94% -
Dignity and Respect while in Hospital  97% 97% - 99% 98% 87% 
Overall Rating of Experience 84% 84% 90% 92% 92% - 
Response Rate 50% 41% 40% * 37% 25%
Sources 
England’s information is from the Adult Inpatient Survey 2017 conducted by Care Quality Commission. More information 
is available at: https://www.cqc.org.uk/publications/surveys/adult-inpatient-survey-2017
Scotland’s information is from the 2018 Inpatient Experience Survey conducted by the Scottish Care Experience 
Programme. More information is available at 
http://www.gov.scot/Topics/Statistics/Browse/Health/InpatientSurvey/Inpatient2018
Wales’ information is from the All Wales Patient Experience Audit Summary Report 2015 conducted by the NHS in Wales. 
More information is available at: https://gov.wales/docs/phhs/publications/160615patient-experienceen.pdf
Northern Ireland’s information is from the Inpatient Patient Experience Survey 2017 conducted by the Information 
Analysis Directorate of the Northern Irish Department of Health. More information is available at: 
https://www.health-ni.gov.uk/publications/inpatient-patient-experience-survey-2017
New Zealand’s information is from the Adult Experience Survey conducted by the Health Quality & Safety Commission 
New Zealand. More information is available at: https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/
projects/patient-experience/adult-inpatient-experience/
Notes 
1 In the English survey, respondents were asked “While you were in the A&E Department, how much information about   
  your condition or treatment was given to you?”
2 In the Scottish survey, respondents were asked to respond to the statement “I understood what my medicines were for”
3 In the Welsh survey, respondents were asked “Throughout your stay/attendance, how often did you feel that you were,
  as far as possible, kept free from pain?”
4 These results were from surveys conducted in 2016
123
D
O
M
A
IN
 4: N
A
TIO
N
A
L PATIEN
T EX
PER
IEN
C
E SU
R
V
EY
NHQRS Annual Report 2019
Figure 61: Patient Reported Overall Rating of Hospital Experience by Hospital and Hospital Group, 2018
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported.
Source: National Patient Experience Survey, 2018
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Overall Experience Rating 
Definition 
Hospital, hospital group and national patient reported overall rating of hospital experience on a scale of 1 to 10.  
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Figure 62: Communication in the Emergency Department: Patient Reported Responses by Hospital and 
Hospital Group, 2018
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported. Some hospitals who participated in the National Patient Experience Survey do not have an Emergency Department and hence do not have results for 
this indicator.
Source: National Patient Experience Survey, 2018
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Admission to Hospital: Communication in the Emergency Department 
Definition 
The percentage responses by hospitals, hospital groups and national to the question to the question “While 
you were in the Emergency Department, did a doctor or nurse explain your condition in a way you could 
understand?”
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Figure 63: Pain Control on the Ward: Patient Reported Responses by Hospital and Hospital Group, 2018
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported.
Source: National Patient Experience Survey, 2018
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Care on the Ward: Pain Control on the Ward 
Definition  
The percentage responses by hospital, hospital group and nationally to the question: “Do you think the hospital staff 
did everything they could to help control your pain?”
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Figure 64: Emotional Support the Ward: Patient Reported Responses by Hospital and Hospital 
Group, 2018
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported.
Source: National Patient Experience Survey, 2018
Care on the Ward: Emotional Support Provided on the Ward
Definition 
The percentage responses by hospital, hospital group and nationally to the question: “Did you find someone 
on the hospital staff to talk to about your worries and fears?”
31%
35%
47%
36%
41%
33%
31%
37%
26%
41%
39%
44%
40%
35%
33%
35%
37%
55%
38%
36%
32%
35%
36%
32%
29%
32%
35%
33%
29%
31%
28%
32%
26%
34%
38%
34%
39%
39%
34%
30%
31%
31%
37%
32%
32%
34%
21%
15%
21%
21%
18%
20%
22%
20%
24%
12%
17%
15%
10%
20%
18%
19%
21%
14%
20%
15%
24%
20%
20%
23%
22%
21%
20%
21%
19%
20%
15%
21%
31%
9%
19%
18%
18%
16%
19%
20%
20%
17%
18%
18%
19%
19%
14%
6%
5%
7%
9%
12%
12%
9%
13%
4%
9%
4%
4%
10%
11%
10%
9%
5%
14%
10%
8%
10%
10%
12%
13%
15%
13%
13%
14%
14%
7%
13%
7%
5%
11%
12%
11%
5%
11%
13%
12%
12%
10%
10%
12%
11%
35%
43%
26%
36%
32%
35%
36%
34%
38%
42%
34%
37%
46%
35%
38%
36%
33%
27%
28%
38%
36%
35%
35%
33%
36%
32%
32%
33%
38%
35%
49%
34%
35%
52%
33%
35%
32%
40%
36%
36%
37%
41%
35%
40%
37%
36%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
University Hospital Limerick
St. John's Hospital
Nenagh Hospital
Ennis Hospital
Croom Orthopaedic Hospital
UL Hospitals
University Hospital Waterford
University Hospital Kerry
South Tipperary General Hospital
South Infirmary Victoria University Hospital
Mercy University Hospital
Mallow General Hospital
Lourdes Orthopaedic Hospital Kilcreene
Cork University Hospital
Bantry General Hospital
South/South West Hospital Group
Sligo University Hospital
Roscommon University  Hospital
Portiuncula University Hospital
Mayo University Hospital
Letterkenny University Hospital
Galway University Hospi tal
Saolta University  Health Care Group
Our Lady of Lourdes Hospital
Connolly Hospital
Cavan and Monaghan Hospital Group
Beaumont Hospital
RCSI Hospital Group
Wexford General Hospital
St. V incent's University Hospi tal
St. Michael's Hospital
St. Luke's General Hospital
St. Columcilles Loughlinstown
Royal Victoria Eye and Ear Hospital
Our Lady's Hospital Navan
Midland Regional Hospital Mull ingar
Mater Miser icordiae University Hospital
Cappagh National Orthopaedic Hospital
Ireland East Hospital Group
Tallaght University Hospital
St James Hospital
Naas General Hospital
Midland Regional Hospital Tullamore
Midland Regional Hospital Portlaoise
Dublin Midlands Hospital Group
National Average
U
L
So
u
th
/ 
So
ut
h
 W
e
st
Sa
o
lt
a
R
C
SI
Ir
e
la
n
d
 E
as
t
D
ub
lin
 M
id
la
nd
s
Yes,  definitely Yes, to some extent No I had no worries or fears
NHQRS Annual Report 2019
Figure 65: Patient Involvement in Decision Making Regarding Care: Patient Reported Responses by 
Hospital and Hospital Group, 2018
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported.
Source: National Patient Experience Survey, 2018
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Examination, Diagnosis and Treatment: Patient Involvement in Decision 
Making Regarding Care 
Definition  
The percentage responses by hospital, hospital group and nationally to the question: “Were you involved as much as 
you wanted to be in decisions about your care?”
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Figure 66: Communication Regarding Continuing Medicines at Patient Discharge: Patient Reported 
Responses by Hospital and Hospital Group, 2018
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported.
Source: National Patient Experience Survey, 2018
Discharge or Transfer: Communication Regarding Continuing Medicines 
at Patient Discharge 
Definition
The percentage responses by hospital, hospital group and nationally to the question: “Did a member of staff 
explain the purpose of medicines you were to take at home in a way you could understand?”
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Figure 67: Dignity and Respect while in Hospital: Patient Reported Responses by Hospital and Hospital 
Group, 2018
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Other Aspects of Care: Dignity and Respect while in Hospital 
Definition  
The average score by hospital, hospital group and nationally to the question: “Overall, did you feel you were treated 
with respect and dignity while you were in hospital?”
Note: If a hospital has fewer than 30 responses, its results will not be published to protect respondent anonymity and ensure that only reliable results are 
reported.
Source: National Patient Experience Survey, 2018
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Overview of selected indicators
There are 4 indicators in this domain in the following 3 areas:
• Healthcare associated infections (HCAIs)
• Antibiotic consumption in the community
• Medication safety
Healthcare associated 
infections
Healthcare associated infections (HCAIs) 
are infections people contract while 
they are receiving treatment for another 
condition in a healthcare setting. This is 
most frequently while in hospital, but can 
also occur in outpatient clinics, nursing 
homes and other healthcare settings. 
Most common HCAIs only cause minor 
illness. However, some can cause serious 
illnesses, such as blood infections. About 
one third of HCAIs can be prevented by 
good hand-hygiene and appropriate care 
when dealing with patients [59]. 
A number of National Clinical Guidelines 
are in place to support good practice 
including the National Clinical 
Effectiveness Committee (NCEC) 
Methicillin-resistant Staphylococcus aureus 
(MRSA) and C. difficile Guidelines [60, 
61]. The number of patients who acquire 
HCAIs is recognised as a measure of the 
quality and safety of care provided and 
therefore rates of HCAIs are included in 
this report.
The indicators for healthcare associated 
infections are:
• Staphylococcal aureus and Methicillin 
resistant Staphylococcal aureus (MRSA) 
blood stream rates
• Clostridium difficile (C. difficile)
• Carbapenemase-producing 
Enterobacteriales
Medication Safety
According to the World Health 
Organisation, unsafe medication practices 
and medication errors are a leading cause 
of injury and avoidable harm in health care 
systems across the world.
The indicator for medication safety is: 
• Chronic benzodiazepine usage in the 
community in people aged 65 and over
Antibiotic consumption
Since the 1940s, antimicrobials (medicines specifically 
used to combat infections caused by microorganisms) 
have substantially reduced mortality from infectious 
diseases and have provided protection against 
infectious complications for many modern medical 
practices including surgery, neonatal care and cancer 
treatment. Many advances in modern medicine could 
not be safely carried out without effective
antimicrobial cover. 
The sheer volume of antimicrobials being used globally 
in humans, animals and in other situations has led to 
significant increases in rates of resistance against these 
medicines; consequently, many common infections are 
becoming more difficult to treat and microorganisms 
that are resistant to many antibiotics and other 
antimicrobials, so-called ‘superbugs’, are emerging.
In recognition of the need for all countries to develop a
plan to tackle antimicrobial resistance (AMR) the World
Health Organization published its Global Action Plan on
Antimicrobial Resistance 2015. This Plan aims to ensure
the development and implementation of multifaceted
interventions which will safeguard against inappropriate
prescribing, dispensing and consumption of medicines,
while simultaneously promoting rational use in patients
and animals that are expected to benefit from 
treatment.
In fulfillment of Ireland’s commitment to the Global
Action Plan, Ireland’s National Action Plan on
Antimicrobial Resistance (2017-2020), known as
iNAP, was launched by both the Minister for Health
and Minister for Agriculture Food and the Marine in
October 2017. This was developed jointly in 
recognition of the requirement for a One Health 
approach to tackling AMR. iNAP provides a road map 
to target HCAIs and AMR across the human veterinary 
and environmental sectors.
Surveillance and reporting of antibiotic use plays a key
role in encouraging prudent use of these agents and
the NHQRS includes two indicators of antibiotic use in 
Ireland:
• Antibiotic consumption in the community
• Antibiotic consumption in public acute hospitals.
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Staphylococcus aureus and Methicillin resistant Staphylococcus aueus (MRSA) 
blood steam infection rates 
Definition
Rate of Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA) blood stream infections in 
acute hospitals per 1,000 bed days used. 
Description
MRSA is a type of S. aureus that has become resistant to meticillin as well as all other penicillins. This means 
that none of the penicillin class of antibiotics are useful to treat MRSA infections. MRSA are also often 
resistant to other classes of antibiotics also. This makes infection caused by MRSA more difficult to treat.  
Healthcare interventions like intravenous catheters increase the risk of developing S. aureus blood stream and 
many of these infections can be prevented. Acquisition of MRSA is associated with healthcare. In some people 
who acquire MRSA the bacteria can cause serious infections, such as septicaemia (also known as bloodstream 
infection).  For these reasons MRSA blood stream infection rate are sometimes used as an quality indicator for 
healthcare associated infection. 
However, another measure of quality has also been utilised. This is the rate of hospital acquired bloodstream 
S. aureus infections. This measure should be used in conjunction with the Rate of Staphylococcus aureus (S. 
aureus) and methicillin resistant S. aureus (MRSA) bloodstream infection in acute hospitals per 1,000 bed days 
used for the purposes of quality improvement. 
In recent years MRSA blood stream infection has declined as a proportion of total S. aureus blood stream 
infections.  The rate of MRSA blood stream infection has also declined in absolute terms. There is currently no 
consensus on the specific causes of this decline. The rate of MSSA blood stream infection has increased so 
that the total rate of S. aureus blood stream infection is relatively stable. 
Under the case definition for the European Antimicrobial Resistance Surveillance Network (EARS-Net), data 
are collected on the first bloodstream isolate of S. aureus per patient per quarter.
Rationale for the inclusion of indicator 
Most people who carry MRSA on their bodies or in their noses do not suffer any ill effects and this is known 
as “colonisation”. However, MRSA can sometimes cause infection; this is more likely to happen to people 
who are already unwell, particularly those who are in hospital with a serious illness and in those who have 
intravenous devices.
Commentary 
• Figure 68 shows national MRSA bloodstream infection rates per 1,000 bed days used between 2008 and 
2017. In 2017, there was a S. aureus rate of 0.28 per 1,000 bed days used and a MRSA rate of 0.05 per 
1,000 bed days used. This rate has decreased annually over the last 10 years with a 82% reduction seen 
over the time period. 
• Figure 69 shows Ireland and other European countries who are part of the European Antimicrobial
 Resistance Surveillance Network (EARS-Net). This Network collects and reports on the proportion of S.
 aureus bloodstream infections that are methicillin-resistant (MRSA) for the participating countries. Ireland 
reported a rate of 16.3 MRSA cases as a proportion of S. aureus cases. 
• In 2017, in Ireland 15% of S. aureus bloodstream infections were methicillin resistant; this is as compared 
with 2008 when 38% of these infections were methicillin resistant. These improvements notwithstanding, in 
2017 Ireland still ranked 19th out of 30 countries who participate in EARS-Net.
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Figure 69: MRSA cases as a proportion of Staphylococcus aureus cases, 2017
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Figure 68: Staphylococcus aureus and MRSA bloodstream infection rates per 1,000 bed days used, 
2008-2017
Source: Health Protection Surveillance Centre 
Notes: Rates calculated for acute public hospitals only, as no demoninator is available for private hospitals.
See appendix for detailed indicator definitions and methodology.
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Source: Health Protection Surveillance Centre (HPSC)
Note: See appendix for detailed indicator definitions and methodology.
Clostridium difficile (C. difficile) infection rates
Definition
Rate of new cases of Clostridium difficile infection (CDI) in acute hospitals per 10,000 bed days used.
Description
Clostridium difficile (C. difficile) is a bacterium that is normally found in small amounts in the large bowel. A 
small proportion (less than 1 in 20) of the healthy adult population, carry this bacterium in their bowel and 
don’t experience any problem with it. However, sometimes when a person takes an antibiotic, some “good” 
bacteria die allowing the C. difficile bacteria to multiply, leading to an infection in the large bowel. Symptoms 
of C. difficile infection (CDI) include diarrhoea, stomach cramps, fever, nausea and loss of appetite. While 
most people experience a mild illness and make a full recovery, patients can, in certain circumstances, develop 
serious complications including colitis (inflammation of the bowel) which can be life threatening. Control of C. 
difficile requires good antibiotic stewardship (only using antibiotics when required and using the right antibiotic 
at the right time) and good infection prevention and control (for example, ensuring that patients, their family 
members and hospital staff are regularly washing their hands, and that appropriate measures for cleaning and 
disinfection of equipment are in place).
Rationale for the inclusion of indicator 
CDI rates in hospitals are recognised and used internationally as one measure of the quality and safety of a 
healthcare service.
Commentary 
• Figure 70 shows new hospital-acquired CDI cases per 10,000 bed days used, between 2010 and 2017 at a 
national level. The rate has decreased over the five years as a whole.
• Figure 70 also shows the number of hospitals participating in this reporting scheme. This has increased 
annually and, since 2012, there has been complete participation in CDI enhanced surveillance by all tertiary 
and general hospitals. There are now 54 hospitals now contribute this data.
Figure 70: New hospital-acquired Clostridium difficile infection cases per 10,000 bed days used, 
2010 –2017 
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Carbapenem-producing Enterobacteriales (CPE)
Rationale for the inclusion of indicator
CPE has been identified throughout the world in recent years. Ireland has seen an increase in the number of 
cases year on year since it was first detected here in 2009. The number of cases almost doubled in 2016 and 
increased by a further third in 2017. 
Description
Carbapenemase-producing Enterobacteriales, known as CPE (also referred to as carbapenem-resistant 
Enterobacteriales (CRE)) gram-negative bacteria that are carried in the bowel and are resistant to most, and 
sometimes all, available antibiotics. While often benign in the bowel, it can cause infections in other organ 
systems including blood stream infection in people who are vulnerable, such as the elderly and those with low 
immunity.
The spread of this superbug in hospitals can lead to the closure of beds, wards and units removing thereby, 
essential capacity to provide services, to admit patients from Emergency Departments and to address waiting 
lists effectively.
Public Health and microbiological advice indicates that the opportunity remains for effective interventions to 
be taken which can protect our patients, protect our hospital capacity from unplanned closures and ultimately 
lead to a halting or reduction in the spread of this superbug.
Surveillance of CPE in acute hospitals has increased in over the past year to 18 months, following the 
declaration of a National Public Health Emergency for CPE by the Minister for Health in October 2017. The 
Health Protection Surveillance Centre is now regularly collecting data from a number of sources and reporting 
on CPE monthly. 
Commentary
As data collection has only been ongoing since October 2017, at this time, there is not sufficient information 
to include charts in this report.
In 2017, there were 433 patients newly diagnosed with CPE. In 2018, this number increased to 537 patients. 
In this time, the number of screening tests performed also increased substantially, from 9,821
in October 2017 to 24,463 in April 2019. By screening and diagnosing more patients, CPE patients can be 
managed more effectively in hospitals, limiting its impact on other patients. 
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Antibiotic consumption in the community
Definition
Community antibiotic consumption rates are measured in Defined Daily Dose (DDD) per 1,000 inhabitants 
per day from community consumption data.
DDD is defined as the assumed average maintenance dose per day for a drug used for its main indication in 
adults (62). Community antibiotic consumption data is obtained from the IMS Health (a pharmaceutical market 
research company) dataset which contains regional, monthly wholesaler to retail pharmacy sales data from 
over 95% of the wholesalers and manufacturers in Ireland [63].
Description
Ireland’s National Action Plan on Antimicrobial Resistance 2017-2020 (iNAP) recognises the urgent and 
growing problem of antimicrobial resistance for human health worldwide. It aims to implement policies and 
actions to prevent, monitor and combat AMR across the health, agricultural and environmental sectors. 
Reducing the inappropriate use of antimicrobial medicines, as well as preventing the transmission of infections 
and disease, is vital to stop the development and spread of resistant microorganisms.
Surveillance of antibiotic usage has been identified as a key component in Ireland’s National Action Plan 
on Antimicrobial Resistance (2017–2020), known as iNAP. This plan was developed in conjunction with 
the Department of Agriculture, Food and the Marine in line with the One Health approach to antimicrobial 
resistance.
The European Surveillance of Antimicrobial Consumption Network (ESAC-Net), produces a set of consensus 
quality indicators for antibiotic consumption in primary care in Europe. This set of nine indicators is comprised 
of general antibiotic consumption indicators (e.g. total use, all major antibiotics combined) and more specific 
indicators (e.g. penicillin use, macrolide use). The indicator reported on here is the general indicator 'total use, 
all major antibiotics combined.'
Rationale for the inclusion of indicator 
Excessive prescription of antibiotics is connected to the development of antimicrobial resistance. Antimicrobial 
resistance leads to higher medical costs and prolonged hospital stays. The majority of human antibiotic 
consumption in Ireland takes place at community level, and therefore it is important to have a measure of this 
consumption.
Commentary 
• The total volume of antibiotics consumed annually has increased over the last ten years, although a small
 decrease was seen in 2018 (22.9 DDD) compared with 2017 (23.1 DDD).
• In 2014, the overall community antibiotic consumption for Ireland was 23.0 DDD. Ireland ranked 9th
 highest in community antibiotic consumption in Europe.
• High antibiotic consumption does not automatically equate with inappropriate antibiotic use.
• In 2017, Ireland reported an antibiotic consumption rate of 22.9 DDD per 1000 inhabitants per day to the 
European Centre for Disease Control. 
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Source: Health Protection Surveillance Centre (HPSC)
Note: See appendix for detailed indicator definitions and methodology.
Figure 71: Total antibiotic use in the community in Ireland, 2009-2018, expressed in DDD per
1000 inhabitants per day
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Figure 72: Community antibiotic consumption by country in Europe 2017, expressed in DDD per 
1000 inhabitants per day
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Antibiotic consumption in public acute hospitals
Definition
In-hospital antibiotic consumption rates are measured in Defined Daily Dose (DDD) per 100 bed days used 
(BDU). DDD is defined as the assumed average maintenance dose per day for a drug used for its main 
indication in adults.
Hospital data are based on the volume of antibiotic drugs supplied to inpatient areas by hospital pharmacies 
and is obtained directly from publicly funded hospital pharmacy software systems.
Description
Ireland’s National Action Plan on Antimicrobial Resistance 2017-2020 (iNAP) recognises the urgent and 
growing problem of antimicrobial resistance for human health worldwide. It aims to implement policies and 
actions to prevent, monitor and combat AMR across the health, agricultural and environmental sectors. 
Reducing the inappropriate use of antimicrobial medicines, as well as preventing the transmission of infections 
and disease, is vital to stop the development and spread of resistant microorganisms.
Surveillance of antibiotic usage has been identified as a key component in iNAP. This plan was developed in 
conjunction with the Department of Agriculture, Food and the Marine in line with the One Health approach to 
antimicrobial resistance.
The European Surveillance of Antimicrobial Consumption Network (ESAC-Net), produces a set of consensus 
quality indicators for antibiotic consumption in Europe. This set of nine indicators is comprised of general 
antibiotic consumption indicators (e.g. total use, all major antibiotics combined) and more specific indicators 
(e.g. penicillin use, macrolide use). The indicator reported on here is the general indicator “total use, all major 
antibiotics combined”.
The HSE Antimicrobial Resistance and Infection Control Team report that the median rate of antimicrobial 
consumption in public acute hospitals in Ireland for 2018 was 88.4 defined daily doses per 100 bed days 
used (DDD/100BDU; range = 30.3 to 113.4, n = 41), a slight increase on the rate for the previous year (86.3 
DDD/100BDU). This rate is mid-range in comparison with other European countries.
Notes on Measurement Changes
In 2017 a methodology change was made to the reporting of antibiotic consumption rates in acute hospitals. 
Items returned to the dispensary are now subtracted from the overall consumption rates, which has resulted 
in the decrease of overall rates by 1.5-2%.
Rationale for the inclusion of indicator 
Excessive prescription of antibiotics is connected to the development of antimicrobial resistance. Antimicrobial 
resistance leads to higher medical costs, prolonged hospital stays, and increased mortality.
Commentary 
• The total volume of antibiotics consumed in hospitals annually has increased over the last ten years, from a
 consumption rate of 75.6 per 100 BDU in 2009 to 89.2 per 100 BDU in 2018.
• While considerable variation in antibiotic consumption by hospital is seen, as discussed above, the rate may 
be appropriate to the specific patient population served by individual hospitals.
• However, this caveat notwithstanding, the considerable variation seen at hospital group level warrants 
further consideration and investigation.
NHQRS Annual Report 2019
Source: Health Protection Surveillance Centre
Note: 2018 data is provisional and may be subject to change.
Starting from 2017, returned items to the dispensary are subtracted from the overall consumption rates. This has resulted 
in a decrease of the overall rate by 1.5-2% for the mean and median values of the major classes of drugs, with decreases 
to the total anti-bacterial consumption for individual hospitals ranging from 0% to 9%. Additional stewardship or minor 
methodological changes may have also occurred.
Note: See appendix for detailed indicator definitions and methodology.
Figure 73: Total in-hospital antibiotic consumption, 2009-2018, expressed in DDD per 100 bed 
days used (BDU)
Table 20: Total antibiotic consumption in public hospitals, expressed in DDD per 100 BDU, 2018
Hospital Group 2018
Ireland East 89.8
Cappagh National Orthopaedic Hospital 32.4
Mater Misericordiae University Hospital 92.8
Midland Regional Hospital, Mullingar 91.6
National Maternity Hospital, Holles Street 38.1
Our Lady's Hospital, Navan 106.9
Royal Victoria Eye and Ear Hospital, Dublin 46.7
St. Columcille's Hospital, Loughlinstown 59.2
St. Luke's General Hospital, Kilkenny 96.8
St. Michael's Hospital, Dun Laoghaire 89.0
St. Vincent's University Hospital, Elm Park 104.7
Wexford General Hospital 93.00
Dublin Midlands 90.7
St. James's Hospital 106.8
Tallaght University Hospital 90.2
Coombe Women's and Infant's University Hospital 39.7
Midland Regional Hospital, Portlaoise 90.8
Midland Regional Hospital, Tullamore 89.9
Naas General Hospital 105.4
St Luke's Hospital, Rathgar 35.6
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Source: Health Protection Surveillance Centre (HPSC)
Notes: 2018 data is provisional and subject to change.
It should be noted that the patient cohort in Children's Hospitals is distinct from that in other acute hospitals and 
therefore variation of antimicrobial consumption rates is likely to be observed.
See appendix for detailed indicator definitions and methodology.
Table 20 contd.
Hospital Group 2018
RCSI Hospitals 95.8
Our Lady of Lourdes Hospital, Drogheda 99.3
Beaumont Hospital 102.7
Connolly Hospital, Blanchardstown 90.2
Rotunda Hospital 37.9
Cavan General Hospital 110.6
UL Hospitals 92.7
University Hospital Limerick 98.4
Nenagh Hospital 63.6
Ennis Hospital 80.8
St. Johns Hospital, Limerick 80.6
South / South West 90.6
Cork University Hospital 84.9
University Hospital Waterford 97.0
University Hospital Kerry, Tralee 83.5
South Tipperary General Hospital, Clonmel 121.4
Mercy University Hospital, Cork 94.9
Kilkreene Orthorpaedic Hospital, Co. Kilkenny 41.7
South Infirmary-Victoria Hospital, Cork 56.9
Saolta 78.1
Galway University Hospitals 67.6
Mayo University Hospital 85.5
Letterkenny University Hospital 96.8
Sligo University Hospital 69.9
Portiuncula University Hospital, Ballinasloe 100.2
Roscommon University Hospital 68.0
Children's Hospitals 72.2
Children's University Hospital, Temple St 65.9
Our Lady's Children's Hospital, Crumlin 75.4
National average 89.2
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Chronic benzodiazepine1 usage in the community in people aged 65 years 
and over
Definition
The number of patients aged 65 years and over (per 1,000 patients) who have had a reimbursable prescription 
for a benzodiazepine medication dispensed for 12 months or more2 via the Community Drugs Schemes3. 
Description
Benzodiazepines are a class of medication that can be used in the treatment of a number of conditions, 
including treatment of insomnia, anxiety, addiction, agitation and neurological disorders (70). When they are 
well prescribed, benzodiazepines are considered relatively safe, as they are effective, fast acting and have 
low toxicity (71). Benzodiazepines are also prescribed in the treatment of muscle spasticity, involuntary 
movement disorders, detoxification from alcohol, and anxiety associated with cardiovascular or gastrointestinal 
conditions. In the late 1970’s, benzodiazepines were the most commonly prescribed drugs worldwide (70). 
However, as with any medicine, their use also carries the risk of side effects and toxic reactions, particularly 
among the elderly. With an increased sensitivity to benzodiazepines and a slower metabolism, older patients 
are at high risk of developing delirium and cognitive impairment, and are more susceptible to falls and 
fractures (70). 
Europe has traditionally been the region with the highest calculated average national consumption rates for 
benzodiazepine-type anxiolytics (71). 
Dependence to benzodiazepines is recognised as a significant risk in patients receiving treatment for longer 
than one month (72).
In May 2017 the Misuse of Drugs Regulations 2017 introduced additional controls on the prescribing 
and dispensing of benzodiazepines and z-drugs. The HSE Medicines Management Programme published 
guidelines, toolkits and resources on the prescription of benzodiazepines in February 2018. This guidance is 
relevant to prescribers and may also be useful to pharmacists and other health care professionals.  
Rationale for inclusion of indicator
Benzodiazepines are often prescribed for older adults for anxiety and sleep disorders, despite the risk of 
adverse side effects such as fatigue, dizziness and confusion. Long-term use of benzodiazepines can lead 
to adverse events (falls, road accidents and overdose), tolerance, dependence and dose escalation  (OECD, 
2017). Ireland reports higher than average rates for chronic prescription of benzodiazepines in patients aged 
65 and over. 
Commentary 
• The overall national chronic prescription rate as available via the Primary Care Reimbursement Service in 
Ireland has been declining with a rate of 80 patients per 1,000 aged 65 years and older with a prescription 
for a benzodiaepine for chronic use dispensed in 2013 to a rate of 73 patients per 1,000 in 2017.  It is 
important to note that the Primary Care Reimbursement Service only contains information on prescriptions 
dispensed through one of the public schemes it administers. It excludes information on private presciption 
dispensing. However, it includes information on prescriptions dispensed to nursing home residents where 
these are dispensed through Community Drugs Schemes.
• There is a large variation in the prescription rates between men and women, with women being prescribed 
benzodiazepines for chronic use more frequently. 
• There is also large regional variation in the rate of prescriptions across community health office and local 
health office areas in Ireland. 
• Across the OECD, on average around 25 per 1,000 older adults are chronic benzodiazepine users (≥365 
defined daily doses in one year). Ireland reports the highest rate of chronic benzodiazepine prescription in 
the OECD. It should be noted that only 16 of the 34 countries contributed data to the most recent Health 
at a Glance publication (70).
• The OECD report that some of the international variation can be explained by differences in disease 
prevalence and treatment guidelines as well as by different reimbursement and prescribing policies for 
benzodiazepines. 
1  This indicator refers to benzodiazepine and related drugs which include the following ATC codes: N05BA, N05CD and N05CF. See appendix for detailed 
indicator definitions and methodology.
2  12 months or greater is considered to be equivalent to 365 days or greater. 
3  Community Drugs Schemes refer to the General Medical Services Scheme, the Drug Payments Scheme and the Long Term Illness Scheme.
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Source: Primary Care Reimbursement Service
Notes: Eligible patients refer to those who are eligible to claim for a prescription via Community Drugs Schemes and are 
captured via the Primary Care Reimbursement Service's information system. See appendix for detailed indicator definitions 
and methodology. 
Source: OECD Health Statistics
Notes: Eligible patients refer to those who are eligible to claim for a prescription via Community Drugs Schemes and are 
captured via the Primary Care Reimbursement Service's information system. See appendix for detailed indicator definitions 
and methodology. Differences in coding practices among countries and the definition of an admission may affect the 
comparability of data. Differences in prescription policies and reimbursement systems may also affect data comparability.
Figure 74:  Number of eligible patients per 1,000 with prescriptions dispensed for 
benzodiazepines or related drugs, aged 65 years and over, for 12 months or greater, 2013-2017
Figure 75: Number of people per 1000 with prescriptions dispensed for benzodiazepines or related 
drugs, aged 65 and over, 12 months or greater, for selected OECD countires, 2015 (or nearest year)
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Source: Primary Care Reimbursement Service
Notes: Eligible patients refer to those who are eligible to claim for a prescription via Community Drugs Schemes and 
are captured via the Primary Care Reimbursement Service's information system. See appendix for detailed indicator 
definitions and methodology. 
Figure 76:  Number of eligible patients per 1000 with prescriptions dispensed for benzodiazepines or 
related drugs, aged 65 and over, for 12 months or greater, by Community Health Organisation , 2017 
D
O
M
A
IN
 5: M
ED
IC
A
TIO
N
 SA
FETY
144
CHO 2
CHO 4
CHO 1
CHO 8
CHO 5
CHO 3
CHO 7
CHO 6
CHO 9
Number of patients per 1000 aged 65 years and over
53.9 - 58.6
58.6 - 71.0
71.0 - 74.7
74.7 - 77.8
77.8 - 81.7
NHQRS Annual Report 2019
D
O
M
A
IN
 5: M
ED
IC
A
TIO
N
 SA
FETY
Table 21: Number of eligible patients per 1000 with prescriptions dispensed for benzodiazepines or 
related drugs, aged 65 and over, 12 months or greater, by Community Health Organisation and Local 
Health Office, 2017
Community Health Organisation Local Health Office 2017
CHO 1
Cavan/Monaghan 82.7
Donegal 72.5
Sligo/Leitrim 75.2
CHO 1 Total 76.4
CHO 2
Galway 55.6
Mayo 57.3
Roscommon 71.2
CHO 2 Total 58.6
CHO 3
Clare 65.3
Limerick 85.5
Tipperary NR/East Limerick 76.9
CHO 3 Total 77.6
CHO 4
North Cork 62.1
North Lee 92.2
South Lee 89.2
West Cork 52.2
Kerry 57.0
CHO 4 Total 74.7
CHO 5
Carlow/Kilkenny 78.5
Tipperary South 98.8
Waterford 78.6
Wexford 71.3
CHO 5 Total 80.2
CHO 6
Dublin South 49.1
Dublin South East 58.7
Wicklow 55.3
CHO 6 Total 53.9
CHO 7
Dublin South City 79.9
Dublin South West 83.6
Dublin West 77.6
Kildare/West Wicklow 71.6
CHO 7 Total 77.8
CHO 8
Laois/Offaly 76.6
Longford/Westmeath 88.2
Louth 95.3
Meath 72.2
CHO 8 Total 81.7
CHO 9
Dublin North West 67.2
Dublin North Central 79.0
Dublin North 68.8
CHO9 Total 71.0
National Rate  73.1
Source: Primary Care Reimbursement Service
Notes: Eligible patients refer to those who are eligible to claim for a prescription via Community Drugs Schemes and are 
captured via the Primary Care Reimbursement Service's information system. See appendix for detailed indicator definitions 
and methodology. 
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Appendix 1: Metadata sheets
Indicator Immunisation rate for MMR vaccine 
Definition Percentage of children 24 months of age who have received the MMR (measles, mumps and  
 rubella) vaccine
Years Covered National trend: 2009 – 2018
 Community Health Organisation and Local Health Office: 2018
Classification N/A
Methodology  Numerator: Number of children who have received the 1st dose of MMR vaccination by their  
 second birthday.
  Denominator: Number of children who have reached their second birthday
Notes The data for 2008 and 2010 are incomplete as data for some regions were incomplete.
 Please note while North Lee and South Lee are two separate LHOs their combined
 immunisation uptake data are reported here.
Data Source(s) Health Protection Surveillance Centre
Indicator Immunisation rate for MenC vaccine 
Definition Percentage of children 24 months of age who have received the MenC vaccine 
Years Covered National trend: 2009 – 2018
 Community Health Organisation and Local Health Office: 2018
Classification N/A
Methodology Numerator: Prior to October 1st 2016: Number of children who have received 3 doses of the
 Meningitis C vaccination by their second birthday.
 After October 1st 2016: Number of children who have received 2 doses of the Meningitis C
 vaccination by their second birthday.
  Denominator: Number of children who have reached their second birthday.
Notes Data for Q3 2008 were not available for 2 regions.
 The data for 2009 and 2010 are incomplete as data for some regions were incomplete.
 Please note while North Lee and South Lee are two separate LHOs their combined
 immunisation uptake data are reported here.
 2016 receive one dose of MenC at 6 months and a second dose of MenC (as part of a
 combinedHib/MenC vaccine) at 13 months. The schedule changed to facilitate the    
 introduction of meningococcal B (MenB) vaccine at 2 and 4 months of age.
 The schedule changed again for all babies born on or after October 1st 2016. Babies born on 
 or after October 1st
 
Data Source(s) Health Protection Surveillance Centre
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Indicator Immunisation rate against influenza for persons aged 65 years and older
Definition Percentage of people aged 65 years and over with a medical card or GP Visit Card who have
 been vaccinated against influenza.
Years Covered National trend: 2007/2008 – 2018/2019
 OECD Comparison: 2016 (or nearest year)
Classification N/A
Methodology  Numerator: Number of medical card and GP Visit Card holders aged 65 years and over who
 have received the influenza vaccine from a GP or (from 2012/2013) from a pharmacist.
  Denominator: Number of medical card and GP Visit Card holders aged 65 years and over.
Notes Influenza vaccine data relate to paid claims for influenza vaccine reimbursement for medical
 card holders and GP Visit Card holders aged 65 years old and over attending GP clinics
 and pharmacies for influenza vaccination. Data from pharmacies were only available from
 the 2012/2013 influenza season when administration of influenza vaccine by pharmacists
 commenced.
 Data for the 2018/2019 influenza season is provisional.
Data Source(s) Health Protection Surveillance Centre
 OECD Health Statistics
Indicator Immunisation rate against influenza among healthcare workers in hospitals 
Definition Percentage of healthcare workers in hospitals who received the seasonal influenza vaccine
Years Covered National Trend: HSE-funded hospitals 2011/2012 – 2018/2019
 Staff categories comparison: 2018/2019
Classification N/A
Methodology  Numerator: Number of healthcare workers in HSE-funded hospitals who have received
 seasonal influenza vaccine by the end of the influenza season.
  Denominator: Number of long term or permanent healthcare workers that staff HSE-funded
  hospitals
Notes Data are provisional for the 2018/2019 influenza season.
 Data from other hospitals (private) is provided annually on a voluntary basis to HPSC.
Data Source(s) Health Protection Surveillance Centre
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Indicator Immunisation rate for human papillomavirus (HPV) vaccine
Definition Percentage of girls in first year of second level schools and their age equivalents* who have   
 received the HPV vaccine.
Years Covered National Trend: Academic years (September to September) 2014/15-2016/17
 Community Health Organisation and Local Health Office Comparison: Academic year   
 2016/2017
Classification N/A
Methodology Numerator: Number of girls who have received 2 doses of the HPV vaccine by the end of   
 their first academic year at second level
  Denominator: Number of girls in their first academic year at second level on the school role
  on 30th September and, for their age equivalents, the number of girls on the school role of
  special schools or registered with the National Educational Welfare Board on 30th September
Notes Although the HPV vaccination programme was initiated in May 2010, data for academic years
 prior to 2014/2015 is not directly comparable because in previous years a three dose
 schedule was recommended.
 Due to the unavailability of data for the 2017/2018 academic year was unavailable at time of  
 publication. 
 * Age equivalents include those attending special schools or registered with the Educational
 Welfare Service of the Child and Family Agency, TUSLA as home schooled.
Data Source(s) Health Protection Surveillance Centre
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Indicator Screening rate for breast cancer
Definition Percentage uptake of breast screening by eligible women in the population
Years Covered National and County: Cohort 2008-2017 OECD Comparison: 2016 (or nearest year)
Classification N/A
Methodology Numerator: The number of eligible women in the population who were invited in the   
 reporting period and have had a satisfactory screening test.
  Denominator: The number of eligible women invited in the reporting period.
Notes The data for 2017 is provisional.
 The eligible population refers to the known target population (women of screening age that
 are known to the programme) less those women excluded or suspended by the programme
 based on certain eligibility criteria:
Excluded Women in follow up care for breast cancer, not contactable by An Post, women who
 have a physical/mental incapacity (while BreastCheck attempts to screen all eligible women,
 certain forms of physical or mental incapacity may preclude screening), terminal illness or   
 other.
Suspended Women on extended vacation or working abroad, women who had a mammogram
 within the last year, women who opt to wait until the next round, women who wished to   
 defer appointment, women unwilling to reschedule or other.
Data Source(s) National Screening Service 
 OECD Health Statistics
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Indicator Screening rate for colorectal cancer 
Definition The proportion of the eligible population in Ireland who have availed of a bowel screen a two  
 year time period.
Years Covered National and County 2016-2017
Classification N/A
Methodology  Numerator: The number of eligible people in the population who were invited in the   
 reporting period and have availed of bowel screening.
  Denominator: The number of eligible people invited in the reporting period.
Notes The data for 2016 is provisional.
 The eligible population refers to the known target population less those excluded or   
 suspended by the programme based on certain eligibility criteria.
Data Source(s) National Screening Service
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Indicator Screening rate for cervical cancer 
Definition The proportion of the eligible population in Ireland who had a satisfactory smear test within a  
 five year time period.
Years Covered National level: Rolling 5-year period covering 01/09/2012-31/08/2017
 County level: Rolling 5-year period covering 01/09/2012-31/08/2017
 OECD Comparison: 2016 (or nearest year)
Classification N/A
Methodology  Numerator: The number of women in the eligible population who have had a satisfactory   
 smear test in the 5-year reporting period.
  Denominator: The number of eligible women in the population at the mid-point of the 5-year
  reporting period. Population is based on CSO Census 2011 estimate projected to 2013,
  (adjusted for hysterectomy).
Notes This is a rolling parameter which is updated each year to incorporate the previous 5-year   
 period.
Data Source(s) National Screening Service
 OECD Health Statistics
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Indicator COPD hospitalisation rates
Definition The age-sex standardised rate of hospitalisations of people aged 15 years and older with a   
 principal diagnosis of chronic obstructive pulmonary disease (COPD) per 100,000 population.
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year) 
 County of residence: 2016 – 2018 (aggregated)
Classification ICD-10-AM/ACHI J41, J42, J43, J44, J47 or J40 with a secondary diagnosis of J41, J43, J44  
 or J47
Methodology  Numerator: Number of hospital discharges with a principal diagnosis of COPD in a specified  
 year, ages 15 and over.
  Denominator: Population aged 15 years and older.
 Exclusions:
 i. Cases transferred in from another acute hospital
 ii. Cases in Major Diagnostic Categories 14 (Pregnancy, Childbirth & Puerperium) or 15
  (Newborns & Other Neonates)
 iii. Cases that are discharged on the day of admission
 Age-sex standardisation:
Data have been age and sex standardised based on the methodology developed and used by 
the OECD Health Care Quality Indicators (HCQI) data collection.
Age-sex standardised rates facilitate comparison of rates between populations of different 
age composition (for example hospitals or countries) and also of rates over time. The age-sex
standardised rate is the number of cases per 100,000 population that would occur if the
county or year had the same age structure as the OECD Standard Population and the local
age-sex specific rates applied.
Age-sex standardised rates and associated confidence limits are calculated as follows:
i.  The number of cases in the numerator and the population (i.e. the denominator) are
 calculated by males and females for each 5 year age-group from 15-19 to 85+ years..
ii.  Age & sex specific rates are calculated for males and females for each age-group.
iii.  The age & sex specific rates are multiplied by the number of cases in the OECD standard
 population (based on the total OECD population in 2010)
iv.  The age-sex standardised hospitalisation rate (ASR) is then calculated as the sum of the
 age & sex specific rates multiplied by the standard population, and divided by the total
 number of cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASR ± 1.96 * Standard Error of ASR where the standard error is determined 
from a binomial distribution.
Note that the age-sex standardised hospitalisation rates at county of residence level for 2015
to 2017 refer to the average annual rate over the three year period.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. A small number of non-acute hospitals that are not included in the hospital groups
participate in HIPE for historical reasons; these hospitals have been removed from this 
analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
NHQRS Annual Report 2019
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95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised rates. Where the lower limit of the 95% confidence interval 
is above the upper 95% confidence limit of the national rate, it can be said that the rate is
statistically significantly higher than the national rate at the 95% confidence level. Similarly,
where the upper limit of the 95% confidence interval is below the lower 95% confidence limit
of the national rate, it can be said that the rate is statistically significantly lower than the
national rate at the 95% confidence level. Note that areas with small numbers of cases 
tend to have unstable rates and wider confidence intervals. Caution should be exercised in 
interpreting rates with wide confidence intervals.
Population estimates for years 2012-2016 has been revised following the release of Census
2016 results. Hospitalisation rates are therefore not directly comparable to previous NHQRS
publications.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator Asthma hospitalisation rates
Definition The age-sex standardised rate of hospitalisations of people aged 15 years and older with a
 principal diagnosis of asthma per 100,000 population.
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year)
 County of residence: 2016-2018 (aggregated)
Classification ICD-10-AM J45 or J46
Methodology  Numerator: Number of hospital discharges with a principal diagnosis of asthma in a specified
 year, ages 15 and over.
  Denominator: Population aged 15 years and older.
 Exclusions:
 i.  Cases transferred in from another acute hospital
 ii.  Cases in Major Diagnostic Categories 14 (Pregnancy, Childbirth & Puerperium) or 15
  (Newborns & Other Neonates)
 iii.  Cases with any diagnosis code of cystic fibrosis and anomalies of the respiratory system
  [ICD-10-AM E84, P27, Q25.4, Q31.1 - Q34.9, Q39.0 - Q39.4, Q39.8, Q89.3]
 iv. Cases that are discharged on the day of admission
 Age-sex standardisation:
Data have been age and sex standardised based on the methodology developed and used by 
the OECD Health Care Quality Indicators (HCQI) data collection.
Age-sex standardised rates facilitate comparison of rates between populations of different 
age composition (for example hospitals or countries) and also of rates over time. The age-sex
standardised rate is the number of cases per 100,000 population that would occur if the 
county or year had the same age structure as the OECD Standard Population and the local 
age-sex specific rates applied.
Age-sex standardised rates and associated confidence limits are calculated as follows:
i.  The number of cases in the numerator and the population (i.e. the denominator) are
 calculated by males and females for each 5 year age-group from 15-19 to 85+ years.
ii.  Age & sex specific rates are calculated for males and females for each age-group.
iii.  The age & sex specific rates are multiplied by the number of cases in the OECD standard
 population (based on the total OECD population in 2010)
iv.  The age-sex standardised hospitalisation rate (ASR) is then calculated as the sum of the
 age & sex specific rates multiplied by the standard population, and divided by the total
 number of cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASR ± 1.96 * Standard Error of ASR where the standard error is determined 
from a binomial distribution.
Note that the age-sex standardised hospitalisation rates at county of residence level for 2015
to 2017 refer to the average annual rate over the three year period.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. A small number of non-acute hospitals that are not included in the hospital groups
participate in HIPE for historical reasons; these hospitals have been removed from this 
analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
NHQRS Annual Report 2019
A
PPEN
D
IX
 1: M
ETA
D
ATA
 SH
EETS
155
 95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised rates. Where the lower limit of the 95% confidence interval 
is above the upper 95% confidence limit of the national rate, it can be said that the rate is
statistically significantly higher than the national rate at the 95% confidence level. Similarly,
where the upper limit of the 95% confidence interval is below the lower 95% confidence limit
of the national rate, it can be said that the rate is statistically significantly lower than the
national rate at the 95% confidence level. Note that areas with small numbers of cases 
tend to have unstable rates and wider confidence intervals. Caution should be exercised in 
interpreting rates with wide confidence intervals.
Population estimates for years 2012-2016 has been revised following the release of Census
2016 results. Hospitalisation rates are therefore not directly comparable to previous NHQRS
publications.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
 The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator Diabetes hospitalisation rates
Definition The age-sex standardised rate of hospitalisations of people aged 15 years and older with a   
 principal diagnosis of diabetes per 100,000 population.
 
Years Covered National trend: 2008– 2018
 OECD comparison: 2015 (or nearest year) 
 County of residence: 2016 – 2018 (aggregated)
Classification ICD-10-AM E10 –E14
Methodology  Numerator: Number of hospital discharges with a principal diagnosis of diabetes in a   
 specified year, ages 15 and over.
  Denominator: Population aged 15 years and older.
 Exclusions: 
 i.  Cases transferred in from another acute hospital
ii.  Cases in Major Diagnostic Categories 14 (Pregnancy, Childbirth & Puerperium) or 15
 (New-borns & Other Neonates)
iii.  Cases that are discharged on the day of admission
 Age-sex standardisation: 
Data have been age and sex standardised based on the methodology developed and used by 
the OECD Health Care Quality Indicators (HCQI) data collection.
Age-sex standardised rates facilitate comparison of rates between populations of different 
age composition (for example hospitals or countries) and also of rates over time. The age-sex
standardised rate is the number of cases per 100,000 population that would occur if the
county or year had the same age structure as the OECD Standard Population and the local 
agesex specific rates applied.
Age-sex standardised rates and associated confidence limits are calculated as follows:
i.  The number of cases in the numerator and the population (i.e. the denominator) are
 calculated by males and females for each 5 year age-group from 15-19 to 85+ years.
ii.  Age & sex specific rates are calculated for males and females for each age-group.
iii.  The age & sex specific rates are multiplied by the number of cases in the OECD standard
 population (based on the total OECD population in 2010)
iv.  The age-sex standardised hospitalisation rate (ASR) is then calculated as the sum of the
 age & sex specific rates multiplied by the standard population, and divided by the total
 number of cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASR ± 1.96 * Standard Error of ASR
 where the standard error is determined from a binomial distribution.
Note that the age-sex standardised hospitalisation rates at county of residence level for 2015
to 2017 refer to the average annual rate over the two year period.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. A small number of non-acute hospitals that are not included in the hospital groups
participate in HIPE for historical reasons; these hospitals have been removed from this 
analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
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95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised rates. Where the lower limit of the 95% confidence interval
is above the upper 95% confidence limit of the national rate, it can be said that the rate is
statistically significantly higher than the national rate at the 95% confidence level. Similarly,
where the upper limit of the 95% confidence interval is below the lower 95% confidence limit
of the national rate, it can be said that the rate is statistically significantly lower than the
national rate at the 95% confidence level. Note that areas with small numbers of cases 
tend to have unstable rates and wider confidence intervals. Caution should be exercised in 
interpreting rates with wide confidence intervals.
In 2015, an update to the coding system from ICD-10-AM from 6th to 8th edition which
resulted in a change in how diabetes is reported in HIPE and hence the rates years
subsequent to 2015 are not directly comparable with those from previous years. the
classification.
Population estimates for years 2012-2016 has been revised following the release of Census
2016 results. Hospitalisation rates are therefore not directly comparable to previous NHQRS
publications.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator Heart failure hospitalisation rates
Definition The age-sex standardised rate of hospitalisations of people aged 15 years and older with a   
 principal diagnosis of heart failure per 100,000 population.
 
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year)
 County of residence: 2016 – 2018 (aggregated)
Classification ICD-10-AM I11.0, I13.0, I13.2, I50.0, I50.1 or I50.9
Methodology  Numerator: Number of hospital discharges with a principal diagnosis of heart failure in a   
 specified year, ages 15 and over.
  Denominator: Population aged 15 years and older.
 Exclusions: 
i.  Cases transferred in from another acute hospital
ii.  Cases in Major Diagnostic Categories 14 (Pregnancy, Childbirth & Puerperium) or 15
 (Newborns & Other Neonates)
iii.  Cases that are discharged on the day of admission
 Age-sex standardisation: 
Data have been age and sex standardised based on the methodology developed and used by 
the OECD Health Care Quality Indicators (HCQI) data collection.
Age-sex standardised rates facilitate comparison of rates between populations of different 
age composition (for example hospitals or countries) and also of rates over time. The age-sex
standardised rate is the number of cases per 100,000 population that would occur if the
county or year had the same age structure as the OECD Standard Population and the local 
agesex specific rates applied.
Age-sex standardised rates and associated confidence limits are calculated as follows:
i.  The number of cases in the numerator and the population (i.e. the denominator) are
 calculated by males and females for each 5 year age-group from 15-19 to 85+ years.
ii.  Age & sex specific rates are calculated for males and females for each age-group.
iii.  The age & sex specific rates are multiplied by the number of cases in the OECD standard
 population (based on the total OECD population in 2010)
iv.  The age-sex standardised hospitalisation rate (ASR) is then calculated as the sum of the
 age & sex specific rates multiplied by the standard population, and divided by the total
 number of cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASR ± 1.96 * Standard Error of ASR
 where the standard error is determined from a binomial distribution.
Note that the age-sex standardised hospitalisation rates at county of residence level for 2015
to 2017 refer to the average annual rate over the three year period.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. A small number of non-acute hospitals that are not included in the hospital groups
participate in HIPE for historical reasons; these hospitals have been removed from this 
analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
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95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised rates. Where the lower limit of the 95% confidence interval 
is above the upper 95% confidence limit of the national rate, it can be said that the rate is
statistically significantly higher than the national rate at the 95% confidence level. Similarly,
where the upper limit of the 95% confidence interval is below the lower 95% confidence
limit of the national rate, it can be said that the rate is statistically significantly lower than the
national rate at the 95% confidence level. Note that areas with small numbers of cases 
tend to have unstable rates and wider confidence intervals. Caution should be exercised in 
interpreting rates with wide confidence intervals.
Population estimates for years 2012-2016 has been revised following the release of Census
2016 results. Hospitalisation rates are therefore not directly comparable to previous NHQRS
publications.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
 The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator Breast cancer survival rates
Definition Age-standardised estimates of cumulative 5-year net survival in Ireland for female breast
 cancer patients diagnosed in the period 2010 - 2014 and 2011-2015
Years Covered National and HSE Region: Cohort 2011 – 2015
 OECD: Cohorts 2010-2014 (or nearest period)
Classification ICD-10-AM C50, ICD-9-CM 174
Methodology  Age-standardized period estimates of ‘Pohar Perme’ estimates of net survival for the follow- 
 up period 2011-2015.
Five-year observed survival for women aged 15-99 diagnosed with breast cancer (first 
primary cancer at the specified site) divided by the expected survival of a comparable group 
from the general population (expressed in percentage).
Survival estimates are standardized to the International Cancer Survival Standard (ICSS)
populations [67].
Notes Net survival is used throughout this report for the first time, following on from a 
methodological change by the OECD. Previous NHQRS publications have used the concept 
of relative survival.
Net survival is an ‘improved’ version of relative survival which takes better account of
competing mortality risks (allowing greater comparability between different populations or
age-groups) and represents the cumulative probability of a patient surviving a given time in 
the hypothetical situation in which the disease of interest is the only possible cause of death, 
i.e. survival having controlled for other possible cause of death (by comparison of observed 
survival with the expected survival of persons of the same age and gender in the general 
population).
Estimates here are 'Pohar Perme' estimates of net survival, implemented using the 'Strs' 
algorithm in Stata.
Reference: Pohar Perme M, Henderson R, Stare J. 2009. An approach to estimation in relative 
survival regression.
Biostatistics 10: 136-146.
Survival estimates are standardized to the International Cancer Survival Standard (ICSS) 
populations proposed for each cancer by: Corazziari I., Quinn M. & Capocaccia R. 2004. 
Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 
2307-2316.
Exclusions:
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases;
second or subsequent malignancies in the same patient (or the less serious of two or more
synchronously- diagnosed malignancies); in situ carcinomas, benign tumours and tumours of
uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on the NCRI
database.
As a result, the figures given here may not correspond exactly to those in previous reports or 
to those previously shown on the NCRI website.
Data Source(s) National Cancer Registry of Ireland 
 OECD Health Statistics
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Indicator Cervical cancer survival rates
Definition Age-standardised estimates of cumulative 5-year net survival in Ireland for cervical cancer
 patients during the period 2011- 2015
Years Covered  National and HSE Region: Cohort 2011 – 2015
 OECD: cohorts 2010-2014 (or nearest period)
Classification ICD-10-AM C53, ICD-9-CM 180
Methodology  Age-standardized period estimates of ‘Pohar Perme’ estimates of net survival for the follow-
up period 2011-2015 (for national data only).
Five-year observed survival for women aged 15-99 diagnosed with cervical cancer (first
primary cancer at the specified site) divided by the expected survival of a comparable group
from the general population (expressed in percentage).
Survival estimates are standardized to the International Cancer Survival Standard (ICSS)
populations [67].
Notes Net survival is used throughout this report for the first time, following on from a 
methodological change by the OECD. Previous NHQRS publications have used the concept 
of relative survival.
Net survival is an ‘improved’ version of relative survival which takes better account of
competing mortality risks (allowing greater comparability between different populations or
age-groups) and represents the cumulative probability of a patient surviving a given time in 
the hypothetical situation in which the disease of interest is the only possible cause of death, 
i.e. survival having controlled for other possible cause of death (by comparison of observed 
survival with the expected survival of persons of the same age and gender in the general 
population).
Estimates here are 'Pohar Perme' estimates of net survival, implemented using the 'Strs' 
algorithm in Stata.
Reference: Pohar Perme M, Henderson R, Stare J. 2009. An approach to estimation in relative 
survival regression.
Biostatistics 10: 136-146.
Survival estimates are standardized to the International Cancer Survival Standard (ICSS) 
populations proposed for each cancer by: Corazziari I., Quinn M. & Capocaccia R. 2004. 
Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 
2307-2316.
Exclusions:
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases;
second or subsequent malignancies in the same patient (or the less serious of two or more
synchronously- diagnosed malignancies); in situ carcinomas, benign tumours and tumours of
uncertain behaviour.
Cancer registration is a dynamic process and information is continually updated on the NCRI
database.
As a result, the figures given here may not correspond exactly to those in previous reports or 
to those previously shown on the NCRI website.
Data Source(s) National Cancer Registry of Ireland 
 OECD Health Statistics
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Indicator Colorectal cancer survival rates
Definition Age-sex standardised estimates of cumulative 5-year net survival in Ireland for colorectal
 cancer patients for the period 2011- 2015.
Years Covered National and HSE Region: Cohort 2011 – 2015
 OECD: cohorts 2010-2014 (or nearest period)
Classification ICD-10-AM C18-21, ICD-9-CM 153-154
Methodology  Age-standardized period estimates of ‘Pohar Perme’ estimates of net survival for the follow-
 up period 2010-2014 (for national data only).
 Five-year observed survival for the total population aged 15-99 diagnosed with colorectal
cancer (first primary cancer at the specified site) divided by the expected survival of a
comparable group from the general population (expressed in percentage).
Survival estimates are standardized to the International Cancer Survival Standard (ICSS)
populations [67].
Notes Net survival is used throughout this report for the first time, following on from a 
methodological change by the OECD. Previous NHQRS publications have used the concept 
of relative survival.
Net survival is an ‘improved’ version of relative survival which takes better account of
competing mortality risks (allowing greater comparability between different populations or
age-groups) and represents the cumulative probability of a patient surviving a given time in 
the hypothetical situation in which the disease of interest is the only possible cause of death, 
i.e. survival having controlled for other possible cause of death (by comparison of observed 
survival with the expected survival of persons of the same age and gender in the general 
population).
Estimates here are 'Pohar Perme' estimates of net survival, implemented using the 'Strs' 
algorithm in Stata.
Reference: Pohar Perme M, Henderson R, Stare J. 2009. An approach to estimation in relative 
survival regression.
Biostatistics 10: 136-146.
Survival estimates are standardized to the International Cancer Survival Standard (ICSS) 
populations proposed for each cancer by: Corazziari I., Quinn M. & Capocaccia R. 2004. 
Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 
2307-2316.
Exclusions:
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases;
second or subsequent malignancies in the same patient (or the less serious of two or more
synchronously- diagnosed malignancies); in situ carcinomas, benign tumours and tumours of
uncertain behaviour. Cancer registration is a dynamic process and information is continually
updated on the NCRI database.
As a result, the figures given here may not correspond exactly to those in previous reports or 
to those previously shown on the NCRI website.
Data Source(s) National Cancer Registry of Ireland 
 OECD Health Statistics
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Indicator Lung cancer survival rates
Definition Age-sex standardised estimates of cumulative 5-year net survival in Ireland for lung
 cancer patients for the period 2011- 2015.
Years Covered  National and HSE Region: Cohort 2011 – 2015
 CONCORDE: cohorts 2010-2014 (or nearest period)
Classification ICD-10-AM C18-21, ICD-9-CM 153-154
Methodology  Age-standardized period estimates of ‘Pohar Perme’ estimates of net survival for the follow-
 up period 2011-2015 (for national data only).
Five-year observed survival for the total population aged 15-99 diagnosed with colorectal
cancer (first primary cancer at the specified site) divided by the expected survival of a
comparable group from the general population (expressed in percentage).
Survival estimates are standardized to the International Cancer Survival Standard (ICSS)
populations [67].
Net survival is used throughout this report for the first time, following on from a 
methodological change by the OECD. Previous NHQRS publications have used the concept 
of relative survival.
Net survival is an ‘improved’ version of relative survival which takes better  account of 
competing mortality risks (allowing greater comparability between different populations or 
age-groups) and represents the cumulative probability of a patient surviving a given time in 
the hypothetical situation in which the disease of interest is the only possible cause of death, 
i.e. survival having controlled for other possible cause of death (by comparison of observed 
survival with the expected survival of persons of the same age and gender in the general 
population).
 
Estimates here are 'Pohar Perme' estimates of net survival, implemented using the 'Strs' 
algorithm in Stata.
Reference: Pohar Perme M, Henderson R, Stare J. 2009. An approach to estimation in relative 
survival regression.
Biostatistics 10: 136-146.
Survival estimates are standardized to the International Cancer Survival Standard (ICSS) 
populations proposed for each cancer by: Corazziari I., Quinn M. & Capocaccia R. 2004. 
Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 
2307-2316.
Notes Exclusions:
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases;
second or subsequent malignancies in the same patient (or the less serious of two or more
synchronously- diagnosed malignancies); in situ carcinomas, benign tumours and tumours of
uncertain behaviour. Cancer registration is a dynamic process and information is continually
updated on the NCRI database.
As a result, the figures given here may not correspond exactly to those in previous reports or 
to those previously shown on the NCRI website.
Data Source(s) National Cancer Registry of Ireland 
 Global surveillance of trends in cancer survival 2000–14(CONCORD-3):
 analysis of individual records for 37, 513, 025 patients diagnosed with one of 18 cancers   
 from 322 population-based registries in 71 countries
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Indicator In-hospital mortality within 30 days of admission for acute myocardial   
 infarction/heart attack
Definition The number of patients aged 45 and over who die in hospital within 30 days of being
 admitted with a principal diagnosis of an AMI, as a proportion of the total number of patients
 aged 45 and over admitted to that hospital with a principal diagnosis of an AMI.
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year)
 Hospital & hospital group level: 2016 – 2018 (aggregated)
Classification ICD-10-AM I21 or I22, ICD-9-CM 410
Methodology  Numerator:
Number of deaths in hospital that occurred within 30 days of hospital admission with a 
principal diagnosis of acute myocardial infarction in a specified year, ages 45 and over.
Denominator:
Number of hospitalisations of patients aged 45 and over with a principal diagnosis of acute
myocardial infarction in the specified year.
Age-sex standardisation:
Data have been age and sex standardised based on the methodology developed and used by 
the OECD Health Care Quality Indicators (HCQI) data collection.
Age-sex standardised rates facilitate comparison of rates between populations of different
age composition (for example hospitals or countries) and also of rates over time. The age-sex
standardised death rate (ASDR) is the number of deaths per 100 cases that would occur if the
hospital, country or year had the same age structure as the OECD Standard Population and 
the local age-sex specific rates applied.
Age-sex standardised deaths rates (ASDRs) and associated confidence limits are calculated as
follows:
i.  The number of deaths and cases are calculated by males and females for each 5 year 
agegroup from 45-49 to 85+ years.
ii.  Age & sex specific death rates are calculated for males and females for each age-group.
iii.  The age & sex specific death rates are multiplied by the number of cases in the OECD
 standard population (based on the total number of AMI hospitalisations in the OECD).
iv.  The age-sex standardised death rate (ASDR) is then calculated as the sum of the age & sex
 specific rates multiplied by the standard population, and divided by the total number of 
cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASR ± 1.96 * Standard Error of ASDR where the standard error is 
determined from a binomial distribution.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. Data have been analysed at hospital and hospital group level. A small number 
of nonacute hospitals that are not included in the hospital groups participate in HIPE for 
historical reasons; these hospitals have been removed from this analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
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95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised death rates. Where the lower limit of the 95% confidence
interval is above the upper 95% confidence limit of the national rate, it can be said that the 
rate is statistically significantly higher than the national rate at the 95% confidence level. 
Similarly, where the upper limit of the 95% confidence interval is below the lower 95% 
confidence limit of the national rate, it can be said that the rate is statistically significantly 
lower than the national rate at the 95% confidence level. Note that hospitals with small 
numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 denominator cases, although the 
data for these hospitals have been included in the calculation of the national rates. However 
some hospitals with more than 100 cases may still have unstable rates and caution should be 
exercised in interpreting rates with wide confidence intervals.
It is important to note that transfer patterns between hospitals have the potential to 
influence the in-hospital mortality rates. For some conditions there can be significant volumes 
of patients being transferred out of hospitals and being transferred into other hospitals. The 
indicators presented in this report are high-level indicators and while transfers are included 
in the data, transfer patterns are not taken into account. A more refined analysis of transfer 
patterns would be required to assess the full effect of transfers on the in-hospital mortality 
rates.+
Data Source(s) Hospital In-Patient Enquiry (HIPE)
The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator Stroke admissions to hospitals with stroke units
Definition The proportion of patients nationally whose principal diagnosis is stroke, who are admitted to  
 a hospital with a stroke unit on diagnosis.
Years Covered Nationally 2018
Classification Principal diagnosis: ICD-10-AM I60, I61, I62, I63, I64
 Hospitals with Acute Stroke Unit:
 St Vincent’s University Hospital, St. James’s Hospital, AMNCH Tallaght, Our Lady of Lourdes
 Hospital Drogheda, Cavan General Hospital, Beaumont Hospital, University Hospital
 Waterford, South Tipperary Hospital, Portiuncula Hospital, Mayo General Hospital
 Hospitals with combined Stroke Unit:
 Mater Misercordaie University Hospital, Midland Regional Hospital Mullingar, Wexford
 General Hospital, St. Luke’s Hospital Kilkenny, Naas General Hospital, Midland General
 Hospital Portlaoise, University Hospital Limerick, Cork University Hospital, Mercy Hospital
 Cork, Bantry Hospital, University Hospital Galway.
Methodology  The proportion of patients nationally whose principal diagnosis is stroke (ICD codes above)   
 who are admitted to a hospital with a stroke unit.
Notes Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
 The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on   
 HIPE see http://www.hpo.ie.
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Indicator In-hospital mortality within 30 days of admission for haemorrhagic stroke
Definition The number of patients aged 45 and over who die in hospital within 30 days of being
 admitted with a principal diagnosis of an haemorrhagic stroke, as a proportion of the total
 number of patients aged 45 and over admitted to that hospital with a principal diagnosis of
 an haemorrhagic stroke.
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year)
 Hospital & hospital group level: 2016 – 2018 (aggregated)
Classification ICD-10-AM I60 - I62, ICD-9-CM 430 – 432
Methodology  Numerator: 
 Number of deaths in hospital that occurred within 30 days of hospital admission with a   
 principal diagnosis of haemorrhagic stroke in a specified year, ages 45 and over.
 Denominator: 
 Number of hospitalisations of patients aged 45 and over with a principal diagnosis of
 haemorrhagic stroke in the specified year.
 Age-sex standardisation:
 Data have been age and sex standardised based on the methodology developed and used   
 by  the OECD Health Care Quality Indicators (HCQI) data collection. Age-sex standardised   
rates facilitate comparison of rates between populations of different age composition (for   
 example hospitals or countries) and also of rates over time. The age-sex standardised death 
rate (ASDR) is the number of deaths per 100 cases that would occur if the hospital, country 
or year had the same age structure as the OECD Standard Population and the local age-sex 
specific rates applied.
Age-sex standardised deaths rates (ASDRs) and associated confidence limits are calculated as
follows:
i.  The number of deaths and cases are calculated by males and females for each 5 year 
agegroup from 45-49 to 85+ years.
ii.  Age & sex specific death rates are calculated for males and females for each age-group.
iii.  The age & sex specific death rates are multiplied by the number of cases in the OECD
 standard population (based on the total number of haemorrhagic stroke hospitalisations in
 the OECD)
iv.  The age-sex standardised death rate (ASDR) is then calculated as the sum of the age & sex
 specific rates multiplied by the standard population, and divided by the total number of 
cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASDR ± 1.96 * Standard Error of ASDR where the standard error is 
determined from a binomial distribution.
Notes  Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. Data have been analysed at hospital and hospital group level. A small number 
of nonacute hospitals that are not included in the hospital groups participate in HIPE for 
historical reasons; these hospitals have been removed from this analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
NHQRS Annual Report 2019
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95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised death rates. Where the lower limit of the 95% confidence
interval is above the upper 95% confidence limit of the national rate, it can be said that the 
rate is statistically significantly higher than the national rate at the 95% confidence level. 
Similarly, where the upper limit of the 95% confidence interval is below the lower 95% 
confidence limit of the national rate, it can be said that the rate is statistically significantly 
lower than the national rate at the 95% confidence level. Note that hospitals with small 
numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 denominator cases, although the 
data for these hospitals have been included in the calculation of the national rates. However 
some hospitals with more than 100 cases may still have unstable rates and caution should be 
exercised in interpreting rates with wide confidence intervals.
It is important to note that transfer patterns between hospitals have the potential to 
influence the in-hospital mortality rates. For some conditions there can be significant volumes 
of patients being transferred out of hospitals and being transferred into other hospitals. The 
indicators presented in this report are high-level indicators and while transfers are included 
in the data, transfer patterns are not taken into account. A more refined analysis of transfer 
patterns would be required to assess the full effect of transfers on the in-hospital mortality 
rates.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator In-hospital mortality within 30 days of admission for ischaemic stroke 
Definition The number of patients aged 45 and over who die in hospital within 30 days of being
 admitted with a principal diagnosis of an ischaemic stroke, as a proportion of the total number
 of patients aged 45 and over admitted to that hospital with a principal diagnosis of an
 ischaemic stroke.
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year)
 Hospital & hospital group level: 2016 – 2018 (aggregated)
Classification ICD-10-AM I63 - I64, ICD-9-CM 433, 434 or 436
Numerator: Number of deaths in hospital that occurred within 30 days of hospital admission 
with a principal diagnosis of ischaemic stroke in a specified year, ages 45 and over.
Denominator: Number of hospitalisations of patients aged 45 and over with a principal 
diagnosis of ischaemic stroke in the specified year.
 Age-sex standardisation:  
Data have been age and sex standardised based on the methodology developed and used by 
the OECD Health Care Quality Indicators (HCQI) data collection.
Age-sex standardised rates facilitate comparison of rates between populations of different
age composition (for example hospitals or countries) and also of rates over time. The age-sex
standardised death rate (ASDR) is the number of deaths per 100 cases that would occur if the
hospital, country or year had the same age structure as the OECD Standard Population and 
the local age-sex specific rates applied.
Age-sex standardised deaths rates (ASDRs) and associated confidence limits are calculated as
follows:
i.  The number of deaths and cases are calculated by males and females for each 5 year 
agegroup from 45-49 to 85+ years.
ii.  Age & sex specific death rates are calculated for males and females for each age-group.
iii.  The age & sex specific death rates are multiplied by the number of cases in the OECD
 standard population (based on the total number of ischaemic stroke hospitalisations in the
 OECD)
iv.  The age-sex standardised death rate (ASDR) is then calculated as the sum of the age & sex
 specific rates multiplied by the standard population, and divided by the total number of 
cases in the standard population.
v.  Upper and lower confidence intervals are presented at the 95% confidence level, and are
 calculated by ASDR ± 1.96 * Standard Error of ASDR where the standard error is 
determined from a binomial distribution.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. Data have been analysed at hospital and hospital group level. A small number 
of nonacute hospitals that are not included in the hospital groups participate in HIPE for 
historical reasons; these hospitals have been removed from this analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of
a Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
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95% confidence intervals have been produced and these should be considered when
interpreting the age-standardised death rates. Where the lower limit of the 95% confidence
interval is above the upper 95% confidence limit of the national rate, it can be said that the 
rate is statistically significantly higher than the national rate at the 95% confidence level. 
Similarly, where the upper limit of the 95% confidence interval is below the lower 95% 
confidence limit of the national rate, it can be said that the rate is statistically significantly 
lower than the national rate at the 95% confidence level. Note that hospitals with small 
numbers of cases tend to have unstable rates and wider confidence intervals. For this report 
rates are not displayed for hospitals with less than 100 denominator cases, although the 
data for these hospitals have been included in the calculation of the national rates. However 
some hospitals with more than 100 cases may still have unstable rates and caution should be 
exercised in interpreting rates with wide confidence intervals.
It is important to note that transfer patterns between hospitals have the potential to 
influence the in-hospital mortality rates. For some conditions there can be significant volumes 
of patients being transferred out of hospitals and being transferred into other hospitals. The 
indicators presented in this report are high-level indicators and while transfers are included 
in the data, transfer patterns are not taken into account. A more refined analysis of transfer 
patterns would be required to assess the full effect of transfers on the in-hospital mortality 
rates.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
 OECD Health Statistics
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Indicator In-hospital waiting time for hip fracture surgery
Definition The proportion of patients aged 65 years and older with a hip fracture who have surgery 
within two days of admission to hospital.
Years Covered National trend: 2009 – 2018
 OECD comparison: 2015 (or nearest year)
 Hospital & hospital group level: 2016 – 2018 (aggregated)
Classification Hip fracture diagnostic codes:
ICD-10-AM S72.0, S71.1, S72.2, ICD-9-CM 820
Hip fracture surgery codes:
ACHI blocks 1479, 1486, 1487, 1488, 1489, 1491, 1492 or ICD-9-CM 78.05, 78.15, 78.55,
79.05, 79.15,
79.25, 79.35, 79.75, 79.85, 81.21, 81.40, 81.51, 81.52, 81.53
Methodology  Numerator:
Number of hospitalisations with a principal diagnosis of a hip fracture and who had hip 
fracture surgery on the day of admission, 1 day after admission or 2 days after admission in a 
specified year, ages 65 and older.
Denominator:
Number of hospitalisations with a principal diagnosis of a hip fracture and who had hip 
fracture surgery during the admission in a specified year, ages 65 and older.
Exclusions:
Elective admissions and elective re-admissions.
Data have been calculated according to the methodology used by the OECD Health Care
Quality Indicators (HCQI) project. It should be noted that the methodology specified by the
OECD for the 2012-2013 data collection allowed countries to define the waiting time for hip
fracture surgery based on either 48 hours or 2 days. This may reduce the comparability of this
indicator among OECD countries. The 2014-2015 HCQI data collection defines this indicator
as surgery within 2 calendar days after admission which will improve the comparability of the
data.
Notes Data are based on discharges from publicly funded acute hospitals; private hospitals are not
included. A small number of non-acute hospitals that are not included in the hospital groups
participate in HIPE for historical reasons; these hospitals have been removed from this 
analysis.
Each HIPE discharge record represents one episode of care and patients may have been
admitted to more than one hospital with the same or different diagnoses. In the absence of a
Unique Patient Identifier the records therefore facilitate analyses of hospital activity rather
than incidence of disease.
Data Source(s) Hospital In-Patient Enquiry (HIPE)
The Healthcare Pricing Office (HPO) manages the HIPE system. For more information on 
HIPE see http://www.hpo.ie.
The data presented for this indicator are based on analysis of HIPE data carried out by the
Department of Health using the definitions and methodology developed by the OECD Health
Care Quality Indicators (HCQI) project.
OECD Health Statistics
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Indicator Caesarean section rates
Definition The rate of caesarean section deliveries per 100 live births.
Years Covered National trend: 2007 – 2016
 OECD comparison: 2016 (or nearest year)
 Hospital & hospital group level: 2016
Classification Not applicable
Methodology  Data are based on the caesarean section rate per 100 live births for total maternities. 
 
 Exclusions:
•  Data exclude births in Mount Carmel Private Hospital, Bon Secours Private Hospitals
 (2004-2007) and planned domiciliary home births attended by a self-employed 
community midwife.
•  In accordance with WHO reporting guidelines, live births with birth weight <500g are
 excluded.
Notes Data are based on total maternities where outcome of delivery is live birth(s) and includes 
 total live births, i.e. single and multiple live births. It should be noted that caesarean sections 
rates vary considerably between single and multiple births.
The rates presented in this report differ slightly from those previously published in the 
National Perinatal Reporting System annual reports. This is due to the exclusion of the private 
maternity hospitals.
Data for 2016 is provisional.
Data Source(s)  National Perinatal Reporting System (NPRS)
The Healthcare Pricing Office (HPO) manages the NPRS system. The data presented in this
report were sourced directly from the Healthcare Pricing Office in March 2018 and were
based on the methodology used by the OECD for reporting caesarean section rates. For more
information on NPRS see http://www.hpo.ie
 OECD Health Statistics
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Indicator Overall Rating of Patient Experience 
Definition Hospital, Hospital Group and National patient reported overall rating of hospital experience   
 on a scale of 1 to 10.
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
The question regarding the patient’s overall experience of their hospital stay asked 
respondents to give a score of 1 to 10. These scores were then categorised into "very 
good" (scores of 9 or 10), "good" (scores of 7 or 8), or "fair to poor" (scores of 1 to 6). The 
percentages of responses given under each category were then described.
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. Appendix 4 describes the methods used in other jurisdictions.
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
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Indicator Admission to Hospital: Communication in Emergency Department
Definition The percentage responses by hospital, hospital group and nationally to the question:
 “While you were in the Emergency Department, did a doctor or nurse explain your condition  
 in a way you could understand?”
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
Each question, with the exception of the overall experience rating, within the National Patient
Experience Survey had 3 to 5 answer selections.
The percentage of responses for each available answer choice for each question were then 
described. In some cases, where two or more answer choices indicated that the question 
was not specific or applicable to the respondent's experience, the percentage of responses 
corresponding to those answer choices were combined, as noted in the chart. 
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. 
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
NHQRS Annual Report 2019
175
A
PPEN
D
IX
 1: M
ETA
D
ATA
 SH
EETS
Indicator Care on the Ward: Pain Control on the Ward  
Definition The percentage responses by hospital, hospital group and nationally to the question: “Do you  
 think the hospital staff did everything they could to help control your pain?”
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
Each question, with the exception of the overall experience rating, within the National Patient
Experience Survey had 3 to 5 answer selections. 
The percentage of responses for each available answer choice for each question were then 
described. In some cases, where two or more answer choices indicated that the question 
was not specific or applicable to the respondent's experience, the percentage of responses 
corresponding to those answer choices were combined, as noted in the chart.
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. Appendix 4 describes the methods used in other jurisdictions.
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
 
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
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Indicator Care on the Ward: Emotional Support Provided on the Ward 
Definition The percentage responses by hospital, hospital group and nationally to the question:
 “Did you find someone on the hospital staff to talk to about your worries and fears
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
Each question, with the exception of the overall experience rating, within the National Patient
Experience Survey had 3 to 5 answer selections.
The percentage of responses for each available answer choice for each question were then 
described. In some cases, where two or more answer choices indicated that the question 
was not specific or applicable to the respondent's experience, the percentage of responses 
corresponding to those answer choices were combined, as noted in the chart.
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. Appendix 4 describes the methods used in other jurisdictions.
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
 
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
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Indicator Examinations, Diagnosis and Treatment: Patient Involvement in Decision   
 Making Regarding Care   
Definition The percentage responses by hospital, hospital group and nationally to the question: “Were   
 you involved as much as you wanted to be in decisions about your care?”
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
Each question, with the exception of the overall experience rating, within the National Patient
Experience Survey had 3 to 5 answer selections.
The percentage of responses for each available answer choice for each question were then 
described. In some cases, where two or more answer choices indicated that the question 
was not specific or applicable to the respondent's experience, the percentage of responses 
corresponding to those answer choices were combined, as noted in the chart.
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. Appendix 4 describes the methods used in other jurisdictions.
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
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Indicator Discharge or Transfer: Communication Regarding Continuing Medicines 
 at Patient Discharge 
Definition The percentage responses by hospital, hospital group and nationally to the question: “Did a  
 member of staff explain the purpose of medicines you were to take at home in a way you 
 could understand?”
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
Each question, with the exception of the overall experience rating, within the National Patient
Experience Survey had 3 to 5 answer selections. 
The percentage of responses for each available answer choice for each question were then 
described. In some cases, where two or more answer choices indicated that the question 
was not specific or applicable to the respondent's experience, the percentage of responses 
corresponding to those answer choices were combined, as noted in the chart.
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. Appendix 4 describes the methods used in other jurisdictions.
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
 
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
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Indicator Other Aspects of Care: Dignity and Respect while in Hospital    
Definition The percentage responses by hospital, hospital group and nationally to the question: “Overall, 
 did you feel you were treated with dignity and respect while you were in hospital?”
Years Covered 2018
Classification N/A
Methodology  HIQA have published a Technical Report regarding the survey design, data collection,
and data analysis methods for the National Patient Experience Survey which is available at
https://www.patientexperience.ie/app/uploads/2018/03/NPE_Survey_Technical_
Report_2017.
Pdf Detailed information regarding survey and sample design is available at section 5.2.1 of 
the Technical Report.
Questions for the NPES were pulled from the Picker Institute Europe
Each question, with the exception of the overall experience rating, within the National Patient
Experience Survey had 3 to 5 answer selections.
The percentage of responses for each available answer choice for each question were then 
described. In some cases, where two or more answer choices indicated that the question 
was not specific or applicable to the respondent's experience, the percentage of responses 
corresponding to those answer choices were combined, as noted in the chart.
This report provides information about the patient experiences as reported in similar
jurisdictions who have also conducted acute inpatient experience surveys.
To align the Irish survey outputs to those of other countries, the percentage of survey
participants who responded with “yes definitely” or “yes, sometimes” were combined in Table
19. Appendix 4 describes the methods used in other jurisdictions.
The questions reported on in Domain 4 were identical to those used internationally, unless
noted.
Notes It should be noted that each jurisdiction differs in the method by which they disseminate
and collect information. This can take shape in the format in which they collect information
(online only, post and online, etc.). Jurisdictions may also differ in their selection criteria for
patient respondents according to age cohorts (such as including all those over 16, or including
all those over 18). Some jurisdictions conduct their patient experience surveys on an ongoing
or rolling basis, while others select a period of time annually or biannually in which patients 
are surveyed. All of these differences in methodology may impact upon the results generated 
in each survey. Caution in comparison is advised.
Data Source(s)  National Patient Experience Survey 
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Indicator Staphylococcus aueus and Methicillin resistant Staphylococcus aueus (MRSA)  
 blood stream infection rates 
Definition Rate of Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA)  
 blood stream infections in acute hospitals per 1,000 bed days used. Under the case definition  
 for the European Antimicrobial Resistance Surveillance Network (EARS-Net), data are   
 collected on the first bloodstream isolate of S. aureus per patient per quarter.
Years Covered National trend: 2008 – 2017
 European Antimicrobial Resistance Surveillance Network (EARS-net) comparison 2016
Classification Not applicable
Methodology  Under the case definition for the European Antimicrobial Resistance Surveillance Network  
 (EARS-Net), MRSA rates are calculated based on the number of MRSA cases per 1,000 bed 
 days used.
Notes Not applicable
Data Source(s)  Health Protection Surveillance Centre EARS–Net
Indicator Clostridium difficile (C Difficile) rates
Definition The rate of new cases of C. difficile in acute hospitals per 10,000 bed days used.
Years Covered National trend: 2010 – 2017
Classification Not applicable
Methodology  Rates are calculated based on the number of new hospital acquired cases of Clostridium   
 Difficile per 10,000 bed days used.
Notes Surveillance began in 2009. Between 2009 and 2015, there was a gradual increase in the
 numbers of hospitals participating in the enhanced surveillance system. The numbers of
 participating hospitals should be taken into account when interpreting national trends.
 There is considerable variation in the C. difficile testing methodologies used by participating
 laboratories. Different methodologies have different levels of sensitivity in detecting C.   
 difficile therefore inter-hospital comparison of CDI rates is not recommended unless data is
 adjusted for type of testing method used.
Data Source(s)  Health Protection Surveillance Centre
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Indicator Antibiotic consumption in the community
Definition Community antibiotic consumption rates are measured in Defined Daily Dose (DDD) per 
 1,000 inhabitants per day from community consumption data. 
Years Covered National trend: 2009 -2018
Community antibiotic consumption by county: 2018
European Surveillance of Antimicrobial Consumption Network (ESAC-net) - European Centre 
for Disease Prevention and Control (ECDC) 2016. 
Classification Not applicable
Methodology  Community antibiotic consumption rates are measured in Defined Daily Dose (DDD) per   
 1,000 inhabitants per day (DID) from community consumption data. DDD is defined as the
 assumed average maintenance dose per day for a drug used for its main indication in adults.
Notes Community antibiotic consumption data is obtained from the IMS Health (a pharmaceutical
 market research company) dataset which contains regional, monthly wholesaler to retail
 pharmacy sales data from over 95% of the wholesalers and manufacturers in Ireland.
 DDD is defined as the assumed average maintenance dose per day for a drug used for its   
 main indication in adults.
Data Source(s)  Health Protection Surveillance Centre 
 EARS–Net
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Indicator Antibiotic consumption in public acute hospitals
Definition Hospital antibiotic consumption rates are measured in Defined Daily Dose (DDD) per 1000 
 inhabitants per day from hospital consumption data. 
Years Covered National trend: 2009-2018
 In-hospital antibiotic consumption by county: 2018
Classification Anatomical Therapeutic Chemical (ATC) Classification System
Methodology  Hospital antibiotic consumption rates expressed as Defined Daily Dose (DDD) per 1000 
 inhabitants per day (DID) from hospital consumption data. DDD is defined as the assumed   
 average maintenance dose per day for a drug used for its main indication in adults.
Total acute inpatient antibiotic consumption in Defined Daily Doses per 100 Bed-Days Used
(DDD/100BDU) for each hospital is presented. The denominator data (bed days) were 
obtained from the Business Intelligence Unit of the Corporate Planning and Corporate 
Performance (CPCP) section of the HSE.
Exclusions:
Acute inpatient means that data on antibiotics dispensed to outpatients, day cases and 
external facilities are excluded
Notes Hospital care data are directly from publicly funded hospital pharmacy software systems. The
Irish Health Services Executive sanctioned the appointment of additional antibiotic liaison
hospital pharmacists in 2006/7, and national hospital antibiotic stewardship programmes 
began in 2008.
The consumption data are based on the volume of antimicrobial drugs supplied to inpatient
areas by hospital pharmacies. The data are not based on individual prescriptions and do not
measure the appropriateness of antibiotic therapy. Thus a hospital may report a high rate of
antibiotic consumption, but this rate may be appropriate to the specific patient population
served by that hospital.
There are many hospitals in the sample that provide maternity services and/or paediatric care,
therefore there is an inherent bias in the system. A further limitation with the ATC-DDD 
system which captures prescribing data is that the measure is for the main indication only, 
but a single drug can be used to treat several different conditions. Additionally the rates for 
an individual hospital may vary due to changes in case-mix, guidelines for the optimal dosage 
regimen of an antibiotic, and overall hospital activity levels.
DDD is defined as the assumed average maintenance dose per day for a drug used for its 
main indication in adults 2008 - 2017.
In 2017 a methodology change was made to the reporting of antibiotic consumption rates
in acute hospitals. Items returned to the dispensary are now subtracted from the overall
consumption rates, which has resulted in the decrease of overall rates by 1.5-2%.
Data Source(s)  Health Protection Surveillance Centre
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Indicator Chronic Benzodiazepine Use in the Community in People Aged 65 Years   
 and Older 
Definition The number of patients aged 65 years and over (per 1,000 patients) who have had a 
 reimbursable prescription for a benzodiazepine medication dispensed for 12 months or more 
 via the Community Drugs Schemes. 
Years Covered National trend: 2013-2017
 Chronic benzodiazepine usage by CHO/LHO: 2017
 OECD: 2015 or nearest year
Classification Anatomical Therapeutic Chemical (ATC) Classification System
Methodology  Numerator: Number of people aged 65 years of age on 1st January with one or more 
prescriptions of long-term benzodiazepines for 12 months or greater (ATC - N05BA or 
N05CD or N05CF).
Denominator: Number of people aged 65 years or over on 1st January who claimed for 
prescriptions which are dispensed through through the General Medical Services (GMS) 
scheme or the Drugs Payment Scheme (DPS) or the Long-Term Illness Scheme (LTI).
 The usage over a 12 month period (taking 1st January as the reference point) is based on 
reimbursable claims made where the number of benzodiazepine prescriptions dispensed was 
greater than or equal to 12. 
Calculation of the indicator is based on the number of prescriptions of benzodiazepine 
medication(s) which are reimbursable by PCRS. One reimbursable prescription is considered 
to be equivalent to one month's worth of benzodiazepine medication for a patient for the 
purpose of calculation. 
Internationally most countries report data based on Defined Daily Doses (DDD’s).
Defined Daily Doses (DDD’s), are defined as the assumed average maintenance dose per day 
for a drug used on its main indication in adults. This is the preferred measure to use when 
calculating indicators based off pharmacy related databases. Defined Daily Doses (DDD’s) 
were created by the WHO Collaborating Centre for Drug Statistics Methodology.
Exclusions This data does not capture items dispensed outside of community drug schemes where the 
prescription has been paid for privately by the patient or patient representative.
This data may not capture claims which are under the Drug Payment Scheme (DPS) monthly 
threshold amount.
The information provided on the indicator is based on claim data which has been received by 
the Primary Care Reimbursement Service (PCRS) from Community Pharmacists and includes 
items reimbursed by PCRS only.
Patients who are not actively availing of the Long Term Illness Scheme.
Notes Figures are subject to change. Changes to the figures over time need to be interpreted in the 
context of policy changes in Community Drugs Schemes or change in prescribing practice by 
practitioners. For example, a change in payment threshold in the Drug Payment  Scheme will 
lead to a change in data coverage. 
Figures cover patients participating in the Community Drug Schemes stated below. The 
schemes cover patients in a number of different care settings including long-term care 
settings such as nursing homes. Many OECD countries report information specifically for 
primary care settings only. Therefore caution is advised when comparing this indicator against 
international countries.
 This indicator refers to benzodiazepine and related medications which include the following: 
adinazolam, alprazolam, bentazepam, bromazepam, brotizolam, camazepam, chlordiazepoxide, 
cinolazepam, clobazam, clotiazepam, cloxazolam, diazepam, doxefazepam, estazolam, 
eszopiclone, ethyl loflazepate, etizolam, fludiazepam, flunitrazepam, flurazepam, halazepam, 
ketazolam, loprazolam, lorazepam, lorazepam (combinations), lormetazepam, medazepam, 
midazolam, nitrazepam, nordazepam, oxazepam, pinazepam, potassium clorazepate, 
prazepam, quazepam, temazepam, tofisopam, triazolam, zaleplon, zolpidem, zopiclone.
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 The Primary Care Reimbursement Service (PCRS) is responsible for reimbursing 
GPs, Dentists, Pharmacists, Optometrists/Ophthalmologists and other contractors who 
provide free or reduced-cost services to the public across a range of community health 
schemes. These schemes form the infrastructure through which the HSE delivers a significant 
proportion of primary care to the public.
The above indicator is based on claims data which are reimbursed by PCRS. This indicator is 
based on information from patients participating in the following Community Drug Schemes:
General Medical Services (GMS)
Persons who are unable without undue hardship to arrange general practitioner medical 
and surgical services for themselves and their dependants are eligible for the GMS Scheme. 
Drugs, medicines and appliances approved under the Scheme are provided through 
Community Pharmacists. In most cases the GP gives a completed prescription form to an 
eligible person, who takes it to any Pharmacy that has an agreement with the Health Service 
Executive to dispense drugs, medicines and appliances on presentation of GMS prescription 
forms. In rural areas a small number of GPs hold contracts to dispense drugs and medications 
to GMS cardholders who opt to have their medicines dispensed by him/her directly. All GMS 
claims are processed and paid by the Primary Care Reimbursement Service. Since the 1st 
October 2010, an eligible person who is supplied a drug, medicine or medical or surgical 
appliance on the prescription of a Registered Medical Practitioner, Registered Dentist or 
Registered Nurse Prescriber, is charged a prescription charge by the Community Pharmacy 
Contractor, currently €2.50 per item subject to a limit of €25 per family per month (effective 
1st December 2013). 
From 1st March 2017, the prescription charge for persons aged 70 & over, and their 
dependents, was reduced from €2.50 to €2.00 per item and the monthly cap for prescription 
charges decreased from €25.00 to €20.00 for this cohort. The prescription charge is 
recouped by the HSE from the Pharmacist. 
Drugs Payment Scheme (DPS)
The Drugs Payment Scheme (DPS) provides for payment to the Pharmacist for the supply 
of medicines to individuals and families where the threshold of €144, effective from 1st 
January 2013, has been exceeded in a calendar month. In order to avail of the Drugs 
Payment Scheme a person or family must register for the Scheme with the HSE PCRS. Drugs, 
medicines and appliances currently reimbursable under the Scheme are listed on the HSE 
website. Other items which were reimbursable under the Drug Cost Subsidisation Scheme 
and Refund of Drugs Scheme continue, in certain circumstances, to be reimbursable under 
the Drugs Payment Scheme.
Long-Term Illness Scheme (LTI)
On approval by the Health Service Executive, persons who suffer from one or more of a 
schedule of illnesses are entitled to obtain, without charge, irrespective of income, necessary 
drugs/medicines and/or appliances under the LTI Scheme.
Data Source(s)  Primary Care Reimbursement Service
 OECD Health Statistics
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Ms Marita Kinsella (Chair from April 2019) Director, National Patient Safety Office 
Ms Rosarie Lynch  Patient Safety Surveillance Unit, National Patient
(Interim Chair from September 2018 to March 2019) Safety Office, Department of Health 
Ms Margaret Brennan  HSE Acute Operations 
Mr Niall Byrne  Health and Social Care Regulatory Forum
Mr Tony Canavan  Community Healthcare Organisations 
Mr Ian Carter  Hospital Groups
Mr Andy Conlon Primary Care Division, Department of Health 
Ms Brigid Doherty Patient representative 
Ms Dee Fitzpatrick Patient representative 
Ms Rachel Flynn Health Information and Quality Authority
Ms Rachel Kenna  Chief Nurse's Office, Department of Health 
Mr Richard Lodge  CEO, Pre-Hospital Emergency Care Council
Mr Gavin Maguire  HSE Quality and Verification Division
Dr Jennifer Martin HSE Quality Improvement Division
Mr Liam Morris  Acute Hospitals Policy Division, Department of Health 
Dr Deirdre Mulholland  Departments of Public Health 
Ms Deirdre Murphy HSE Healthcare Pricing Office
Dr Brian Osborne Irish College of General Practitioners 
Dr Cathal O'Keeffe  State Claims Agency
Ms Rosemary Smyth Mental Health Commission
Ms Margaret Swords  Private Hospitals Association
Ms Mary Wynne HSE Office of the Nursing and Midwifery Services 
Secretariat: 
Sarah Treleaven, Patient Safety Surveillance Unit, National Patient Safety Office 
Ronan O’Kelly, Statistics and Analytics Unit
Deirdre Hyland, Patient Safety Surveillance Unit, National Patient Safety Office
Jamie Duncan, Clinical Effectiveness Unit, National Patient Safety Office
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Appendix 3: Technical Group Members
Ms Rosarie Lynch (Chair)  Patient Safety Surveillance Unit, National Patient  
 Safety Office, Department of Health 
Mr Gareth Clifford  HSE Acute Operations 
Ms Grainne Cosgrove   HSE Quality Improvement Division 
Dr Rob Cunney Health Protection Surveillance Centre 
Ms Jacqui Curly  HSE Healthcare Pricing Office 
Ms Fionnola Kelly  National Office of Clinical Audit 
Mr Ivan McConkey HSE Primary Care Reiumbursement Service
Mr Ronan O'Kelly Statistics and Analytics Unit, Department of Health 
Ms Aisling Reidy  Statistics and Analytics Unit, Department of Health 
Ms Sarah Treleaven Patient Safety Surveillance Unit, National Patient  
 Safety Office, Department of Health 
Mr PJ Wynne  HSE Community Operations 
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